band	focal	pos	frequencies	ld	true_region_size	matched_region_size	matched_start	matched_end	region_gen_size	matched_gen_size	selection_snp_count	selection_snp_count_50kb	selection_snp_count_100kb	selection_snp_count_200kb	num_gene_overlaps	meiotic_genes	meiotic_genes_all	gene_overlap_strong	gwas	eqtl
1p34.2	1	41598848	0.58 0.9 0.68 0.56 0.46	0.0 0.01 0.01 0.36 1.16	234105	234104	41476203	41710307	0.02	0.02	0	0	0	0	4	2	1	1	"Appendicular lean mass(rs2885697:0.62:-0.03;rs2885697:0.64:-0.03);Arm fat-free mass (left)(rs2885697:0.64:-0.01);Arm predicted mass (left)(rs2885697:0.64:-0.01);Arm predicted mass (right)(rs2885697:0.64:-0.01);Diastolic blood pressure(rs1740610:0.6:0.01);FEV1(rs2885697:0.64:-0.01);Fat-free mass(rs2885697:0.64:NA);Forced expiratory volume in 1-second (fev1)(rs2885697:0.64:-0.01);Forced expiratory volume in 1-second (fev1), best measure(rs2885697:0.64:-0.02);Forced vital capacity (fvc)(rs2749418:1:-0.02);Forced vital capacity (fvc), best measure(rs2885697:0.64:-0.02);Heel bone mineral density (MTAG)(rs12408576:0.98:-0.02);Heel bone mineral density T score(rs2011982:0.6:0.02);Height(rs6686842:1:-0.05;rs61780435:0.6:NA;rs2011981:0.6:-0.04);Hip circumference adjusted for BMI(rs3157:0.91:0.02);Insulin-like growth factor 1 levels(rs1740610:0.6:0.02);Lung function (FVC)(rs2749418:1:NA;rs2885697:0.64:-0.02);Platelet count(rs2885697:0.64:0.01);Total body bone mineral density (MTAG)(rs12408576:0.98:-0.03);Trunk predicted mass(rs2885697:0.64:-0.11);Waist circumference adjusted for body mass index(rs17357954:0.6:NA)"	CTPS1(eqtl:1:rs11579483;sqtl:0.7:rs11579483);FOXO6(eqtl:0.5:rs4360513);SCMH1(eqtl:0.8:rs4360513;sqtl:1:rs4360513);SLFNL1(eqtl:0.6:rs10889792)
1p34.2	0	6923726	0.57 0.6 0.74 0.64 0.53	0.0 0.01 0.01 0.28 1.08	234105	234105	6806673	7040778	0.02	0.07	0	0	0	0	2	1	0	0	0	CAMTA1(sqtl:0.6:rs1972306);PHF13(eqtl:0.2:rs1972306)
1p34.2	0	8531326	0.58 0.67 0.51 0.83 0.6	0.0 0.01 0.01 0.38 1.01	234105	234105	8414273	8648378	0.02	0.03	0	0	0	0	3	1	0	0	"Allergic disease (asthma, hay fever or eczema)(rs1922983:1:0.04);Asthma or allergic disease (pleiotropy)(rs301805:0.73:NA);Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor(rs1922983:1:0.04);Asthma | non-cancer illness code, self-reported(rs1922983:1:0.04);Asthma(rs159960:0.66:NA;rs1922983:1:0.04;rs1922983:1:0);Daytime nap(rs1922983:1:0.01);Depressed affect(rs3795310:0.65:0.01);Eosinophil counts(rs301805:0.73:0.02;rs1922983:1:0.02;rs1922983:1:0.02;rs1922983:1:0.02);Eosinophil percentage of granulocytes(rs1922983:1:0.03);Eosinophil percentage of white cells(rs1922983:1:0.02;rs1922983:1:0.03);Eosinophill count(rs1922983:1:0.01);Eosinophill percentage(rs1922983:1:0.04);Feeling miserable(rs3795310:0.65:0.01);Feeling tense(rs1922983:1:-0.01);Hayfever, allergic rhinitis or eczema | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor(rs1922983:1:0.04);Heel bone mineral density (bmd) t-score, automated(rs1922983:1:-0.03);Heel bone mineral density (bmd)(rs1922983:1:0);Heel bone mineral density(rs1922983:1:-0.02;rs1922983:1:-0.02);Heel broadband ultrasound attenuation, direct entry(rs1922983:1:-0.4);Heel quantitative ultrasound index (qui), direct entry(rs1922983:1:-0.46);Hypertension | non-cancer illness code, self-reported(rs1922983:1:0.03);Leg fat percentage (left)(rs1922983:1:0.08);Leg fat percentage (right)(rs1922983:1:0.08);Loneliness(rs159960:0.66:NA);Lymphocyte counts(rs301805:0.73:-0.02;rs1922983:1:-0.02;rs1922983:1:-0.02;rs1922983:1:-0.02);Medication use (adrenergics, inhalants)(rs159960:0.72:0.05;rs159960:0.66:0.06);Miserableness(rs3795310:0.65:NA);Neutrophil count(rs301805:0.73:-0.01;rs1922983:1:-0.01;rs1922983:1:-0.01);Neutrophil percentage of granulocytes(rs1922983:1:-0.03);None of the above | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor(rs1922983:1:-0.04);None of the above | vascular/heart problems diagnosed by doctor(rs1922983:1:-0.03);Smoking initiation(rs301805:0.73:NA);Smoking status (ever vs never smokers)(rs301805:0.73:0.01);Smoking status(rs301805:0.73:NA);Systemic lupus erythematosus(rs3795310:0.71:NA);Tense / 'highly strung'(rs1922983:1:-0.04);Thyroid problem (not cancer)(rs301805:0.73:NA;rs1922983:1:0);Vertex-wise sulcal depth(rs3795310:0.65:7.22);White blood cell count(rs1922983:1:-0.02;rs1922983:1:-0.02;rs1922983:1:-0.02)"	ENO1(eqtl:0.8:rs1922983);RERE(eqtl:1:rs1922983;sqtl:0.9:rs1922983);SLC45A1(eqtl:0.4:rs1922983)
1p34.2	0	21234923	0.59 0.54 0.63 0.83 0.6	0.0 0.0 0.0 0.3 0.99	234105	234105	21117870	21351975	0.02	0.02	0	0	0	0	2	1	0	0	Adventurousness(rs12404954:0.82:0.01);Basophil count(rs4654887:1:-0.02;rs4654887:1:-0.01);Basophil percentage of white cells(rs4654887:1:-0.01);Basophill percentage(rs4654887:1:-0.01);C-reactive protein levels(rs4654887:1:-0.01);Chronotype(rs10916892:0.89:NA);Depressive symptoms(rs3767247:0.89:-0.01);Getting up in morning(rs4654887:1:0.01);Height(rs4654887:1:0.01);Hematocrit(rs61781106:0.89:-0.01;rs4654887:1:-0.01);Insulin-like growth factor 1 levels(rs12723255:0.99:0;rs4654887:1:0.01);Life satisfaction(rs10737452:0.89:0.01);Lymphocyte counts(rs6698440:0.76:-0.01);Mean corpuscular hemoglobin concentration(rs4654887:1:0.01);Mean corpuscular hemoglobin(rs4654887:1:0.01;rs4654887:1:0.01);Mean corpuscular volume(rs4654887:1:0.01;rs4654887:1:0.01;rs4654887:1:0.01);Mean sphered cell volume(rs4654887:1:0.01);Mean spheric corpuscular volume(rs4654887:1:0.02);Morning person(rs3767240:0.86:NA;rs10916892:0.89:NA);Morning/evening person (chronotype)(rs4654887:1:-0.01);Morningness(rs10916866:0.83:-0.02);Neuroticism score(rs57351360:0.89:-0.05);Neuroticism(rs3767247:0.89:-0.01);Physical activity (walking duration)(rs7548269:0.82:0.03);Positive affect(rs3767247:0.89:-0.01);Red blood cell (erythrocyte) count(rs1212250949:0.75:-0.01;rs4654887:1:-0.01);Red blood cell count(rs17410008:0.89:NA;rs61781106:0.89:-0.02;rs4654887:1:-0.02;rs4654887:1:-0.02;rs4654887:1:-0.02);Standing height(rs4654887:1:0.09);Well-being spectrum (multivariate analysis)(rs4654874:0.82:0.01)	ECE1(eqtl:0.5:rs4654887;sqtl:0.7:rs4654887);EIF4G3(eqtl:0.8:rs4654887;sqtl:0.7:rs4654887);HP1BP3(eqtl:0.9:rs4654887);KIF17(eqtl:0.5:rs4654887;sqtl:0.6:rs4654887);SH2D5(eqtl:0.2:rs4654887)
1p34.2	0	48691564	0.63 0.88 0.57 0.39 0.75	0.0 0.02 0.03 0.36 1.21	234105	234105	48574511	48808616	0.02	0.04	0	0	0	0	3	1	0	0	0	SLC5A9(eqtl:0.9:rs12139099;sqtl:0.3:rs12139099);SPATA6(eqtl:0.6:rs12139099;sqtl:0.6:rs12139099)
1p34.2	0	84465545	0.55 0.74 0.66 0.72 0.55	0.0 0.01 0.02 0.15 1.1	234105	234105	84348492	84582597	0.02	0.03	0	0	0	0	3	2	0	0	0	PRKACB(eqtl:0.3:rs2147950;sqtl:0.1:rs2147950);TTLL7(eqtl:0.6:rs2147950)
1p34.2	0	117960332	0.63 0.6 0.57 0.67 0.73	0.0 0.0 0.01 0.62 1.18	234105	234105	117843279	118077384	0.02	0.02	0	0	0	0	2	1	0	0	0	MAN1A2(eqtl:0.5:rs61805765)
1p34.2	0	155172379	0.54 0.62 0.55 0.78 0.71	0.0 0.01 0.01 0.17 1.19	234105	234105	155055326	155289431	0.02	0.05	5	6	6	9	19	12	0	0	Benign neoplasm of other parts of digestive system(rs2066981:1:0.15);Dentures | mouth/teeth dental problems(rs2066981:1:0.04);Estimated glomerular filtration rate in non-diabetics(rs6676150:0.66:NA);Gout(rs6676150:0.65:NA);Haematocrit percentage(rs2066981:1:0.07);Haemoglobin concentration(rs2066981:1:0.02);Hematocrit(rs6676150:0.65:-0.04);Hemoglobin concentration(rs6676150:0.65:-0.03;rs6676150:0.65:-0.03);Impedance of leg (left)(rs2066981:1:0.47);Impedance of leg (right)(rs2066981:1:0.45);Low density lipoprotein cholesterol levels(rs6676150:0.65:-0.01);None of the above | mouth/teeth dental problems(rs2066981:1:-0.03);Red blood cell (erythrocyte) count(rs2066981:1:0.01);Red blood cell count(rs6676150:0.65:-0.02;rs6676150:0.65:-0.03;rs6676150:0.65:-0.03)	ADAM15(eqtl:0.9:rs2066981);DAP3(eqtl:0.6:rs2066981);DPM3(eqtl:0.4:rs2066981);GBA(eqtl:0.4:rs2066981);KRTCAP2(eqtl:0.4:rs2066981);MTX1(eqtl:0.8:rs2066981);RIT1(eqtl:0.4:rs2066981);SEMA4A(eqtl:0.1:rs2066981);SYT11(eqtl:0.4:rs2066981);THBS3(eqtl:1:rs2066981);TRIM46(eqtl:0.5:rs2066981);YY1AP1(eqtl:0.6:rs2066981)
1p34.2	0	184172366	0.55 0.8 0.55 0.57 0.7	0.0 0.02 0.06 0.5 1.05	234105	234105	184055313	184289418	0.02	0.08	0	0	0	0	1	1	0	0	0	COLGALT2(eqtl:0.5:rs4651182);TSEN15(eqtl:0.8:rs4651182)
1p34.2	0	210027026	0.61 0.7 0.56 0.75 0.65	0.01 0.01 0.04 0.57 1.35	234105	234105	209909973	210144078	0.02	0.08	0	0	0	0	6	1	0	0	Mean corpuscular volume(rs6689839:1:0.01);Mean spheric corpuscular volume(rs6689839:1:0.01);Monobrow(rs7542091:0.7:NA)	IRF6(eqtl:0.9:rs6689839);SYT14(eqtl:0.9:rs6689839);TRAF3IP3(eqtl:0.8:rs6689839;sqtl:0.1:rs6689839);UTP25(eqtl:0.9:rs6689839)
1p33	1	48820294	0.66 0.34 0.56 0.79 0.54	0.0 0.0 0.01 0.32 1.07	198607	198606	48725511	48924117	0.01	0.01	0	0	0	0	1	1	1	1	0	SLC5A9(eqtl:0.9:rs11205476);SPATA6(eqtl:0.4:rs11205476;sqtl:0.3:rs11205476)
1p33	0	39944180	0.66 0.28 0.79 0.57 0.59	0.01 0.02 0.03 0.32 0.93	198607	198607	39844876	40043483	0.01	0.04	0	0	0	0	7	2	0	0	FEV1(rs6665948:1:0.02);Hemoglobin concentration(rs6665948:1:0.01);Lung function (FEV1/FVC)(rs6665948:1:0.01);Mean corpuscular haemoglobin(rs6665948:1:0.04);Mean corpuscular hemoglobin concentration(rs6665948:1:0.02;rs6665948:1:0.02;rs6665948:1:0.02);Mean corpuscular hemoglobin(rs6665948:1:0.03;rs6665948:1:0.03;rs6665948:1:0.02);Mean corpuscular volume(rs6665948:1:0.02;rs6665948:1:0.09;rs6665948:1:0.02);Optic disc size(rs599892:0.69:NA);Peak expiratory flow(rs6665948:1:0.02);Platelet crit(rs10652572:0.66:0);Platelet distribution width(rs6665948:1:0.02);Red blood cell (erythrocyte) distribution width(rs6665948:1:-0.02);Red cell distribution width(rs6665948:1:-0.02;rs6665948:1:-0.03;rs6665948:1:-0.02;rs6665948:1:-0.02);Serum alkaline phosphatase levels(rs879037:0.62:-7.99;rs1180322:0.61:-0.02);Sex hormone-binding globulin levels adjusted for BMI(rs6665948:1:0.01;rs6665948:1:0.01;rs6665948:1:0.01);Sex hormone-binding globulin levels(rs6665948:1:0.01;rs6665948:1:0.01;rs6665948:1:0.01);Sitting height(rs12402990:0.92:-0.06;rs6665948:1:-0.06);Snoring(rs75144690:0.62:NA);Total testosterone levels(rs6665948:1:0.02)	BMP8A(eqtl:0.9:rs6665948;sqtl:0.6:rs6665948);HPCAL4(eqtl:0.7:rs6665948);MACF1(eqtl:0.9:rs6665948;sqtl:0.5:rs6665948);PABPC4(eqtl:0.8:rs6665948;sqtl:0.7:rs6665948);PPIE(eqtl:0.2:rs6665948)
1p33	0	60584802	0.69 0.5 0.78 0.44 0.53	0.0 0.03 0.03 0.24 0.89	198607	198607	60485498	60684105	0.01	0.05	0	0	0	0	1	1	0	0	0	C1orf87(eqtl:0.8:rs651719;sqtl:0.4:rs651719);CYP2J2(eqtl:0.2:rs651719);HOOK1(eqtl:0.2:rs651719)
1p33	0	94343023	0.65 0.62 0.47 0.44 0.63	0.01 0.01 0.02 0.89 1.12	198607	198607	94243719	94442326	0.01	0.04	0	0	0	0	4	3	0	0	Serum polyunsaturated fatty acid concentration x sex interaction in metabolic syndrome [total PUFA](rs3747965:0.9:NA)	BCAR3(eqtl:0.2:rs2391322);DNTTIP2(eqtl:1:rs2391322;sqtl:0.2:rs2391322);DR1(eqtl:0.2:rs2391322);GCLM(eqtl:0.1:rs2391322);TMED5(eqtl:0.5:rs2391322)
1p33	0	99108691	0.63 0.45 0.68 0.58 0.63	0.0 0.02 0.03 0.42 1.1	198607	198607	99009387	99207994	0.01	0.04	0	0	0	0	1	0	0	0	0	SNX7(eqtl:0.6:rs12083485)
1p33	0	113566057	0.67 0.72 0.54 0.32 0.63	0.0 0.01 0.01 0.5 0.89	198607	198607	113466753	113665360	0.01	0.02	0	0	0	0	5	2	0	0	0	0
1p33	0	185219680	0.66 0.45 0.58 0.6 0.67	0.0 0.01 0.01 0.41 0.92	198607	198607	185120376	185318983	0.01	0.03	0	0	0	0	4	3	0	0	Cystatin C levels(rs10737256:0.62:-0.01);Hand grip strength (left)(rs3753569:0.62:0.11);Lymphocyte counts(rs10489579:0.85:-0.01);Platelet count(rs10174:0.64:-0.02;rs10174:0.64:-0.02;rs12135172:1:-0.85;rs12135172:1:-0.02;rs12135172:1:-0.02);Platelet crit(rs12135172:1:0);Plateletcrit(rs10174:0.64:-0.02;rs12135172:1:-0.02);Reticulocyte count(rs12044943:0.6:-0.01);Sex hormone-binding globulin levels(rs12081098:0.62:0.01);Urate levels(rs6674490:0.6:0);Walking pace(rs10797999:0.61:0.01)	EDEM3(eqtl:0.3:rs12135172);IVNS1ABP(eqtl:0.7:rs12135172);RNF2(eqtl:0.5:rs12135172);SWT1(eqtl:0.6:rs12135172;sqtl:0.9:rs12135172);TRMT1L(eqtl:0.3:rs12135172)
1p33	0	226383764	0.61 0.6 0.44 0.65 0.58	0.0 0.02 0.02 0.34 0.92	198607	198607	226284460	226483067	0.01	0.04	0	0	0	0	4	2	0	0	0	ACBD3(eqtl:0.9:rs9660542);H3-3A(eqtl:0.6:rs9660542);TMEM63A(eqtl:0.5:rs9660542)
1p33	0	243214611	0.65 0.5 0.46 0.67 0.71	0.0 0.01 0.02 0.49 1.04	198607	198607	243115307	243313914	0.01	0.05	0	0	0	0	2	1	0	0	Acceptance of an invitation to participate in a mental health questionnaire(rs2789111:0.62:NA);Diastolic blood pressure(rs6662118:0.61:0.02);Mean arterial pressure(rs4658552:0.61:0.01);Mental health study participation (completed survey)(rs2789111:0.62:-0.01);Multisite chronic pain(rs12071912:0.93:0.02;rs9700909:0.93:NA);Red blood cell (erythrocyte) distribution width(rs140816120:0.61:0.02);Red cell distribution width(rs67686929:0.61:0.02;rs2171974:0.61:NA;rs2171973:0.62:0.02)	CEP170(eqtl:0.4:rs9700808);SDCCAG8(eqtl:0.8:rs9700808)
1p33	0	246476240	0.7 0.78 0.44 0.27 0.64	0.0 0.01 0.03 0.32 1.0	198607	198607	246376936	246575543	0.01	0.05	0	0	0	0	1	1	0	0	0	0
1q25.1-1	1	176043089	0.45 0.31 0.31 0.44 0.44	0.0 0.0 0.01 0.27 1.21	274264	274263	175906676	176180939	0.02	0.02	0	0	0	0	3	0	0	1	Bipolar disorder or major depressive disorder(rs10913112:0.81:NA);Depression(rs10913112:0.81:NA);Depressive symptoms(rs4526571:0.81:-0.01);Hip index(rs12024295:0.72:NA);Life satisfaction(rs4526571:0.81:-0.01);Major depressive disorder (MTAG)(rs12040241:0.81:-0.03);Neuroticism(rs4526571:0.81:-0.01);Positive affect(rs4526571:0.81:-0.01);Well-being spectrum (multivariate analysis)(rs10913160:0.72:NA)	COP1(eqtl:0.9:rs10218714;sqtl:0.1:rs10218714);PAPPA2(eqtl:0.9:rs10218714)
1q25.1-1	0	6790946	0.41 0.29 0.4 0.45 0.4	0.02 0.03 0.04 0.37 1.04	274264	274264	6653814	6928078	0.02	0.07	0	0	0	0	7	2	0	0	Externalizing behaviour (multivariate analysis)(rs277686:0.66:NA);Heel bone mineral density(rs11122122:1:-0.01);Mean spheric corpuscular volume(rs11122122:1:-0.01)	CAMTA1(sqtl:0.2:rs11122122);NOL9(eqtl:0.4:rs11122122);PHF13(eqtl:0.8:rs11122122);PLEKHG5(eqtl:0.3:rs11122122);THAP3(eqtl:0.5:rs11122122;sqtl:0.1:rs11122122);TNFRSF25(eqtl:0.3:rs11122122)
1q25.1-1	0	8738937	0.43 0.36 0.55 0.16 0.38	0.0 0.01 0.01 0.21 1.34	274264	274264	8601805	8876069	0.02	0.03	0	0	0	0	1	1	0	0	"Allergic disease (asthma, hay fever or eczema)(rs4908507:1:0.04);Asthma or allergic disease (pleiotropy)(rs301805:0.66:NA);Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor(rs4908507:1:0.04);Asthma | non-cancer illness code, self-reported(rs4908507:1:0.04);Asthma(rs4908507:1:0.04;rs4908507:1:0);Body fat percentage(rs301806:0.65:0.1);Daytime nap(rs4908507:1:0.01);Eczema(rs301806:0.65:NA);Eosinophil counts(rs301805:0.66:0.02;rs4908507:1:0.02;rs4908507:1:0.01;rs4908507:1:0.01);Eosinophil percentage of granulocytes(rs4908507:1:0.03);Eosinophil percentage of white cells(rs4908507:1:0.02;rs4908507:1:0.03);Eosinophill count(rs4908507:1:0.01);Eosinophill percentage(rs4908507:1:0.04);Feeling tense(rs4908507:1:-0.01);Hayfever, allergic rhinitis or eczema | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor(rs4908507:1:0.04);Heel bone mineral density (bmd) t-score, automated(rs4908507:1:-0.03);Heel bone mineral density (bmd)(rs4908507:1:0);Heel bone mineral density(rs4908507:1:-0.02;rs4908507:1:-0.02);Heel broadband ultrasound attenuation, direct entry(rs4908507:1:-0.41);Heel quantitative ultrasound index (qui), direct entry(rs4908507:1:-0.46);Leg fat percentage (left)(rs4908507:1:0.07);Leg fat percentage (right)(rs4908507:1:0.08);Lymphocyte counts(rs301805:0.66:-0.02;rs4908507:1:-0.02;rs4908507:1:-0.02;rs4908507:1:-0.02);Medication use (adrenergics, inhalants)(rs159960:0.67:0.05);Neutrophil count(rs301805:0.66:-0.01;rs4908507:1:-0.01;rs4908507:1:-0.01);Neutrophil percentage of granulocytes(rs4908507:1:-0.02);None of the above | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor(rs4908507:1:-0.04);Smoking initiation(rs301805:0.66:NA);Smoking status (ever vs never smokers)(rs301805:0.66:0.01);Smoking status(rs301805:0.66:NA);Systemic lupus erythematosus(rs3795310:0.66:NA);Tense / 'highly strung'(rs4908507:1:-0.04);Thyroid problem (not cancer)(rs301805:0.66:NA);White blood cell count(rs4908507:1:-0.02;rs4908507:1:-0.01)"	ENO1(eqtl:0.8:rs4908507);RERE(eqtl:1:rs4908507;sqtl:0.9:rs4908507);SLC45A1(eqtl:0.5:rs4908507)
1q25.1-1	0	21241432	0.42 0.23 0.35 0.53 0.49	0.0 0.0 0.0 0.3 1.06	274264	274264	21104300	21378564	0.02	0.02	0	0	0	0	3	2	0	0	Appendicular lean mass(rs6699704:1:-0.02;rs6699704:1:-0.01);Basophil count(rs6699704:1:0.02;rs6699704:1:0.02);Basophil percentage of granulocytes(rs546464445:0.95:0.02;rs6699704:1:0.02);Basophil percentage of white cells(rs546464445:0.95:0.02;rs6699704:1:0.02);Basophill percentage(rs6699704:1:0.01);Comparative height size at age 10(rs6699704:1:-0.01);Eosinophil counts(rs2100382:0.99:0.01;rs12042978:1:0.01;rs6699704:1:0.01;rs6699704:1:0.01);Eosinophil percentage of white cells(rs2100382:0.99:0.01;rs6699704:1:0.01);Lymphocyte counts(rs6698440:0.67:-0.01;rs6699704:1:0.01);Mean corpuscular hemoglobin(rs10916916:0.61:0.02;rs7556221:0.66:NA;rs6699704:1:-0.01;rs6699704:1:-0.01);Mean corpuscular volume(rs6699704:1:-0.01;rs6699704:1:-0.01);Mean sphered cell volume(rs12035087:0.66:-0.08;rs6699704:1:-0.07);Mean spheric corpuscular volume(rs6699704:1:-0.02);Morningness(rs10916866:0.61:-0.02);Neutrophil percentage of white cells(rs3121071:1:-0.01;rs6699704:1:-0.01);Red blood cell count(rs6699704:1:0.01;rs6699704:1:0.01);Red cell distribution width(rs541464:0.79:NA;rs6699704:1:0.01);Sitting height(rs6699704:1:-0.05);Social science traits (pleiotropy) (HIPO component 1)(rs2874367:0.67:NA);Standing height(rs6699704:1:-0.12);Trunk fat-free mass(rs6699704:1:-0.05);Trunk predicted mass(rs6699704:1:-0.04);Well-being spectrum (multivariate analysis)(rs4654874:0.61:0.01);White blood cell count (basophil)(rs10799673:1:0.02;rs6699704:1:0.02)	ECE1(eqtl:0.2:rs6699704;sqtl:0.5:rs6699704);EIF4G3(eqtl:0.8:rs6699704;sqtl:0.7:rs6699704);HP1BP3(eqtl:1:rs6699704);KIF17(eqtl:0.8:rs6699704;sqtl:0.7:rs6699704)
1q25.1-1	0	48704437	0.5 0.23 0.42 0.4 0.42	0.0 0.02 0.03 0.36 1.2	274264	274264	48567305	48841569	0.02	0.05	0	0	0	0	3	1	0	0	0	SLC5A9(eqtl:0.9:rs1005538);SPATA6(eqtl:0.1:rs1005538;sqtl:0.3:rs1005538)
1q25.1-1	0	111567469	0.41 0.13 0.57 0.48 0.38	0.0 0.03 0.08 0.58 1.4	274264	274264	111430337	111704601	0.02	0.1	0	0	0	0	4	2	0	0	Mean platelet (thrombocyte) volume(rs1282334:1:-0.02);Mean platelet volume(rs1282334:1:-0.02;rs1282334:1:-0.02)	CD53(eqtl:0.5:rs1282334);CEPT1(eqtl:0.6:rs1282334);CHI3L2(eqtl:0.6:rs1282334);DENND2D(eqtl:0.6:rs1282334;sqtl:0.7:rs1282334);DRAM2(eqtl:1:rs1282334;sqtl:1:rs1282334)
1q25.1-1	0	158553332	0.42 0.42 0.25 0.49 0.44	0.01 0.02 0.03 0.45 1.2	274264	274264	158416200	158690464	0.02	0.1	0	0	0	0	9	0	0	0	Hemoglobin A1c levels(rs2779116:0.75:0.03);Hemoglobin concentration(rs863368:1:-0.01);Hemoglobin(rs863368:1:-0.01);High light scatter reticulocyte count(rs863368:1:0;rs863368:1:-0.04;rs863368:1:-0.04);High light scatter reticulocyte percentage of red cells(rs863368:1:-0.04;rs863368:1:-0.04);High light scatter reticulocyte percentage(rs863368:1:-0.01);Immature fraction of reticulocytes(rs863368:1:0.02);Immature reticulocyte fraction(rs863368:1:0);Lymphocyte counts(rs857708:1:NA;rs863368:1:0.02;rs863368:1:0.02;rs863368:1:0.02);Lymphocyte percentage of white cells(rs863368:1:0.02;rs863368:1:0.02);Lymphocyte percentage(rs863368:1:0.11);Mean corpuscular haemoglobin concentration(rs863368:1:-0.03);Mean corpuscular hemoglobin concentration(rs857684:0.78:NA;rs863368:1:-0.04;rs863368:1:-0.04;rs863368:1:-0.05);Mean corpuscular volume(rs863368:1:0.08;rs863368:1:0.02;rs863368:1:0.02);Mean platelet volume(rs863368:1:0.01;rs863368:1:0.01);Mean reticulocyte volume(rs863368:1:0.08;rs863368:1:0.56);Mean sphered cell volume(rs863368:1:0.45);Mean spheric corpuscular volume(rs863368:1:0.11);Neurofibrillary tangles (SNP x SNP interaction)(rs1103852:0.99:NA);Neutrophil percentage of white cells(rs863368:1:-0.02;rs863368:1:-0.02);Neutrophill percentage(rs863368:1:-0.12);Platelet distribution width(rs863368:1:-0.01);Red blood cell (erythrocyte) distribution width(rs863368:1:0.01);Red cell distribution width(rs863368:1:0.02;rs863368:1:0.02);Reticulocyte count(rs863368:1:-0.07;rs863368:1:-0.07;rs863368:1:0);Reticulocyte fraction of red cells(rs863368:1:-0.07;rs863368:1:-0.07);Reticulocyte percentage(rs863368:1:-0.03);Total bilirubin levels(rs2022003:0.74:NA)	CD1B(eqtl:0.2:rs863368);CD1D(eqtl:0.4:rs863368);CD1E(eqtl:0.4:rs863368);SPTA1(eqtl:0.4:rs863368)
1q25.1-1	0	166845122	0.47 0.53 0.34 0.3 0.34	0.0 0.01 0.03 0.33 1.13	274264	274264	166707990	166982254	0.02	0.1	0	0	0	0	4	2	0	0	0	ILDR2(eqtl:0.9:rs6427038;sqtl:0.7:rs6427038);MAEL(eqtl:1:rs6427038);POGK(eqtl:0.9:rs6427038);TADA1(eqtl:0.8:rs6427038)
1q25.1-1	0	211232350	0.4 0.3 0.49 0.3 0.4	0.0 0.03 0.05 0.35 1.02	274264	274264	211095218	211369482	0.02	0.08	0	0	0	0	2	0	0	0	0	0
1q25.1-1	0	228738446	0.42 0.1 0.46 0.49 0.41	0.0 0.0 0.02 0.28 1.02	274264	274264	228601314	228875578	0.02	0.09	0	0	0	0	26	1	0	0	0	H2AW(eqtl:0.5:rs4653978);MRPL55(sqtl:0.2:rs4653978);OBSCN(eqtl:0.4:rs4653978);RHOU(eqtl:0.4:rs4653978);RNF187(eqtl:0.5:rs4653978)
1q42.12	1	225247025	0.88 0.33 0.78 0.71 0.73	0.0 0.0 0.0 0.09 0.45	183069	183068	225156683	225339751	0.02	0.02	0	0	0	0	1	1	0	0	0	DNAH14(eqtl:0.1:rs2489346;sqtl:0.5:rs2489346)
1q42.12	0	10218377	0.86 0.2 0.79 0.7 0.81	0.0 0.03 0.04 0.16 0.65	183069	183069	10126842	10309911	0.02	0.05	0	0	0	0	2	2	0	0	Height(rs2273298:1:0.02;rs2273298:1:0.02);Hip circumference adjusted for BMI(rs11121525:0.88:0.03);Sex hormone-binding globulin levels(rs61782924:0.81:0.01;rs10864443:0.84:0.01;rs2273298:1:0.01);Sitting height(rs11121522:0.69:0.09);Standing height(rs11121522:0.69:0.21;rs2273298:1:0.19)	DFFA(eqtl:0.4:rs2273298);LZIC(eqtl:0.9:rs2273298;sqtl:0.4:rs2273298);NMNAT1(eqtl:0.6:rs2273298);RBP7(eqtl:0.9:rs2273298);UBE4B(eqtl:0.9:rs2273298;sqtl:0.7:rs2273298)
1q42.12	0	36281336	0.9 0.6 0.88 0.33 0.63	0.0 0.0 0.02 0.09 0.25	183069	183069	36189801	36372870	0.02	0.02	0	0	0	0	3	3	0	0	Schizophrenia(rs12083902:1:NA);Sex hormone-binding globulin levels adjusted for BMI(rs727005:1:-0.01;rs727005:1:-0.01);Sex hormone-binding globulin levels(rs727005:1:-0.01);Type 1 diabetes(rs574384:0.63:NA);Waist circumference adjusted for body mass index(rs72661605:0.75:NA)	AGO1(eqtl:0.5:rs727005);AGO4(eqtl:0.4:rs727005);C1orf216(eqtl:1:rs727005;sqtl:0.2:rs727005);COL8A2(sqtl:0.4:rs727005);MAP7D1(eqtl:0.6:rs727005);THRAP3(sqtl:0.4:rs727005);ZMYM1(eqtl:0.7:rs727005)
1q42.12	0	52864264	0.84 0.26 0.72 0.77 0.82	0.0 0.0 0.01 0.06 0.32	183069	183069	52772729	52955798	0.02	0.01	0	0	0	0	5	4	0	0	0	CC2D1B(eqtl:0.7:rs6700000);GPX7(eqtl:1:rs6700000;pqtl:0.8:rs6700000);NRDC(eqtl:0.7:rs6700000);PRPF38A(eqtl:0.4:rs6700000);RAB3B(eqtl:0.2:rs6700000);TUT4(eqtl:0.7:rs6700000);TXNDC12(eqtl:0.4:rs6700000)
1q42.12	0	78507648	0.83 0.41 0.7 0.76 0.71	0.0 0.01 0.01 0.13 0.29	183069	183069	78416113	78599182	0.02	0.03	0	0	0	0	3	2	0	0	Lung function (FEV1/FVC)(rs10735751:1:-0.02)	DNAJB4(eqtl:0.2:rs10735751);NEXN(eqtl:0.5:rs10735751)
1q42.12	0	96751964	0.84 0.9 0.61 0.39 0.66	0.0 0.0 0.01 0.17 0.3	183069	183069	96660429	96843498	0.02	0.04	0	0	0	0	1	0	0	0	"Light diy (eg: pruning, watering the lawn) | types of physical activity in last 4 weeks(rs113840386:0.77:NA)"	0
1q42.12	0	105854597	0.86 0.51 0.76 0.59 0.75	0.01 0.02 0.03 0.39 0.64	183069	183069	105763062	105946131	0.02	0.04	0	0	0	0	0	0	0	0	0	0
1q42.12	0	152245544	0.86 0.99 0.57 0.42 0.61	0.0 0.0 0.0 0.19 0.52	183069	183069	152154009	152337078	0.02	0.03	18	35	45	102	4	0	0	0	Atopic dermatitis(rs3126085:0.83:NA)	HRNR(eqtl:0.7:rs9700758);TDRKH(eqtl:0.3:rs9700758);THEM4(eqtl:0.5:rs9700758)
1q42.12	0	173658207	0.84 0.21 0.9 0.73 0.75	0.0 0.01 0.01 0.04 0.37	183069	183069	173566672	173749741	0.02	0.01	0	0	0	0	4	4	0	0	Body mass index(rs61828917:0.67:NA);Hemoglobin concentration(rs28825469:1:-0.01);Schizophrenia(rs61826793:0.65:NA)	ANKRD45(sqtl:0.9:rs28825469);DARS2(eqtl:0.8:rs28825469);GPR52(eqtl:0.7:rs28825469);KLHL20(eqtl:0.6:rs28825469);PRDX6(eqtl:0.9:rs28825469;sqtl:0.9:rs28825469);RABGAP1L(eqtl:0.7:rs28825469);RC3H1(eqtl:0.1:rs28825469);SERPINC1(eqtl:0.9:rs28825469);SLC9C2(eqtl:0.9:rs28825469)
1q42.12	0	227931560	0.84 0.45 0.71 0.58 0.77	0.0 0.01 0.02 0.22 0.35	183069	183069	227840025	228023094	0.02	0.04	0	0	0	0	6	3	0	0	0	CDC42BPA(eqtl:0.3:rs2031132);COQ8A(eqtl:0.4:rs2031132);JMJD4(eqtl:0.5:rs2031132);SNAP47(eqtl:0.7:rs2031132;sqtl:0.7:rs2031132);ZNF678(eqtl:0.7:rs2031132)
1q42.13	1	227365304	0.39 0.36 0.31 0.26 0.33	0.0 0.01 0.01 0.16 0.39	289071	289070	227217956	227507026	0.03	0.03	0	0	0	0	1	1	1	1	CD14- CD16- Absolute Count(rs3014270:0.64:-0.26);Low density lipoprotein cholesterol levels(rs7412928:1:0.01);Sex hormone-binding globulin levels adjusted for BMI(rs3768420:0.81:-0.01;rs3768420:0.81:-0.01);Sex hormone-binding globulin levels(rs17600747:0.8:-0.01)	CDC42BPA(eqtl:0.1:rs6685823);COQ8A(eqtl:1:rs11582863;sqtl:1:rs11582863);H3-3A(eqtl:0.3:rs10916080);PSEN2(eqtl:0.7:rs11582863)
1q42.13	0	44194512	0.39 0.04 0.42 0.49 0.28	0.0 0.01 0.01 0.13 0.58	289071	289071	44049976	44339047	0.03	0.05	0	0	0	0	6	1	0	0	Eosinophil percentage of white cells(rs10890258:0.61:-0.01);Left-handedness(rs34550543:0.95:NA);Liver enzyme levels (alkaline phosphatase)(rs11210918:0.97:NA);Mean corpuscular volume(rs11210908:1:0.01;rs11210908:1:0.01);Mean reticulocyte volume(rs12118210:0.73:0.01;rs11210908:1:0.01);Mean spheric corpuscular volume(rs3791048:0.98:0.01;rs11210908:1:0.01);Monocyte count(rs2240517:0.99:-0.01;rs11210908:1:-0.01);Monocyte percentage of white cells(rs812490:0.79:-0.01);Red blood cell (erythrocyte) count(rs11210908:1:-0.01);Red blood cell count(rs11210908:1:-0.02;rs11210908:1:-0.02);Serum alkaline phosphatase levels(rs2240517:0.99:-0.02;rs3791045:0.76:-0.02;rs12750525:0.86:-7.3)	CCDC24(eqtl:0.9:rs11210908);DPH2(eqtl:0.1:rs11210908);HYI(eqtl:0.2:rs11210908);MED8(eqtl:0.3:rs11210908);PTPRF(eqtl:0.1:rs11210908);ST3GAL3(eqtl:0.7:rs11210908)
1q42.13	0	46627546	0.4 0.03 0.3 0.55 0.41	0.0 0.03 0.04 0.09 0.4	289071	289071	46483010	46772081	0.03	0.05	0	0	0	0	11	7	0	0	Haematocrit percentage(rs7552775:1:-0.05);Haemoglobin concentration(rs7552775:1:-0.02);Hematocrit(rs7552775:1:-0.02;rs7552775:1:-0.02);Hemoglobin concentration(rs7552775:1:-0.02);Hemoglobin(rs7552775:1:-0.02);High light scatter reticulocyte count(rs7552775:1:-0.01);Mean corpuscular hemoglobin(rs7552775:1:0.01;rs7552775:1:0.01);Mean corpuscular volume(rs7552775:1:0.01;rs7552775:1:0.01);Neutrophil count(rs7552775:1:-0.02;rs7552775:1:-0.01);Red blood cell (erythrocyte) count(rs7552775:1:-0.01);Red blood cell count(rs7552775:1:-0.02;rs7552775:1:-0.02;rs7552775:1:-0.02);Red cell distribution width(rs7552775:1:-0.01;rs7552775:1:-0.01);Reticulocyte count(rs7552775:1:-0.02);Reticulocyte fraction of red cells(rs7552775:1:-0.01);White blood cell count(rs7552775:1:-0.02;rs7552775:1:-0.01)	AKR1A1(eqtl:0.1:rs7552775);CCDC163(eqtl:0.9:rs7552775;sqtl:0.4:rs7552775);CCDC17(eqtl:0.5:rs7552775);IPP(eqtl:0.8:rs7552775);LURAP1(eqtl:0.9:rs7552775;sqtl:0.3:rs7552775);MAST2(eqtl:0.4:rs7552775;sqtl:0.2:rs7552775);MKNK1(eqtl:0.4:rs7552775);MOB3C(eqtl:0.6:rs7552775);MUTYH(eqtl:0.5:rs7552775;sqtl:0.4:rs7552775);NASP(eqtl:0.2:rs7552775);NSUN4(eqtl:0.7:rs7552775);PIK3R3(eqtl:0.9:rs7552775);POMGNT1(eqtl:0.8:rs7552775);PRDX1(eqtl:0.5:rs7552775;sqtl:0.2:rs7552775);RAD54L(eqtl:0.2:rs7552775);TESK2(eqtl:0.3:rs7552775);TMEM69(eqtl:0.3:rs7552775)
1q42.13	0	73768366	0.4 0.11 0.32 0.2 0.54	0.0 0.0 0.01 0.05 0.22	289071	289071	73623830	73912901	0.03	0.03	185	227	347	361	1	0	0	0	"Anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, or Tourette syndrome (pleiotropy)(rs12129573:1:NA);Appendicular lean mass(rs12129573:1:-0.01);Depression(rs12129573:1:NA);Major depressive disorder or stress-related disorder(rs12129573:1:NA);Major depressive disorder(rs12129573:1:NA);Schizophrenia vs Tourette's syndrome and other tic disorders (ordinary least squares (OLS))(rs12129573:1:0.02);Schizophrenia vs major depressive disorder (ordinary least squares (OLS))(rs12129573:1:0.01);Schizophrenia(rs12129573:1:NA;rs12129573:1:NA;rs12129573:1:NA;rs10890032:1:NA)"	0
1q42.13	0	179454859	0.41 0.15 0.45 0.37 0.32	0.0 0.01 0.02 0.16 0.52	289071	289071	179310323	179599394	0.03	0.07	0	0	0	0	4	3	0	0	Bioavailable testosterone levels(rs72704417:1:-0.01);Household income (MTAG)(rs6678546:0.63:0.01);Total testosterone levels(rs72704417:1:-0.01;rs72704417:1:-0.02)	ABL2(eqtl:0.1:rs72704417);AXDND1(eqtl:0.9:rs72704417;sqtl:0.7:rs72704417);SOAT1(eqtl:0.9:rs72704417);TDRD5(eqtl:1:rs72704417);TOR3A(eqtl:0.7:rs72704417)
1q42.13	0	189207576	0.35 0.1 0.4 0.46 0.28	0.0 0.0 0.01 0.05 0.42	289071	289071	189063040	189352111	0.03	0.02	0	0	0	0	0	0	0	0	0	0
1q42.13	0	190277483	0.43 0.34 0.31 0.37 0.27	0.0 0.0 0.01 0.13 0.57	289071	289071	190132947	190422018	0.03	0.05	0	0	0	0	1	0	0	0	Adult body size(rs815163:0.99:-0.01);Arm fat mass (left)(rs1899444:1:-0.01);Arm fat mass (right)(rs815163:0.99:-0.01;rs1899444:1:-0.01);Arm fat percentage (left)(rs815163:0.99:-0.12;rs1899444:1:-0.12);Arm fat percentage (right)(rs1899444:1:-0.12);Basal metabolic rate(rs1899444:1:-11.61);Body fat percentage(rs1899444:1:-0.08);Body mass index (bmi)(rs815163:0.99:-0.09;rs1899444:1:-0.09;rs1899444:1:-0.08);Body mass index(rs1412971:0.99:-0.01;rs10920678:1:-0.01;rs10920678:0.99:-0.02;rs10920678:0.97:-0.02;rs10920678:1:-0.01;rs10920678:1:-0.02;rs1899444:1:-0.02;rs3098843:1:-0.02;rs815163:0.99:NA);Hip circumference(rs12744191:0.82:0.16;rs1899444:1:-0.16);Impedance of leg (left)(rs12744191:0.82:-0.55;rs1899444:1:0.52);Impedance of leg (right)(rs1899444:1:0.61);Impedance of whole body(rs12744191:0.82:-0.96;rs1899444:1:0.92);Leg fat mass (left)(rs1899444:1:-0.02);Leg fat mass (right)(rs1899444:1:-0.02);Leg fat-free mass (left)(rs1899444:1:-0.02);Leg fat-free mass (right)(rs1899444:1:-0.02);Leg predicted mass (left)(rs1899444:1:-0.02);Leg predicted mass (right)(rs1899444:1:-0.02);Subjective well-being (MTAG)(rs10920678:1:0.01);Subjective well-being(rs10920678:1:0.01);Trunk fat mass(rs1899444:1:-0.07);Waist circumference(rs1899444:1:-0.18);Weight(rs6428016:0.99:-0.01;rs1899444:1:-0.23;rs1899444:1:-0.23);Whole body fat mass(rs815163:0.99:-0.15;rs1899444:1:-0.14)	0
1q42.13	0	190815816	0.38 0.25 0.42 0.24 0.33	0.0 0.01 0.01 0.1 0.23	289071	289071	190671280	190960351	0.03	0.05	0	0	0	0	1	0	0	0	Adolescent idiopathic scoliosis(rs10920828:0.94:NA);Smoking initiation (ever regular vs never regular) (MTAG)(rs35656245:0.62:0.01);Smoking initiation (ever regular vs never regular)(rs35656245:0.62:0.02)	0
1q42.13	0	196814955	0.4 0.12 0.36 0.4 0.32	0.0 0.01 0.02 0.1 0.33	289071	289071	196670419	196959490	0.03	0.06	0	0	0	0	6	1	0	0	"Age-related macular degeneration (whether dry or wet)(rs572515:0.63:NA);Age-related macular degeneration(rs1061170:0.62:NA);Amino-terminal enhancer of split measurement(rs1329421:0.62:-0.1);Coagulation factor XIII measurement(rs61818922:1:0.12);Complement component C8 gamma chain measurement(rs12029785:0.63:0.09;rs61818922:1:-0.08);Complement component C8 measurement(rs61818922:1:0.25);Complement factor B measurement(rs61818922:1:-0.16);Dry age-related macular degeneration (includes geographic atrophy)(rs572515:0.63:NA);ERO1-like protein beta measurement(rs1329424:0.62:0.08);Early age-related macular degeneration(rs61818922:1:0.13);Electron transfer flavoprotein subunit alpha, mitochondrial measurement(rs61818922:1:0.15);Fibulin-5 measurement(rs61818922:1:0.11);GDP-fucose protein O-fucosyltransferase 1 measurement(rs61818922:1:-0.08);Interleukin-1 receptor antagonist protein measurement(rs1329424:0.62:0.09);Macular degeneration | eye problems/disorders(rs61818922:1:0.23);Monocyte differentiation antigen CD14 measurement(rs12029785:0.63:-0.1;rs61818922:1:0.08);Scavenger receptor class A member 5 measurement(rs1329422:0.62:0.09);Serum levels of protein ANAPC7(rs572515:0.63:0.42);Serum levels of protein C10orf105(rs572515:0.63:0.13);Serum levels of protein CTXN3(rs572515:0.63:0.14);Serum levels of protein EFCAB14(rs570618:0.63:-0.24);Serum levels of protein GSKIP(rs572515:0.63:0.34);Serum levels of protein MAN1B1(rs7529589:0.62:0.38);Serum levels of protein NCF2(rs572515:0.63:0.14);Wet age-related macular degeneration(rs572515:0.63:NA)"	CFH(pqtl:0.2:rs61818922);CFHR3(eqtl:0.9:rs61818922);CFHR5(pqtl:0.6:rs61818922)
1q42.13	0	225248621	0.42 0.04 0.41 0.51 0.37	0.0 0.0 0.0 0.09 0.45	289071	289071	225104085	225393156	0.03	0.03	0	0	0	0	1	1	0	0	0	0
2p23.1-1	1	30775151	0.88 0.91 0.77 0.77 0.78	0.0 0.01 0.02 1.3 2.14	165637	165636	30698249	30863885	0.03	0.03	0	0	0	0	1	0	0	1	Heel bone mineral density T score(rs12467646:0.99:0.01);Heel bone mineral density(rs13405340:0.98:NA)	LBH(eqtl:0.8:rs4144806);LCLAT1(eqtl:1:rs4144806)
2p23.1-1	0	2392679	0.91 0.87 0.88 0.62 0.84	0.01 0.03 0.12 1.33 2.27	165637	165637	2309860	2475497	0.03	0.16	0	0	0	0	2	1	0	0	0	0
2p23.1-1	0	6220389	0.92 0.92 0.78 0.78 0.78	0.01 0.04 0.08 1.03 2.06	165637	165637	6137570	6303207	0.03	0.16	0	0	0	0	0	0	0	0	0	0
2p23.1-1	0	46837075	0.91 0.59 0.84 0.96 0.91	0.0 0.01 0.06 0.58 1.97	165637	165637	46754256	46919893	0.03	0.11	0	0	0	0	5	4	0	0	0	ATP6V1E2(eqtl:0.9:rs57955462);CRIPT(eqtl:0.9:rs57955462);PIGF(eqtl:0.9:rs57955462;sqtl:0.3:rs57955462)
2p23.1-1	0	133505873	0.85 0.79 0.91 0.7 0.89	0.0 0.05 0.09 0.94 2.02	165637	165637	133423054	133588691	0.03	0.11	0	0	0	0	2	0	0	0	0	LYPD1(eqtl:0.4:rs7606532)
2p23.1-1	0	206152106	0.85 0.66 0.92 0.72 0.9	0.02 0.06 0.09 1.1 1.98	165637	165637	206069287	206234924	0.03	0.12	0	0	0	0	1	1	0	0	0	0
2p23.1-1	0	217049473	0.89 0.51 0.83 0.93 0.88	0.0 0.01 0.03 0.93 2.0	165637	165637	216966654	217132291	0.03	0.04	0	0	0	0	4	1	0	0	0	0
2p23.1-1	0	218358998	0.85 0.71 0.77 0.97 0.82	0.01 0.01 0.11 0.51 1.95	165637	165637	218276179	218441816	0.03	0.15	0	0	0	0	1	0	0	0	Breast cancer(rs12473831:1:0.05);FEV1(rs12473831:1:-0.02)	0
2p23.1-1	0	228236106	0.83 0.71 0.9 0.78 0.87	0.03 0.07 0.12 1.0 2.23	165637	165637	228153287	228318924	0.03	0.17	0	0	0	0	5	2	0	0	0	MFF(eqtl:0.8:rs6733389;sqtl:0.1:rs6733389)
2p23.1-1	0	237840437	0.9 0.55 0.88 0.92 0.9	0.01 0.09 0.13 0.77 1.97	165637	165637	237757618	237923255	0.03	0.19	0	0	0	0	0	0	0	0	0	0
4p14	1	36446003	0.51 0.79 0.41 0.48 0.57	0.0 0.01 0.02 0.62 0.9	79618	79617	36434528	36514145	0.02	0.02	0	0	0	0	1	0	0	0	0	ARAP2(eqtl:0.1:rs7658469);DTHD1(eqtl:0.1:rs7437040)
4p14	0	12080007	0.52 0.77 0.58 0.38 0.54	0.01 0.02 0.02 0.5 0.79	79618	79618	12040198	12119816	0.02	0.02	0	0	0	0	0	0	0	0	Photic sneeze reflex(rs9991510:0.76:NA;rs6448862:0.76:NA)	0
4p14	0	31941906	0.53 0.52 0.58 0.57 0.63	0.0 0.01 0.02 0.46 0.93	79618	79618	31902097	31981715	0.02	0.02	0	0	0	0	0	0	0	0	0	0
4p14	0	60453609	0.48 0.55 0.55 0.62 0.55	0.0 0.01 0.03 0.22 0.72	79618	79618	60413800	60493418	0.02	0.02	0	0	0	0	0	0	0	0	0	0
4p14	0	94355622	0.54 0.47 0.52 0.7 0.51	0.0 0.01 0.02 0.37 0.84	79618	79618	94315813	94395431	0.02	0.02	0	0	0	0	1	1	0	0	0	0
4p14	0	101299450	0.5 0.21 0.58 0.92 0.6	0.0 0.01 0.03 0.61 0.79	79618	79618	101259641	101339259	0.02	0.02	0	0	0	0	2	0	0	0	0	DDIT4L(eqtl:0.4:rs12647890);EMCN(sqtl:0.6:rs12647890)
4p14	0	110567758	0.56 0.46 0.69 0.52 0.54	0.0 0.01 0.03 0.28 0.84	79618	79618	110527949	110607567	0.02	0.02	0	0	0	0	1	0	0	0	Risk-taking tendency (4-domain principal component model)(rs5030594:0.62:-0.02)	CASP6(eqtl:0.3:rs12504784);CFI(sqtl:1:rs12504784;pqtl:0.5:rs12504784);MCUB(eqtl:0.9:rs12504784);PLA2G12A(eqtl:0.7:rs12504784;sqtl:1:rs12504784)
4p14	0	113406671	0.47 0.59 0.53 0.65 0.41	0.0 0.01 0.02 0.45 0.75	79618	79618	113366862	113446480	0.02	0.02	0	0	0	0	2	0	0	0	Meat-related diet(rs701760:0.88:NA);Vertex-wise cortical surface area(rs13144474:0.94:-7.51)	LARP7(eqtl:0.5:rs17044746;sqtl:0.5:rs17044746);NEUROG2(eqtl:0.6:rs17044746);ZGRF1(eqtl:0.7:rs17044746;sqtl:0.6:rs17044746)
4p14	0	139075616	0.52 0.55 0.53 0.61 0.58	0.0 0.01 0.06 0.6 1.09	79618	79618	139035807	139115425	0.02	0.02	0	0	0	1	3	0	0	0	Depressive symptoms(rs7674870:0.73:-0.01);Eosinophil counts(rs7674870:0.73:NA;rs13125040:1:-0.01;rs13125040:1:-0.01);Eosinophil percentage of white cells(rs13125040:1:-0.01);Life satisfaction(rs1371325:0.81:0.01);Neurociticism(rs4530683:0.88:0.01);Neuroticism conditioned on Townsend deprivation index (multi-trait conditioning and joint analysis)(rs10519447:0.88:NA);Neuroticism conditioned on average household income before tax (multi-trait conditioning and joint analysis)(rs6842049:0.89:NA);Neuroticism conditioned on cognitive performance (multi-trait conditioning and joint analysis)(rs2241848:0.79:NA);Neuroticism conditioned on educational attainment (multi-trait conditioning and joint analysis)(rs10519447:0.88:NA);Neuroticism conditioned on highest math class (multi-trait conditioning and joint analysis)(rs6836734:0.71:NA);Neuroticism conditioned on self-rated math ability (multi-trait conditioning and joint analysis)(rs6836734:0.71:NA);Neuroticism score(rs10032297:0.81:0.05);Neuroticism(rs10032297:0.81:NA;rs1595693:0.6:-5.54;rs1371325:0.81:0.01;rs6842049:0.89:NA);Positive affect(rs1371325:0.81:0.01);Well-being spectrum (multivariate analysis)(rs1371325:0.81:0.01)	SLC7A11(eqtl:0.2:rs13125040)
4p14	0	168690655	0.51 0.25 0.58 0.85 0.54	0.0 0.01 0.02 0.43 0.96	79618	79618	168650846	168730464	0.02	0.02	0	0	0	0	0	0	0	0	0	0
4q13.2	1	70232423	0.85 0.63 0.75 0.89 0.8	0.01 0.01 0.02 0.19 0.51	205232	205231	70080653	70285884	0.03	0.03	0	0	0	0	2	0	0	0	Vitamin D levels(rs7665631:1:-0.03)	UGT2B11(eqtl:1:rs12499641);UGT2B28(eqtl:0.8:rs6811537);UGT2B4(eqtl:0.3:rs12499641);UGT2B7(sqtl:0.1:rs12499641)
4q13.2	0	19216507	0.81 0.89 0.71 0.63 0.85	0.0 0.01 0.02 0.18 0.65	205232	205232	19113891	19319123	0.03	0.03	0	0	0	0	0	0	0	0	Age at first sexual intercourse(rs34412847:0.6:-0.01);Creatinine levels(rs17495401:0.68:-0.02);Gut microbiota presence (genus Enterorhabdus id.820)(rs207281:0.77:-5.51)	0
4q13.2	0	47818103	0.86 0.78 0.81 0.68 0.77	0.01 0.01 0.03 0.17 0.63	205232	205232	47715487	47920719	0.03	0.04	0	0	0	0	4	1	0	0	0	ATP10D(eqtl:0.2:rs17654526);CNGA1(eqtl:0.9:rs17654526;sqtl:0.3:rs17654526);COMMD8(eqtl:0.5:rs17654526);CORIN(eqtl:0.9:rs17654526);NFXL1(eqtl:1:rs17654526);NIPAL1(eqtl:0.7:rs17654526);TXK(eqtl:0.8:rs17654526)
4q13.2	0	69159696	0.83 0.6 0.9 0.96 0.61	0.0 0.01 0.02 0.04 0.42	205232	205232	69057080	69262312	0.03	0.02	0	0	0	0	4	1	0	0	Mean corpuscular haemoglobin(rs13127027:1:-0.03);Mean corpuscular hemoglobin concentration(rs11732554:0.98:-0.02);Mean corpuscular hemoglobin(rs1730872:0.93:NA;rs34223548:0.93:0.02;rs1406696:0.94:0.02;rs13127027:1:-0.02;rs13127027:1:-0.02);Mean corpuscular volume(rs11732554:0.98:-0.02;rs1715086:0.94:0.1;rs1406696:0.94:0.02;rs1406696:0.94:0.02;rs13127027:1:-0.02;rs13127027:1:-0.09;rs13127027:1:-0.02)	UGT2B17(eqtl:0.4:rs13127027)
4q13.2	0	81523085	0.88 0.58 0.72 0.88 0.89	0.0 0.01 0.02 0.06 0.68	205232	205232	81420469	81625701	0.03	0.02	0	0	0	0	1	0	0	0	0	CFAP299(eqtl:0.7:rs35990705;sqtl:0.6:rs35990705)
4q13.2	0	86108324	0.83 0.86 0.74 0.73 0.81	0.0 0.0 0.01 0.31 0.7	205232	205232	86005708	86210940	0.03	0.04	0	0	0	0	0	0	0	0	0	WDFY3(eqtl:0.3:rs75563480)
4q13.2	0	95077769	0.82 0.78 0.85 0.79 0.69	0.0 0.01 0.02 0.12 0.7	205232	205232	94975153	95180385	0.03	0.05	0	0	0	0	2	1	0	0	"Heel bone mineral density (bmd) t-score, automated(rs10013456:0.77:0.03;rs4693372:1:0.03);Heel bone mineral density (bmd)(rs10013456:0.77:0;rs4693372:1:0);Heel bone mineral density T score(rs10029551:0.84:0.03);Heel bone mineral density(rs10013456:0.77:0.03;rs10013456:0.77:NA;rs10013456:0.77:NA;rs10013456:0.77:0.03;rs4693372:1:0.02;rs4693372:1:0.03);Heel broadband ultrasound attenuation (right)(rs1368708339:0.79:0.52);Heel broadband ultrasound attenuation, direct entry(rs28893245:0.78:0.49;rs4693372:1:0.45);Heel quantitative ultrasound index (qui), direct entry(rs10013456:0.77:0.53;rs4693372:1:0.49);Impedance of arm (right)(rs6813484:0.74:0.71);Impedance of whole body(rs9993839:0.67:1.26;rs4693372:1:1.13);Mean platelet volume(rs12108452:0.68:-0.02;rs17377951:0.62:-0.02;rs17377951:0.62:-0.02;rs4693372:1:-0.02;rs4693372:1:-0.02);Serum levels of protein HPGDS(rs6857003:0.84:0.36)"	HPGDS(pqtl:0.8:rs4693372);PDLIM5(sqtl:0.5:rs4693372);SMARCAD1(eqtl:0.8:rs4693372)
4q13.2	0	100511414	0.88 0.71 0.81 0.55 0.89	0.0 0.01 0.02 0.49 0.61	205232	205232	100408798	100614030	0.03	0.05	6	7	37	332	4	3	0	0	Guilty feelings(rs17029165:0.99:NA;rs4699756:1:-0.04);Height(rs10516446:0.6:NA;rs10516446:0.8:NA);Hip circumference adjusted for BMI(rs10516446:0.6:NA)	TRMT10A(eqtl:0.9:rs4699756;sqtl:0.7:rs4699756)
4q13.2	0	104145981	0.83 0.82 0.67 0.83 0.83	0.0 0.01 0.02 0.27 0.5	205232	205232	104043365	104248597	0.03	0.04	248	288	321	522	1	1	0	0	0	BDH2(eqtl:1:rs56186349);CENPE(eqtl:0.6:rs56186349);MANBA(eqtl:0.4:rs56186349;sqtl:0.2:rs56186349;pqtl:0.1:rs56186349);SLC9B2(eqtl:0.5:rs56186349;sqtl:0.5:rs56186349)
4q13.2	0	106270353	0.81 0.41 0.93 0.97 0.85	0.0 0.01 0.02 0.45 0.64	205232	205232	106167737	106372969	0.03	0.05	0	0	0	0	3	1	0	0	"Heel bone mineral density (bmd) (right)(rs111584493:0.84:0);Heel bone mineral density (bmd) t-score, automated (right)(rs111584493:0.84:-0.04);Heel bone mineral density(rs6857688:1:-0.02);Heel quantitative ultrasound index (qui), direct entry (right)(rs111584493:0.84:-0.64);Serum total protein level(rs66517713:0.69:0.03);Sitting height(rs6857688:1:0.09);Standing height(rs6857688:1:0.16)"	PPA2(eqtl:0.8:rs6857688)
5q11.2	1	52954514	0.17 0.3 0.28 0.49 0.18	0.0 0.0 0.01 0.2 0.6	201077	201076	52853385	53054461	0.03	0.03	0	0	0	0	1	1	0	0	Processed meat intake(rs10454812:0.65:-0.02)	FST(eqtl:0.6:rs535277);NDUFS4(eqtl:0.2:rs535277;sqtl:0.2:rs535277)
5q11.2	0	55020976	0.19 0.19 0.18 0.45 0.45	0.01 0.02 0.02 0.14 0.74	201077	201077	54920437	55121514	0.03	0.03	0	0	0	0	2	2	0	0	Height(rs7704138:0.69:-0.03)	DDX4(eqtl:0.3:rs3900067;sqtl:0.3:rs3900067);SLC38A9(eqtl:0.2:rs3900067)
5q11.2	0	81386756	0.2 0.37 0.35 0.22 0.18	0.0 0.0 0.0 0.15 0.6	201077	201077	81286217	81487294	0.03	0.03	0	0	0	0	1	1	0	0	0	ATG10(eqtl:0.3:rs324912)
5q11.2	0	84885845	0.2 0.23 0.2 0.44 0.27	0.0 0.01 0.01 0.11 0.46	201077	201077	84785306	84986383	0.03	0.02	0	0	0	0	0	0	0	0	0	0
5q11.2	0	91556837	0.22 0.4 0.11 0.44 0.29	0.0 0.0 0.01 0.12 0.65	201077	201077	91456298	91657375	0.03	0.04	0	0	0	0	0	0	0	0	Insomnia(rs35539975:0.96:NA)	0
5q11.2	0	109997119	0.2 0.53 0.27 0.24 0.19	0.0 0.01 0.01 0.12 0.63	201077	201077	109896580	110097657	0.03	0.02	0	0	0	0	2	2	0	0	"Allergic rhinitis(rs114699821:1:0);Allergy, hypersensitivity or anaphylaxis(rs114699821:1:0);Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor(rs114699821:1:0.07);Asthma | non-cancer illness code, self-reported(rs114699821:1:0.07);Asthma(rs114699821:1:0.05;rs114699821:1:0.01);Hayfever, allergic rhinitis or eczema | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor(rs114699821:1:0.07);Hayfever/allergic rhinitis | non-cancer illness code, self-reported(rs114699821:1:0.08);None of the above | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor(rs114699821:1:-0.06);Respiratory or ear-nose-throat disease(rs114699821:1:0.01)"	SLC25A46(eqtl:0.7:rs114699821);TMEM232(eqtl:0.8:rs114699821)
5q11.2	0	114228722	0.18 0.26 0.26 0.27 0.39	0.0 0.01 0.01 0.22 0.64	201077	201077	114128183	114329260	0.03	0.04	0	0	0	0	0	0	0	0	Cardiac arrhytmias(rs12186481:0.72:NA)	0
5q11.2	0	139563208	0.22 0.15 0.51 0.2 0.24	0.0 0.01 0.02 0.39 0.77	201077	201077	139462669	139663746	0.03	0.04	0	0	0	0	6	2	0	0	Serum phosphate levels(rs4913070:0.96:0.02)	CYSTM1(eqtl:0.8:rs37354;sqtl:0.6:rs37354);PFDN1(eqtl:0.6:rs37354);SRA1(eqtl:0.5:rs37354)
5q11.2	0	144230668	0.17 0.36 0.24 0.38 0.19	0.0 0.01 0.02 0.13 0.51	201077	201077	144130129	144331206	0.03	0.03	0	0	0	0	0	0	0	0	0	YIPF5(eqtl:0.4:rs7727080)
5q11.2	0	152177113	0.22 0.16 0.17 0.55 0.29	0.01 0.01 0.02 0.15 0.43	201077	201077	152076574	152277651	0.03	0.04	0	0	0	0	1	0	0	0	0	0
5q21.3	1	109123878	0.15 0.05 0.38 0.62 0.24	0.0 0.01 0.01 0.52 1.34	137369	137368	109053314	109190682	0.02	0.02	0	0	0	0	1	0	0	0	Coagulation factor XIII measurement(rs12657204:0.98:0.14);Schizophrenia(rs4388249:0.94:NA;rs4388249:0.94:NA;rs4388249:0.94:NA)	MAN2A1(eqtl:0.5:rs961663;sqtl:0.6:rs961663);PJA2(eqtl:0.5:rs961663)
5q21.3	0	25989054	0.2 0.53 0.18 0.25 0.32	0.01 0.04 0.07 0.45 1.22	137369	137369	25920369	26057738	0.02	0.07	0	0	0	1	0	0	0	0	0	0
5q21.3	0	30743725	0.15 0.33 0.28 0.38 0.26	0.01 0.02 0.04 0.57 1.25	137369	137369	30675040	30812409	0.02	0.06	0	0	0	0	0	0	0	0	0	0
5q21.3	0	37700502	0.14 0.7 0.3 0.1 0.14	0.0 0.0 0.01 0.67 1.21	137369	137369	37631817	37769186	0.02	0.04	0	0	0	0	1	1	0	0	Appendicular lean mass(rs11953199:1:-0.02)	WDR70(eqtl:0.3:rs11953199;sqtl:0.1:rs11953199)
5q21.3	0	56077993	0.19 0.33 0.22 0.43 0.36	0.0 0.01 0.02 0.72 1.49	137369	137369	56009308	56146677	0.02	0.02	0	0	0	0	2	0	0	0	0	0
5q21.3	0	78689118	0.11 0.35 0.15 0.44 0.3	0.0 0.01 0.04 0.23 1.34	137369	137369	78620433	78757802	0.02	0.05	0	0	0	0	2	1	0	0	0	JMY(eqtl:0.6:rs6895195)
5q21.3	0	135074697	0.16 0.54 0.22 0.23 0.36	0.0 0.01 0.04 0.65 1.4	137369	137369	135006012	135143381	0.02	0.04	0	0	0	0	2	0	0	0	0	SLC25A48(sqtl:0.5:rs12515479)
5q21.3	0	140843364	0.19 0.5 0.27 0.19 0.25	0.0 0.02 0.04 0.38 1.22	137369	137369	140774679	140912048	0.02	0.04	0	1	1	1	24	0	0	7	Mean platelet (thrombocyte) volume(rs58523023:1:0.02);Mean platelet volume(rs58523023:1:0.02;rs58523023:1:0.01)	ARAP3(eqtl:0.8:rs58523023);PCDHGA6(eqtl:0.2:rs58523023);RELL2(eqtl:0.1:rs58523023);SRA1(eqtl:0.2:rs58523023)
5q21.3	0	147949611	0.15 0.63 0.14 0.24 0.26	0.0 0.02 0.05 0.62 1.27	137369	137369	147880926	148018295	0.02	0.06	0	0	0	0	1	0	0	0	0	0
5q21.3	0	151252032	0.17 0.04 0.35 0.63 0.27	0.0 0.01 0.02 0.36 1.27	137369	137369	151183347	151320716	0.02	0.03	0	0	0	0	2	0	0	0	0	ATOX1(eqtl:0.8:rs6869666)
5q23.1	1	115510953	0.18 0.7 0.15 0.2 0.26	0.0 0.01 0.02 0.44 1.74	173416	173415	115423526	115596941	0.03	0.03	0	0	0	0	2	0	0	1	Ankle-brachial index [Puerto Rican](rs4466200:0.7:-0.02);Body mass index(rs9327000:0.73:NA)	COMMD10(eqtl:1:rs13159102;sqtl:0.5:rs10069947);SEMA6A(eqtl:0.7:rs1396478)
5q23.1	0	33219521	0.15 0.47 0.17 0.43 0.2	0.0 0.02 0.04 0.36 1.68	173416	173416	33132813	33306229	0.03	0.06	0	0	0	0	1	0	0	0	Height(rs112958363:0.75:NA);Lung function (FVC)(rs73083169:1:0.02)	0
5q23.1	0	56128999	0.19 0.3 0.22 0.43 0.35	0.0 0.0 0.0 0.88 1.56	173416	173416	56042291	56215707	0.03	0.03	0	0	0	0	4	2	0	0	C-reactive protein levels(rs28710284:0.99:0.02;rs2432195:0.99:0.02);Diastolic blood pressure(rs832582:1:0.01);Standing height(rs863840:1:0.11);Vertex-wise sulcal depth(rs702689:0.61:-9.75)	MAP3K1(eqtl:0.2:rs863840);MIER3(eqtl:0.4:rs863840);SETD9(eqtl:1:rs863840;sqtl:0.5:rs863840)
5q23.1	0	66020457	0.18 0.1 0.29 0.47 0.36	0.02 0.06 0.07 0.74 1.87	173416	173416	65933749	66107165	0.03	0.09	0	0	0	0	1	1	0	0	Seborrheic dermatitis(rs58331610:1:NA)	0
5q23.1	0	76623931	0.2 0.54 0.15 0.33 0.22	0.01 0.02 0.05 0.76 1.61	173416	173416	76537223	76710639	0.03	0.12	0	0	0	0	1	1	0	0	"""Hypothyroidism,  other/unspecified""(rs7717216:1:0.07);""Hypothyroidism, strict autoimmune""(rs7717216:1:0.08);""Hypothyroidism, strict autoimmune, 3 medication purchases required""(rs7717216:1:0.07)"	WDR41(eqtl:0.8:rs7717216)
5q23.1	0	77698222	0.23 0.15 0.25 0.37 0.48	0.0 0.0 0.01 0.36 1.64	173416	173416	77611514	77784930	0.03	0.11	0	0	0	0	3	1	0	0	Arm fat-free mass (left)(rs10805920:1:-0.01);Arm fat-free mass (right)(rs10805920:1:-0.01);Arm predicted mass (right)(rs10805920:1:-0.01);Bipolar disorder or major depressive disorder(rs4529173:0.86:NA);Highest math class taken(rs1560197:0.84:-0.02);Self-reported math ability (MTAG) [MTAG](rs6896927:1:-0.01);Self-reported math ability(rs6896927:1:-0.01);Whole body fat-free mass(rs10805920:1:-0.09);Whole body water mass(rs10805920:1:-0.07)	AP3B1(eqtl:0.4:rs10805920);SCAMP1(eqtl:0.9:rs10805920)
5q23.1	0	125502626	0.23 0.25 0.26 0.35 0.38	0.0 0.01 0.03 0.31 1.63	173416	173416	125415918	125589334	0.03	0.04	0	0	0	0	1	0	0	0	0	0
5q23.1	0	150174527	0.15 0.23 0.29 0.63 0.16	0.03 0.07 0.07 0.51 1.69	173416	173416	150087819	150261235	0.03	0.08	0	0	0	16	3	0	0	0	Crohn's disease vs rheumatoid arthritis (ordinary least squares (OLS))(rs72660274:1:0.05);Crohn's disease(rs72660274:1:0.2);Inflammatory bowel disease(rs72660274:1:0.12)	IRGM(eqtl:0.8:rs72660274);RBM22(eqtl:0.5:rs72660274);TNIP1(eqtl:0.2:rs72660274);ZNF300(eqtl:0.7:rs72660274)
5q23.1	0	150721871	0.2 0.5 0.33 0.41 0.13	0.03 0.05 0.07 1.27 1.93	173416	173416	150635163	150808579	0.03	0.12	0	0	0	14	3	2	0	0	0	GM2A(eqtl:0.2:rs12654497);SLC36A1(eqtl:0.1:rs12654497);SLC36A2(sqtl:0.2:rs12654497)
5q23.1	0	159040143	0.22 0.63 0.2 0.26 0.23	0.0 0.01 0.05 1.04 1.63	173416	173416	158953435	159126851	0.03	0.11	0	0	0	0	0	0	0	0	0	0
6p21.2	1	37933881	0.35 0.1 0.21 0.09 0.28	0.0 0.0 0.01 0.31 1.12	344149	344148	37774460	38118608	0.03	0.03	0	0	0	0	1	1	1	1	0	BTBD9(eqtl:0.5:rs259723);GLO1(eqtl:0.3:rs11756656);MDGA1(eqtl:0.8:rs7755089);ZFAND3(eqtl:0.7:rs259723;sqtl:0.8:rs259723)
6p21.2	0	44710152	0.33 0.24 0.2 0.04 0.22	0.0 0.01 0.03 0.55 1.09	344149	344149	44538077	44882226	0.03	0.21	0	0	0	0	1	1	0	0	Appendicular lean mass(rs10807302:1:-0.01;rs10807302:1:-0.02);Body mass index(rs857601:0.82:0.01);Chin dimples(rs17336368:1:NA);Heel bone mineral density(rs10807302:1:-0.01);Hip minimal joint space width(rs10948155:0.81:-0.07);Impedance of leg (left)(NA:0.73:0.66;rs10807302:1:0.56);Impedance of leg (right)(rs111997036:0.71:0.65;rs10807302:1:0.56);Impedance of whole body(NA:0.73:1.2;rs10807302:1:1.03);Osteoarthritis (hip)(rs10948172:0.83:NA;rs10807302:1:0.07);Osteoarthritis; localized(rs10948196:0.66:NA);Pattern 1 | hair/balding pattern(rs10807302:1:-0.05);Pattern 4 | hair/balding pattern(rs10807302:1:0.06);Red blood cell count(rs860741:0.89:NA;rs10807302:1:-0.01);Total body bone mineral density(rs184065563:0.71:-0.04)	RUNX2(eqtl:0.6:rs10807302;sqtl:0.5:rs10807302);SUPT3H(eqtl:0.9:rs10807302)
6p21.2	0	71341048	0.31 0.08 0.18 0.13 0.26	0.01 0.13 0.15 0.22 0.97	344149	344149	71168973	71513122	0.03	0.17	0	0	0	0	3	2	0	0	Mean platelet (thrombocyte) volume(rs2691475:0.65:0.02;rs2462508:1:0.02);Mean platelet volume(rs2691475:0.65:0.02;rs2691475:0.65:0.02;rs1917342:0.99:0.02;rs2462508:1:0.02;rs2462508:1:0.02);Platelet distribution width(rs2842061:0.99:0.02;rs2494979:1:0.02;rs2462506:0.97:0.01;rs2462508:1:0.01;rs2462508:1:0.02;rs2462508:1:0.02)	SMAP1(eqtl:0.8:rs2462508;pqtl:0.5:rs2462508)
6p21.2	0	89512208	0.3 0.03 0.22 0.18 0.28	0.0 0.0 0.01 0.36 0.95	344149	344149	89340133	89684282	0.03	0.08	0	0	0	0	1	1	1	1	0	RNGTT(eqtl:0.9:rs12204839)
6p21.2	0	90204719	0.34 0.16 0.24 0.03 0.22	0.01 0.01 0.01 0.46 1.09	344149	344149	90032644	90376793	0.03	0.21	0	0	0	0	6	3	0	0	0	LYRM2(eqtl:0.6:rs10944449);RRAGD(eqtl:0.9:rs10944449);UBE2J1(eqtl:0.2:rs10944449)
6p21.2	0	102400144	0.38 0.01 0.26 0.07 0.27	0.02 0.03 0.04 0.57 1.03	344149	344149	102228069	102572218	0.03	0.14	0	0	0	0	1	0	0	0	0	0
6p21.2	0	131114301	0.34 0.05 0.31 0.05 0.25	0.03 0.09 0.11 0.44 1.0	344149	344149	130942226	131286375	0.03	0.19	0	0	0	0	2	1	0	0	"Forced expiratory volume in 1-second (fev1), best measure(rs761840:1:-0.01);Forced vital capacity (fvc)(rs761840:1:-0.01);Forced vital capacity (fvc), best measure(rs1338872735:0.67:-0.01;rs761840:1:-0.01);Monocyte count(rs761840:1:0.01);Platelet count(rs761841:0.72:0.01;rs761840:1:0.01;rs761840:1:0.01)"	AKAP7(eqtl:0.4:rs761840);EPB41L2(sqtl:0.1:rs761840)
6p21.2	0	133325650	0.33 0.07 0.2 0.13 0.21	0.0 0.01 0.04 0.28 1.06	344149	344149	133153575	133497724	0.03	0.14	0	0	0	0	1	0	0	0	"Bone mineral density (paediatric, skull) [EA](rs3012465:0.84:0.12);Bone mineral density (paediatric, skull)(rs3012465:0.84:0.13);Bone mineral density [Cortical vBMD](rs271170:0.99:0.11);Heel bone mineral density (bmd) (left)(rs4053080:1:0);Heel bone mineral density (bmd) (right)(rs1451085653:0.87:-0.01;rs4053080:1:-0.01);Heel bone mineral density (bmd) t-score, automated (left)(rs4053080:1:-0.04);Heel bone mineral density (bmd) t-score, automated (right)(rs1451085653:0.87:-0.05;rs4053080:1:-0.05);Heel bone mineral density (bmd) t-score, automated(rs2926352:0.95:-0.04;rs4053080:1:-0.04);Heel bone mineral density (bmd)(rs2926352:0.95:0;rs4053080:1:0);Heel bone mineral density T score(rs2926349:0.94:-0.04);Heel bone mineral density(rs3012465:0.84:-0.04;rs3012465:0.84:-0.04;rs4053080:1:-0.04;rs4053080:1:-0.04);Heel broadband ultrasound attenuation (right)(rs1451085653:0.87:-0.89;rs4053080:1:-0.85);Heel broadband ultrasound attenuation, direct entry(rs34115816:0.9:0.74;rs4053080:1:-0.71);Heel quantitative ultrasound index (qui), direct entry (right)(rs1451085653:0.87:-0.94;rs4053080:1:-0.89);Heel quantitative ultrasound index (qui), direct entry(rs2926352:0.95:-0.74;rs4053080:1:-0.72)"	SLC18B1(eqtl:0.5:rs4053080);VNN2(sqtl:0.1:rs4053080)
6p21.2	0	136795028	0.34 0.02 0.18 0.18 0.26	0.0 0.01 0.01 0.55 1.11	344149	344149	136622953	136967102	0.03	0.18	0	0	0	0	3	1	0	0	0	0
6p21.2	0	160890842	0.32 0.3 0.22 0.1 0.15	0.0 0.01 0.03 0.35 0.96	344149	344149	160718767	161062916	0.03	0.1	4	5	5	5	3	0	0	0	"Angiostatin measurement(rs1112073:1:-0.14);Cholesterol, total(rs1112073:1:0.03);Coronary artery disease(rs1112073:1:0.03);High cholesterol(rs1112073:1:0);Low density lipoprotein cholesterol levels(rs1112073:1:0.03);Mean reticulocyte volume(rs3124784:0.86:-0.01;rs1112073:1:-0.01);Plasminogen measurement(rs1112073:1:-0.11);Prostate cancer(rs1112073:1:0.06);Sex hormone-binding globulin levels adjusted for BMI(rs1112073:1:-0.01;rs1112073:1:-0.01;rs1112073:1:-0.01);Sex hormone-binding globulin levels(rs1112073:1:-0.01;rs1112073:1:-0.01;rs1112073:1:-0.01);Standing height(rs1112073:1:-0.09);Triglyceride levels(rs3127599:0.97:0.02)"	PLG(pqtl:0.7:rs1112073);SLC22A3(eqtl:0.1:rs1112073;sqtl:0.1:rs1112073)
6p21.1	1	45184453	0.5 0.79 0.61 0.73 0.55	0.0 0.0 0.01 0.17 0.55	339727	339726	45009722	45349448	0.03	0.03	0	0	0	0	3	2	0	0	"Appendicular lean mass(rs3957281:0.72:-0.05;rs1159131:0.71:-0.03;rs9357470:0.93:0.02;rs9357471:0.87:0.02);Arm fat-free mass (left)(rs112143344:0.81:0.01);Arm fat-free mass (right)(rs9395069:0.86:0.01);Arm predicted mass (left)(rs112143344:0.81:0.01);Basal metabolic rate(rs9395069:0.87:13.09);Body mass index(rs857601:0.89:0.01);Chin dimples(rs17336368:0.74:NA);Estimated glomerular filtration rate(rs720989:0.61:0);Facial morphology (forehead protrusion 1)(rs10948192:0.77:NA);Glaucoma (multi-trait analysis)(rs2145826:0.79:-0.07);Heel bone mineral density (bmd) (right)(rs227831:0.64:0);Heel bone mineral density (bmd) t-score, automated (left)(rs227831:0.64:-0.03);Heel bone mineral density (bmd) t-score, automated (right)(rs227831:0.64:-0.04);Heel bone mineral density(rs5875893:0.65:0.03);Heel quantitative ultrasound index (qui), direct entry (right)(rs227831:0.64:-0.66);Height(rs6938592:0.61:NA;rs3799969:0.89:NA;rs9395066:0.93:0.02);Impedance of arm (right)(rs573931721:0.91:0.56);Impedance of leg (left)(NA:1:0.66);Impedance of leg (right)(rs111997036:0.98:0.65);Impedance of whole body(NA:1:1.2);Leg fat-free mass (right)(rs9395069:0.86:0.02);Leg predicted mass (right)(rs9395069:0.87:0.02);Lung function (FVC)(rs9369530:1:-0.01;rs9349309:1:NA);Lymphocyte counts(rs227849:0.68:0.01;rs9395049:0.74:-0.01;rs9395049:0.74:-0.01);Male-pattern baldness(rs559694420:0.69:-0.05);Nose morphology(rs66604011:1:NA;rs4714845:1:NA;rs12208924:0.87:NA);Nose size(rs778450774:0.76:NA);Osteoarthritis (hip)(rs10948172:0.89:NA);Osteoarthritis of the hip or knee(rs12193102:0.61:NA);Otosclerosis(rs13192457:0.82:NA);Red blood cell count(rs860741:0.7:NA);Sitting height(rs9357471:0.87:0.11);Total body bone mineral density (age over 60)(rs184065563:0.99:-0.06);Total body bone mineral density [European](rs12201899:1:-0.05);Total body bone mineral density(rs184065563:1:-0.04);Trunk fat-free mass(rs9395069:0.87:0.06);Trunk predicted mass(rs9395069:0.86:0.06);Type 2 diabetes(rs538801:0.92:NA);White matter microstructure (axial diusivities) [Corticospinal tract ](rs5875893:0.65:NA);White matter microstructure (mean diusivities) [Corticospinal tract ](rs227847:0.65:NA;rs5875893:0.65:NA;rs7763421:0.71:NA);Whole body fat-free mass(rs9395069:0.86:0.11);Whole body water mass(rs9395069:0.87:0.08);facial morphology traits (multivariate analysis)(rs1852985:0.96:NA);middle facial morphology traits (quantitative measurement) [Nose bridge breadth](rs1852985:0.96:0)"	ENPP4(eqtl:0.2:rs1285005);RUNX2(sqtl:0.9:rs9381365;eqtl:0.8:rs1300126);SUPT3H(eqtl:1:rs6933553)
6p21.1	0	25883106	0.48 0.81 0.56 0.71 0.6	0.01 0.02 0.03 0.21 0.75	339727	339727	25713242	26052969	0.03	0.08	289	394	420	466	16	1	0	0	"Celiac disease(rs596774:1:0.26);Disorders of iron metabolism(rs596774:1:-1.06);Disorders of mineral metabolism(rs596774:1:-0.29);FEV1(rs596774:1:-0.01);Forced expiratory volume in 1-second (fev1)(rs596774:1:-0.01);Forced expiratory volume in 1-second (fev1), best measure(rs596774:1:-0.01);Intestinal malabsorption (non-celiac)(rs596774:1:0.24);Liver iron content(rs596774:1:-0.04);Lymphocyte counts(rs596774:1:-0.02;rs596774:1:-0.02;rs596774:1:-0.02);Malabsorption/coeliac disease | non-cancer illness code, self-reported(rs596774:1:0.3);Monocyte count(rs596774:1:-0.01);Peak expiratory flow(rs596774:1:-0.01);Red cell distribution width(rs596774:1:-0.01;rs596774:1:-0.01);Type 1 diabetes(rs596774:1:0.14);Urate levels(rs596774:1:0.02)"	BTN2A1(eqtl:0.4:rs596774);BTN3A1(eqtl:0.5:rs596774);BTN3A2(eqtl:0.8:rs596774);CARMIL1(eqtl:0.4:rs596774);H2BC5(eqtl:0.6:rs596774);H4C3(eqtl:0.5:rs596774);H4C8(eqtl:0.3:rs596774);HMGN4(eqtl:0.4:rs596774);SLC17A1(eqtl:0.8:rs596774);SLC17A3(eqtl:0.9:rs596774;sqtl:0.5:rs596774);TRIM38(eqtl:0.4:rs596774)
6p21.1	0	48098680	0.54 0.61 0.61 0.68 0.7	0.01 0.03 0.03 0.22 0.54	339727	339727	47928816	48268543	0.03	0.09	0	0	0	0	1	0	0	0	0	0
6p21.1	0	81493824	0.54 0.68 0.7 0.69 0.51	0.0 0.01 0.02 0.15 0.39	339727	339727	81323960	81663687	0.03	0.09	0	0	0	0	0	0	0	0	Cystatin C levels(rs3903133:1:-0.02);Scavenger receptor class A member 5 measurement(rs1377985:0.93:0.08;rs9361656:1:-0.07);Waist circumference adjusted for body mass index(rs1339382:0.61:NA;rs1339382:0.61:-0.03);Waist-hip ratio(rs9352872:1:NA);Waist-to-hip ratio adjusted for BMI(rs1339382:0.61:NA;rs6900642:0.67:-0.02)	0
6p21.1	0	83183465	0.52 0.54 0.7 0.72 0.6	0.0 0.0 0.02 0.14 0.6	339727	339727	83013601	83353328	0.03	0.09	0	0	0	0	1	0	0	0	0	0
6p21.1	0	87279401	0.53 0.92 0.52 0.56 0.59	0.0 0.01 0.02 0.21 0.45	339727	339727	87109537	87449264	0.03	0.09	0	0	0	0	0	0	0	0	0	0
6p21.1	0	101204126	0.49 0.66 0.78 0.74 0.53	0.0 0.0 0.01 0.07 0.43	339727	339727	101034262	101373989	0.03	0.05	0	0	0	0	1	1	0	0	Age at first sexual intercourse(rs9386250:1:-0.01);Age when periods started (menarche)(rs11458788:0.79:-0.02;rs9386250:1:-0.02);Arm fat-free mass (left)(rs11458788:0.79:0.01;rs9386250:1:0.01);Arm fat-free mass (right)(rs11458788:0.79:0.01;rs9386250:1:0.01);Arm predicted mass (left)(rs11458788:0.79:0.01;rs9386250:1:0.01);Arm predicted mass (right)(rs11458788:0.79:0.01;rs9386250:1:0.01);Basal metabolic rate(rs9386250:1:11.34);Body mass index (bmi)(rs240764:0.78:0.06);Depression(rs240764:0.78:0.02);Depressive symptoms(rs4461738:0.81:0.01);Impedance of arm (left)(rs11458788:0.79:-0.64;rs9386250:1:-0.56);Impedance of arm (right)(rs11458788:0.79:-0.62;rs9386250:1:-0.55);Impedance of leg (left)(rs9386250:1:-0.42);Impedance of whole body(rs11458788:0.79:-1.13;rs9386250:1:-1.07);Lifetime number of sexual partners(rs9386250:1:0.01);Neuroticism(rs240764:0.78:0.03;rs4461738:0.81:0.01);Positive affect(rs4461738:0.81:0.01);Trunk fat-free mass(rs11458788:0.79:0.05;rs9386250:1:0.05);Trunk predicted mass(rs11458788:0.79:0.05;rs9386250:1:0.04);Well-being spectrum (multivariate analysis)(rs4461738:0.81:0.01);Whole body fat-free mass(rs11458788:0.79:0.09;rs9386250:1:0.09);Whole body water mass(rs11458788:0.79:0.07;rs9386250:1:0.06)	ASCC3(eqtl:0.8:rs9386250;sqtl:0.7:rs9386250);GRIK2(eqtl:0.3:rs9386250)
6p21.1	0	111641850	0.5 0.95 0.5 0.58 0.56	0.0 0.01 0.01 0.19 0.55	339727	339727	111471986	111811713	0.03	0.05	0	0	0	0	4	3	0	0	Hair color(rs7760535:0.76:NA);Mean corpuscular hemoglobin(rs457492:1:-0.01;rs457492:1:-0.01);Mean corpuscular volume(rs457492:1:-0.01;rs457492:1:-0.06;rs457492:1:-0.01);Mean reticulocyte volume(rs457492:1:-0.01;rs457492:1:-0.11);Mean spheric corpuscular volume(rs457492:1:-0.01);Metabolic traits [isoleucine/tyrosine + 10 other traits](rs7760535:0.76:NA);Psoriasis(rs456865:1:NA)	MFSD4B(eqtl:0.6:rs457492);REV3L(eqtl:0.2:rs457492);TRAF3IP2(eqtl:0.8:rs457492)
6p21.1	0	114831921	0.53 0.76 0.42 0.69 0.71	0.0 0.03 0.05 0.32 0.57	339727	339727	114662057	115001784	0.03	0.08	0	0	0	0	1	0	0	0	0	0
6p21.1	0	127054588	0.49 0.3 0.69 0.97 0.68	0.0 0.0 0.01 0.05 0.38	339727	339727	126884724	127224451	0.03	0.03	0	0	0	0	0	0	0	0	"""Diabetes, insuline treatment (Kela reimbursement)""(rs1262557:1:-0.05);Age when periods started (menarche)(rs1262557:1:0.02);Ankle spacing width(rs1262557:1:-0.07);Appendicular lean mass(rs9388490:0.61:0.05;rs1262557:1:-0.04;rs1262557:1:-0.04;rs1262557:1:-0.04);Arm fat percentage (left)(rs1262557:1:0.11);Arm fat percentage (right)(rs1262557:1:0.11);Arm fat-free mass (left)(rs1262557:1:-0.01);Arm fat-free mass (right)(rs9388490:0.61:0.01;rs1262557:1:-0.01);Arm predicted mass (left)(rs1262557:1:-0.01);Arm predicted mass (right)(rs1262557:1:-0.01);Basal metabolic rate(rs1262557:1:-20.86);Body fat percentage(rs1262557:1:0.1);Brain region volumes [left lateral orbitofrontal](rs17754780:0.65:NA);Comparative height size at age 10(rs1262557:1:-0.03);Coronary artery disease(rs1262557:1:0.03);Feeling nervous(rs6919397:0.65:-0.01);Forced expiratory volume in 1-second (fev1)(rs1262557:1:-0.01);Forced expiratory volume in 1-second (fev1), best measure(rs1262557:1:-0.01);Forced expiratory volume in 1-second (fev1), predicted(rs1262557:1:-0.01);Forced vital capacity (fvc)(rs1262557:1:-0.02);Forced vital capacity (fvc), best measure(rs1262557:1:-0.02);Haematocrit percentage(rs9375435:0.64:-0.06;rs1262557:1:0.04);Haemoglobin concentration(rs1262557:1:0.01);Hematocrit(rs1262557:1:0.02;rs1262557:1:0.02;rs1262557:1:0.02);Hemoglobin concentration(rs1262557:1:0.02);Hemoglobin(rs1262557:1:0.02);Highest math class taken(rs9388490:0.61:0.01);Hip circumference adjusted for BMI(rs1030807851:0.65:0.03);Impedance of arm (left)(rs35510806:0.73:-0.61);Impedance of arm (right)(rs9388487:0.73:-0.58);Impedance of whole body(rs9398803:0.73:-1.11);Kidney volume(rs1262557:1:-0.04);Leg fat percentage (left)(rs1262557:1:0.08);Leg fat percentage (right)(rs1262557:1:0.08);Leg fat-free mass (left)(rs9388490:0.61:0.03;rs1262557:1:-0.02);Leg fat-free mass (right)(rs1262557:1:-0.02);Leg predicted mass (left)(rs1262557:1:-0.02);Leg predicted mass (right)(rs1262557:1:-0.02);Liver volume(rs1262557:1:-0.04);Low density lipoprotein cholesterol levels(rs1262557:1:0.01);Lung function (FEV1/FVC)(rs9398804:0.64:NA);Lung function (FVC)(rs1262557:1:-0.02);Male-pattern baldness(rs9398803:0.73:0.12;rs1262557:1:0.05);Neutrophil count(rs1262557:1:0.01;rs1262557:1:0.01);Neutrophill count(rs1262557:1:0.02);Pattern 1 | hair/balding pattern(rs1262557:1:-0.08);Pattern 3 | hair/balding pattern(rs1262557:1:0.06);Pattern 4 | hair/balding pattern(rs9398803:0.73:NA;rs1262557:1:0.09);Red blood cell count(rs1262557:1:0.01;rs1262557:1:0.01);Serum phosphate levels(rs9388489:0.65:0.02);Sex hormone-binding globulin levels adjusted for BMI(rs1262557:1:0.01;rs1262557:1:0.01);Sitting height(rs1262557:1:-0.14);Standing height(rs1262557:1:-0.29);Trunk fat percentage(rs1262557:1:0.1);Trunk fat-free mass(rs1262557:1:-0.11);Trunk predicted mass(rs9388490:0.61:0.13;rs1262557:1:-0.11);Type 1 diabetes(rs2045258:0.65:NA;rs9388489:0.65:NA;rs1262557:1:-0.08);Weight(rs9388490:0.61:0.22);White blood cell (leukocyte) count(rs1262557:1:0.03);White blood cell count(rs1262557:1:0.01;rs1262557:1:0.01);Whole body fat-free mass(rs9388490:0.61:0.23;rs1262557:1:-0.18);Whole body water mass(rs1262557:1:-0.13)"	CENPW(eqtl:0.7:rs1262557)
6p11.2	1	57491547	0.18 0.01 0.28 0.08 0.14	0.0 0.01 0.02 0.09 0.32	346139	346138	57317174	57663312	0.06	0.06	0	0	0	0	1	0	0	0	Chronotype(rs9476310:0.6:NA);Daytime nap(rs113493369:0.62:-0.01);Lung function (FEV1/FVC)(NA:0.79:-0.02);Peak expiratory flow(NA:0.81:-0.02);Pulse pressure(rs9404922:0.73:0.01);Serum 25-Hydroxyvitamin D levels(rs9476310:0.6:0.01;rs9476310:0.6:0.01;rs9476310:0.6:0.01;rs9476310:0.6:0.01;rs9476310:0.6:0.01)	RAB23(eqtl:0.4:rs7745064)
6p11.2	0	26573631	0.13 0.19 0.17 0.12 0.07	0.0 0.01 0.01 0.19 0.35	346139	346139	26400561	26746700	0.06	0.05	99	119	160	205	11	6	0	0	"Abdominal hernia(rs13214027:1:-0.06);Ankle spacing width(rs13214027:1:0.1);Arm fat mass (left)(rs13214027:1:0.01);Arm fat mass (right)(rs13214027:1:0.01);Autoimmune diseases(rs13214027:1:0.09);Barrett's esophagus(rs13214027:1:-0.13);Basophil count(rs3734537:0.76:NA;rs13214027:1:-0.02;rs13214027:1:-0.02);Body mass index (bmi)(rs13214027:1:0.09);Celiac disease(rs13214027:1:1.05);Coeliac disease(rs13214027:1:0.71);Cognitive performance(rs13214027:1:0.03);Connective tissue disorder(rs13214027:1:0);Daytime nap(rs13214027:1:-0.01);Dentures | mouth/teeth dental problems(rs13214027:1:0.05);Dermatitis herpetiformis(rs13214027:1:0.89);Diabetes or endocrine disease(rs13214027:1:0.01);Disorders of iron metabolism(rs13214027:1:-0.59);Doctor diagnosed sarcoidosis(rs13214027:1:0.68);Eosinophil counts(rs2072806:0.75:-0.04;rs9358938:0.73:-0.04;rs3734537:0.76:NA;rs13214027:1:-0.04;rs13214027:1:-0.04;rs13214027:1:-0.04);Eosinophil percentage of white cells(rs13214027:1:-0.02);Eosinophill count(rs13214027:1:-0.03);Esophageal disorder(rs13214027:1:0);FEV1(rs13214027:1:-0.04);Fluid intelligence score(rs13214027:1:0.07);Forced expiratory volume in 1-second (fev1)(rs13214027:1:-0.02);Forced expiratory volume in 1-second (fev1), best measure(rs13214027:1:-0.02);Forced expiratory volume in 1-second (fev1), predicted percentage(rs13214027:1:-0.76);Forced vital capacity (fvc)(rs13214027:1:-0.02);Forced vital capacity (fvc), best measure(rs13214027:1:-0.02);Gastroesophageal reflux disease(rs13214027:1:-0.04);Granulocyte count(rs13214027:1:-0.04);Haematocrit percentage(rs13214027:1:-0.11);Haemoglobin concentration(rs13214027:1:-0.05);Headache | pain type(s) experienced in last month(rs2072803:0.75:NA;rs13214027:1:-0.05);Headache(rs2072806:0.75:NA);Heel bone mineral density(rs13214027:1:0.02);Hematocrit(rs13214027:1:-0.04;rs13214027:1:-0.04;rs13214027:1:-0.04);Hematuria(rs13214027:1:-0.1);Hemoglobin concentration(rs13214027:1:-0.05;rs13214027:1:-0.05);Hemoglobin levels(rs13214027:1:-0.03);Hemoglobin(rs13214027:1:-0.05);High light scatter reticulocyte count(rs13214027:1:0;rs13214027:1:-0.03;rs13214027:1:-0.03);High light scatter reticulocyte percentage of red cells(rs13214027:1:-0.03);Hip circumference(rs13214027:1:0.21);Hyperthyroidism or thyrotoxicosis(rs13214027:1:0);Hyperthyroidism/thyrotoxicosis | non-cancer illness code, self-reported(rs13214027:1:0.31);Hypothyroidism nos(rs13214027:1:0.12);Hypothyroidism(rs13214027:1:0.11);Insulin product | treatment/medication code(rs13214027:1:0.2);Intestinal malabsorption (non-celiac)(rs13214027:1:0.92);Leg fat mass (left)(rs13214027:1:0.03);Leg fat mass (right)(rs13214027:1:0.03);Leg fat-free mass (left)(rs13214027:1:0.02);Leg predicted mass (left)(rs13214027:1:0.02);Liver iron content(rs13214027:1:-0.07);Lung function (FEV1/FVC)(rs13214027:1:-0.02);Lung function (FVC)(rs13214027:1:-0.03);Lymphocyte count(rs13214027:1:-0.03);Lymphocyte counts(rs12176317:0.69:-0.06;rs3734537:0.76:NA;rs13214027:1:-0.06;rs13214027:1:-0.06;rs13214027:1:-0.06);Lymphocyte percentage of white cells(rs13214027:1:-0.02);Major depressive disorder(rs58825580:0.65:NA);Malabsorption/coeliac disease | non-cancer illness code, self-reported(rs13214027:1:1.17);Mean corpuscular haemoglobin concentration(rs13214027:1:-0.03);Mean corpuscular haemoglobin(rs13214027:1:-0.08);Mean corpuscular hemoglobin concentration(rs13214027:1:-0.03;rs13214027:1:-0.03;rs13214027:1:-0.04;rs13214027:1:-0.03);Mean corpuscular hemoglobin(rs13214027:1:-0.05;rs13214027:1:-0.04;rs13214027:1:-0.05);Mean corpuscular volume(rs13214027:1:-0.04;rs13214027:1:-0.04;rs13214027:1:-0.17;rs13214027:1:-0.03;rs13214027:1:-0.04);Mean reticulocyte volume(rs13214027:1:0.2;rs13214027:1:0.04);Membranous nephropathy(rs13214027:1:0.55);Monocyte count(rs9393703:0.68:-0.01;rs3734537:0.76:NA;rs13214027:1:-0.04;rs13214027:1:-0.05;rs13214027:1:-0.01);Myeloid white cell count(rs13214027:1:-0.04);Neutrophil count(rs3734537:0.76:NA;rs13214027:1:-0.03;rs13214027:1:-0.03;rs13214027:1:-0.03);Neutrophil percentage of white cells(rs13214027:1:0.02);Neutrophill count(rs13214027:1:-0.04);Neutrophill percentage(rs13214027:1:0.16);None of the above | medication for pain relief, constipation, heartburn(rs13214027:1:0.04);Number of fluid intelligence questions attempted within time limit(rs13214027:1:0.03);Oily fish consumption(rs9366656:0.77:NA);Oily fish intake(rs13214027:1:-0.02);Other (e.g. cornflakes, frosties) | cereal type(rs13214027:1:0.06);Other diseases of the digestive system(rs13214027:1:0.26);Paracetamol | medication for pain relief, constipation, heartburn(rs1977:0.7:NA;rs13214027:1:-0.05);Peak expiratory flow (pef)(rs13214027:1:-2.93);Peak expiratory flow(rs13214027:1:-0.05);Platelet count(rs13214027:1:0.02);Platelet-to-lymphocyte ratio(rs3734537:0.76:NA);Pork consumption(rs9366656:0.77:NA);Primary biliary cirrhosis(rs9393710:0.68:NA);Red blood cell (erythrocyte) distribution width(rs13214027:1:0.04);Red blood cell count(rs13214027:1:-0.01;rs13214027:1:-0.02);Red cell distribution width(rs13214027:1:0.05;rs13214027:1:0.04;rs13214027:1:0.05;rs13214027:1:0.05;rs13214027:1:0.03);Reticulocyte count(rs13214027:1:-0.04;rs13214027:1:-0.04);Reticulocyte fraction of red cells(rs13214027:1:-0.04;rs13214027:1:-0.04);Seen a psychiatrist for nerves, anxiety, tension or depression(rs13214027:1:-0.06);Seen doctor (gp) for nerves, anxiety, tension or depression(rs13214027:1:-0.04);Serotransferrin measurement(rs13214027:1:0.12);Sitting height(rs13214027:1:0.07);Sum basophil neutrophil counts(rs13214027:1:-0.04);Sum eosinophil basophil counts(rs13214027:1:-0.04);Sum neutrophil eosinophil counts(rs13214027:1:-0.04);Systemic lupus erythematosus(rs13214027:1:0.38;rs13214027:1:0.38);Thyroid problem (not cancer)(rs13214027:1:0.01);Time to complete round(rs13214027:1:-2.2);Trunk fat mass(rs13214027:1:0.1);Type 1 diabetes with other specified/multiple/unspecified complications(rs13214027:1:0.23);Type 1 diabetes(rs13214027:1:0.23;rs13214027:1:0.27;rs13214027:1:0.18);Varicella zoster virus glycoproteins E and I antibody levels(rs13214027:1:0.14);Weight(rs13214027:1:0.3;rs13214027:1:0.29);White blood cell (leukocyte) count(rs13214027:1:-0.09);White blood cell count(rs13214027:1:-0.06;rs13214027:1:-0.05;rs13214027:1:-0.06);Whole body fat mass(rs13214027:1:0.19)"	BTN2A1(eqtl:0.4:rs13214027;sqtl:0.6:rs13214027);BTN2A2(eqtl:0.8:rs13214027);BTN3A1(eqtl:0.5:rs13214027;sqtl:0.7:rs13214027);BTN3A2(eqtl:1:rs13214027;sqtl:0.3:rs13214027);BTN3A3(eqtl:1:rs13214027);H2BC12(eqtl:0.4:rs13214027);H2BC5(eqtl:0.8:rs13214027);H4C8(eqtl:0.5:rs13214027);HMGN4(sqtl:0.3:rs13214027);PRSS16(eqtl:0.6:rs13214027);ZNF391(eqtl:0.3:rs13214027)
6p11.2	0	27075483	0.14 0.08 0.08 0.2 0.11	0.0 0.0 0.01 0.08 0.14	346139	346139	26902413	27248552	0.06	0.04	67	89	119	157	10	0	0	0	"Arm fat-free mass (left)(rs9348752:1:-0.01);Arm fat-free mass (right)(rs9348752:1:-0.01);Arm predicted mass (left)(rs9348752:1:-0.01);Arm predicted mass (right)(rs9348752:1:-0.01);Basal metabolic rate(rs9348752:1:-22.54);Body fat percentage(rs9348752:1:-0.16);Coeliac disease(rs9348752:1:-0.22);Comparative height size at age 10(rs9348752:1:-0.02);Epidural or caudal anaesthetic | anaesthetics administered during delivery(rs2393805:0.64:NA);Forced expiratory volume in 1-second (fev1), predicted(rs9348752:1:-0.01);Hip circumference adjusted for BMI [EA](rs12210905:0.75:-0.03);Hip circumference adjusted for BMI(rs858975:0.82:0.03);Hip circumference(rs9348752:1:-0.26);Leg fat mass (left)(rs9348752:1:-0.04);Leg fat mass (right)(rs9348752:1:-0.04);Leg fat-free mass (left)(rs9348752:1:-0.03);Leg fat-free mass (right)(rs9348752:1:-0.03);Leg predicted mass (left)(rs9348752:1:-0.03);Leg predicted mass (right)(rs9348752:1:-0.03);Mean corpuscular haemoglobin(NA:0.6:-0.07;rs9348752:1:-0.08);Mean corpuscular hemoglobin concentration(rs9348752:1:-0.02;rs9348752:1:-0.03;rs9348752:1:-0.02);Mean corpuscular hemoglobin(rs9348752:1:-0.05;rs9348752:1:-0.05;rs9348752:1:-0.05);Mean corpuscular volume(rs9348752:1:-0.05;rs9348752:1:-0.05;rs9348752:1:-0.19;rs9348752:1:-0.04);Mean sphered cell volume(rs9348752:1:-0.14);Mean spheric corpuscular volume(rs9348752:1:-0.03);Other diseases of the digestive system(rs9348752:1:-0.11);Red blood cell count(rs9348752:1:0.02;rs9348752:1:0.02);Red cell distribution width(rs9348752:1:0.02;rs9348752:1:0.02;rs9348752:1:0.02);Sitting height(rs9348752:1:-0.11);Standing height(rs9348752:1:-0.25);Trunk fat mass(rs9348752:1:-0.17);Trunk fat percentage(rs9348752:1:-0.2);Trunk fat-free mass(rs9348752:1:-0.08);Trunk predicted mass(rs9348752:1:-0.07);Type 1 diabetes(rs9348752:1:0.13);Urate levels(rs6920115:0.74:-0.03);Weight(rs9348752:1:-0.42;rs9348752:1:-0.43);Whole body fat mass(rs9348752:1:-0.26);Whole body fat-free mass(rs9348752:1:-0.16);Whole body water mass(rs9348752:1:-0.12)"	ABT1(eqtl:0.6:rs9348752);BTN2A1(sqtl:1:rs9348752);BTN2A2(eqtl:0.9:rs9348752);BTN3A1(eqtl:0.8:rs9348752);BTN3A2(eqtl:0.9:rs9348752);H2BC11(eqtl:0.6:rs9348752);H2BC12(eqtl:1:rs9348752);H2BC5(eqtl:0.9:rs9348752);H4C8(eqtl:0.5:rs9348752);H4C9(eqtl:0.3:rs9348752);HMGN4(sqtl:0.4:rs9348752);ZNF322(eqtl:0.6:rs9348752)
6p11.2	0	27855625	0.14 0.2 0.1 0.07 0.15	0.0 0.01 0.02 0.07 0.15	346139	346139	27682555	28028694	0.06	0.05	216	249	284	383	20	0	0	0	"""Diabetes, insuline treatment (Kela reimbursement) (more control exclusions)""(rs200975:1:0.08);""Diabetes, insuline treatment (Kela reimbursement)""(rs200975:1:0.08);""Diabetes, several complications""(rs200975:1:0.2);""Type 1 diabetes, strict (exclude DM2)""(rs200975:1:0.39);""Type 1 diabetes, strict definition""(rs200975:1:0.39);""Type 1 diabetes, strict definition, subgroup 1""(rs200975:1:0.41);""Type 1 diabetes, wide definition""(rs200975:1:0.27);""Type 1 diabetes, wide definition, subgroup 1""(rs200975:1:0.35);""Type1 diabetes, definitions combined""(rs200975:1:0.39);Abdominal hernia(rs200975:1:-0.05);Age started wearing glasses or contact lenses(rs200975:1:-0.37);Autoimmune diseases(rs200975:1:0.11);Background diabetic retinopathy(rs200975:1:0.33);Barrett's esophagus(rs200975:1:-0.11);Cardiovascular disease(rs200975:1:-0.01);Celiac disease(rs200975:1:0.88);Coeliac disease(rs200975:1:0.63);Cognitive performance(rs200975:1:0.02);Comparative body size at age 10(rs200975:1:0.01);Comparative height size at age 10(rs200975:1:-0.01);Dermatitis herpetiformis(rs200975:1:0.72);Diabetes or endocrine disease(rs200975:1:0.01);Diabetic background retinopathy(rs200975:1:0.32);Diabetic ketoacidosis(rs200975:1:0.28);Diabetic maculopathy (more control exclusions)(rs200975:1:0.34);Diabetic maculopathy(rs200975:1:0.32;rs200975:1:0.33);Diabetic retinopathy (more control exclusions)(rs200975:1:0.15);Diabetic retinopathy(rs200975:1:0.15;rs200975:1:0.27);Disorders of choroid and retina(rs200975:1:0.11);Disorders of iron metabolism(rs200975:1:-0.52);Eosinophil counts(rs200975:1:-0.03;rs200975:1:-0.03;rs200975:1:-0.03);Eosinophil percentage of white cells(rs200975:1:-0.02);Eosinophill count(rs200975:1:-0.02);Esophageal disorder(rs200975:1:0);FEV1(rs200975:1:-0.03);Forced expiratory volume in 1-second (fev1)(rs200975:1:-0.02);Forced expiratory volume in 1-second (fev1), best measure(rs200975:1:-0.02);Forced expiratory volume in 1-second (fev1), predicted percentage(rs200975:1:-0.49);Forced vital capacity (fvc)(rs200975:1:-0.02);Forced vital capacity (fvc), best measure(rs200975:1:-0.02);Gastroesophageal reflux disease(rs200975:1:-0.04);Granulocyte count(rs200975:1:-0.03);Haematocrit percentage(rs200975:1:-0.11);Haemoglobin concentration(rs200975:1:-0.05);Hematocrit(rs200975:1:-0.04;rs200975:1:-0.04;rs200975:1:-0.04);Hematuria(rs200975:1:-0.11);Hemoglobin concentration(rs200975:1:-0.05;rs200975:1:-0.05);Hemoglobin(rs200975:1:-0.05);High light scatter reticulocyte count(rs200975:1:0;rs200975:1:-0.03;rs200975:1:-0.03);High light scatter reticulocyte percentage of red cells(rs200975:1:-0.03);Hypertension(rs200975:1:-0.01);Hyperthyroidism or thyrotoxicosis(rs200975:1:0);Hyperthyroidism/thyrotoxicosis | non-cancer illness code, self-reported(rs200975:1:0.25);Inguinal hernia(rs200975:1:-0.1);Insulin product | treatment/medication code(rs200975:1:0.22);Insulin | medication for cholesterol, blood pressure, diabetes, or take exogenous hormones(rs200975:1:0.26);Intestinal malabsorption (non-celiac)(rs200975:1:0.78);Liver iron content(rs200975:1:-0.06);Lung function (FEV1/FVC)(rs200975:1:-0.02);Lung function (FVC)(rs200975:1:-0.02);Lymphocyte count(rs200975:1:-0.02);Lymphocyte counts(rs200975:1:-0.05;rs200975:1:-0.04;rs200975:1:-0.04);Malabsorption/coeliac disease | non-cancer illness code, self-reported(rs200975:1:0.99);Mean corpuscular haemoglobin concentration(rs200975:1:-0.03);Mean corpuscular haemoglobin(rs200975:1:-0.07);Mean corpuscular hemoglobin concentration(rs200975:1:-0.03;rs200975:1:-0.03;rs200975:1:-0.03);Mean corpuscular hemoglobin(rs200975:1:-0.04;rs200975:1:-0.04;rs200975:1:-0.04);Mean corpuscular volume(rs200975:1:-0.03;rs200975:1:-0.03;rs200975:1:-0.14;rs200975:1:-0.03);Mean reticulocyte volume(rs200975:1:0.04;rs200975:1:0.2);Membranous nephropathy(rs200975:1:0.47);Monocyte count(rs200975:1:-0.04;rs200975:1:-0.03;rs200975:1:-0.01);Myeloid white cell count(rs200975:1:-0.03);Neurociticism(rs200975:1:-0.02);Neuroticism score(rs200975:1:-0.06);Neutrophil count(rs200975:1:-0.02;rs200975:1:-0.02;rs200975:1:-0.03);Neutrophil percentage of white cells(rs200975:1:0.02);Neutrophill count(rs200975:1:-0.03);None of the above | medication for pain relief, constipation, heartburn(rs200975:1:0.04);Other diabetic retinopathy(rs200975:1:0.45);Other diseases of the digestive system(rs200975:1:0.22);Other retinal disorders(rs200975:1:0.13);Other type of bread | bread type(rs200975:1:0.08);Paracetamol | medication for pain relief, constipation, heartburn(rs200975:1:-0.04);Peak expiratory flow (pef)(rs200975:1:-2.49);Peak expiratory flow(rs200975:1:-0.04);Proliferative diabetic retinopathy(rs200975:1:0.2;rs200975:1:0.38);Red blood cell (erythrocyte) distribution width(rs200975:1:0.03);Red blood cell count(rs200975:1:-0.02;rs200975:1:-0.02);Red cell distribution width(rs200975:1:0.03;rs200975:1:0.04;rs200975:1:0.04);Reticulocyte count(rs200975:1:0;rs200975:1:-0.04;rs200975:1:-0.04);Reticulocyte fraction of red cells(rs200975:1:-0.04;rs200975:1:-0.04);Sarcoidosis | non-cancer illness code, self-reported(rs200975:1:0.37);Seen a psychiatrist for nerves, anxiety, tension or depression(rs200975:1:-0.06);Seen doctor (gp) for nerves, anxiety, tension or depression(rs200975:1:-0.04);Started insulin within one year diagnosis of diabetes(rs200975:1:0.24);Sum basophil neutrophil counts(rs200975:1:-0.03);Sum eosinophil basophil counts(rs200975:1:-0.03);Sum neutrophil eosinophil counts(rs200975:1:-0.03);Systemic lupus erythematosus(rs200975:1:0.35;rs200975:1:0.35);Thyroid problem (not cancer)(rs200975:1:0);Time to complete round(rs200975:1:-2.16);Type 1 diabetes with coma(rs200975:1:0.48);Type 1 diabetes with ketoacidosis(rs200975:1:0.45);Type 1 diabetes with neurological complications(rs200975:1:0.47);Type 1 diabetes with ophthalmic complications(rs200975:1:0.45);Type 1 diabetes with other specified/multiple/unspecified complications(rs200975:1:0.36);Type 1 diabetes with renal complications(rs200975:1:0.43);Type 1 diabetes without complications(rs200975:1:0.36);Type 1 diabetes(rs200975:1:0.39;rs200975:1:0.31;rs200975:1:0.31;rs200975:1:0.29);Unspecified diabetes(rs200975:1:0.24);Unspecified diabetic retinopathy(rs200975:1:0.33);Varicella zoster virus glycoproteins E and I antibody levels(rs200975:1:0.11);Varicose veins of lower extremity(rs200975:1:-0.09);Varicose veins(rs200975:1:-0.09);White blood cell (leukocyte) count(rs200975:1:-0.06);White blood cell count(rs200975:1:-0.04;rs200975:1:-0.04;rs200975:1:-0.04);Worry(rs200975:1:-0.02)"	H2BC11(eqtl:0.3:rs200975);H2BC12(eqtl:0.9:rs200975);H3C12(eqtl:1:rs200975);H4C13(eqtl:0.8:rs200975);PRSS16(eqtl:0.4:rs200975);ZKSCAN3(eqtl:0.4:rs200975);ZKSCAN4(eqtl:0.5:rs200975;sqtl:0.5:rs200975);ZKSCAN8(eqtl:0.8:rs200975);ZKSCAN8P1(sqtl:0.7:rs200975);ZNF165(eqtl:0.6:rs200975);ZNF184(eqtl:0.3:rs200975);ZNF391(eqtl:0.4:rs200975);ZSCAN16(eqtl:0.6:rs200975);ZSCAN23(eqtl:0.7:rs200975);ZSCAN26(eqtl:0.9:rs200975;sqtl:0.6:rs200975);ZSCAN31(eqtl:0.7:rs200975;sqtl:0.1:rs200975);ZSCAN9(eqtl:0.8:rs200975;sqtl:0.4:rs200975)
6p11.2	0	49155199	0.13 0.01 0.19 0.17 0.08	0.01 0.02 0.02 0.08 0.25	346139	346139	48982129	49328268	0.06	0.05	0	0	0	0	0	0	0	0	0	CENPQ(eqtl:0.7:rs56104201;sqtl:0.5:rs56104201);CRISP2(pqtl:0.2:rs56104201);MMUT(eqtl:0.9:rs56104201)
6p11.2	0	62587682	0.18 0.15 0.11 0.04 0.16	0.0 0.0 0.01 0.08 0.12	346139	346139	62414612	62760751	0.06	0.06	0	0	0	0	1	0	0	0	Barrett's esophagus  or Esophageal adenocarcinoma(rs62423175:0.77:NA);Esophageal adenocarcinoma(rs76014404:0.94:NA);Mean corpuscular hemoglobin(rs62416604:0.94:0.02;rs2065065:0.91:0.02;rs17349002:1:0.01;rs17349002:1:0.02);Mean corpuscular volume(rs62416604:0.94:0.01;rs2065065:0.91:0.01;rs17349002:1:0.01;rs17349002:1:0.01);Peak expiratory flow(rs17349002:1:-0.02);Red blood cell count(rs60972132:0.89:-0.01;rs56254604:0.88:-0.01);Sunburns(rs12524852:0.8:NA)	KHDRBS2(eqtl:0.3:rs17349002)
6p11.2	0	63087857	0.15 0.07 0.23 0.15 0.13	0.0 0.01 0.01 0.06 0.15	346139	346139	62914787	63260926	0.06	0.05	0	0	0	0	1	0	0	0	Cheese intake(rs2842790:1:0.02)	0
6p11.2	0	63604533	0.15 0.01 0.06 0.2 0.16	0.01 0.02 0.02 0.07 0.21	346139	346139	63431463	63777602	0.06	0.05	0	0	0	0	0	0	0	0	0	LGSN(eqtl:0.7:rs75555315)
6p11.2	0	79502277	0.17 0.17 0.1 0.13 0.08	0.0 0.02 0.02 0.14 0.47	346139	346139	79329207	79675346	0.06	0.06	0	0	0	0	2	2	0	0	LDL cholesterol levels x loop diuretics use interaction [African](rs12208017:0.61:NA)	IRAK1BP1(eqtl:0.7:rs7757382;sqtl:0.7:rs7757382);PHIP(eqtl:0.9:rs7757382)
6p11.2	0	101281527	0.22 0.02 0.11 0.07 0.18	0.0 0.02 0.03 0.08 0.41	346139	346139	101108457	101454596	0.06	0.06	0	0	0	0	1	1	0	0	0	ASCC3(sqtl:0.2:rs72947079)
6p11.2-2	1	58546704	0.49 0.1 0.55 0.23 0.33	0.0 0.0 0.01 0.04 0.1	228462	228461	58432834	58661295	0.02	0.02	0	0	0	0	0	0	0	0	0	0
6p11.2-2	0	28669698	0.53 0.07 0.41 0.33 0.43	0.01 0.02 0.02 0.08 0.17	228462	228462	28555467	28783929	0.02	0.05	321	442	518	655	2	1	0	0	"""Ankylosing spondylitis, strict definition""(rs9295777:1:-0.41);""Disorders of sclera, cornea, iris and ciliary body""(rs9295777:1:-0.08);""Other predominantly sexually transmitted diseases, not elsewhere classified""(rs9295777:1:-0.13);Acute and subacute iridocyclitis(rs9295777:1:-0.18);Ankylosing spondylitis(rs9295777:1:-0.37);Celiac disease(rs9295777:1:-0.42);Coeliac disease(rs9295777:1:-0.18);Comparative height size at age 10(rs9295777:1:0.01);Disorders of iron metabolism(rs9295777:1:0.65);Disorders of mineral metabolism(rs9295777:1:0.19);Eosinophil counts(rs9295777:1:0.01;rs9295777:1:0.01);Eosinophill count(rs9295777:1:0.01);FEV1(rs9295777:1:0.02);Forced expiratory volume in 1-second (fev1)(rs9295777:1:0.01);Forced expiratory volume in 1-second (fev1), best measure(rs9295777:1:0.01);Forced vital capacity (fvc)(rs9295777:1:0.01);Granulocyte count(rs9295777:1:0.02);Haematocrit percentage(rs9295777:1:0.05);Haemoglobin concentration(rs9295777:1:0.02);Hematocrit(rs9295777:1:0.02;rs9295777:1:0.02;rs9295777:1:0.02);Hemoglobin concentration(rs9295777:1:0.03;rs9295777:1:0.02);Hemoglobin(rs9295777:1:0.03);High light scatter reticulocyte count(rs9295777:1:0.02);High light scatter reticulocyte percentage of red cells(rs9295777:1:0.02);Infections with a predominantly sexual mode of transmission(rs9295777:1:-0.1);Intestinal malabsorption (non-celiac)(rs9295777:1:-0.36);Iridocyclitis(rs9295777:1:-0.18);KELA_REIMBURSEMENT_202(rs9295777:1:-0.1);Liver iron content(rs9295777:1:0.06);Lymphocyte counts(rs9295777:1:0.03;rs9295777:1:0.03;rs9295777:1:0.03);Malabsorption/coeliac disease | non-cancer illness code, self-reported(rs9295777:1:-0.43);Mean corpuscular haemoglobin concentration(rs9295777:1:0.02);Mean corpuscular haemoglobin(rs9295777:1:0.07);Mean corpuscular hemoglobin concentration(rs9295777:1:0.02;rs9295777:1:0.02;rs9295777:1:0.02);Mean corpuscular hemoglobin(rs9295777:1:0.04;rs9295777:1:0.04;rs9295777:1:0.04);Mean corpuscular volume(rs9295777:1:0.04;rs9295777:1:0.03;rs9295777:1:0.16;rs9295777:1:0.04);Mean platelet volume(rs9295777:1:0.01;rs9295777:1:0.01);Mean sphered cell volume(rs9295777:1:0.07);Mean spheric corpuscular volume(rs9295777:1:0.01);Monocyte count(rs9295777:1:0.02;rs9295777:1:0.02);Myeloid white cell count(rs9295777:1:0.02);Neutrophil count(rs9295777:1:0.01;rs9295777:1:0.01;rs9295777:1:0.02);Other specified/unspecified inflammatory spondylopathies(rs9295777:1:-0.27);Peak expiratory flow(rs9295777:1:0.02);Red blood cell (erythrocyte) distribution width(rs9295777:1:-0.02);Red cell distribution width(rs9295777:1:-0.02;rs9295777:1:-0.02;rs9295777:1:-0.02);Reticulocyte count(rs9295777:1:0.02);Reticulocyte fraction of red cells(rs9295777:1:0.02;rs9295777:1:0.02);Sitting height(rs9295777:1:0.05);Spondyloarthritis(rs9295777:1:-0.22);Spondylopathies (FG)(rs9295777:1:-0.3);Spondylopathies(rs9295777:1:-0.06);Standing height(rs9295777:1:0.09);Sum basophil neutrophil counts(rs9295777:1:0.02);Sum neutrophil eosinophil counts(rs9295777:1:0.02);Type 1 diabetes(rs9295777:1:-0.19);White blood cell (leukocyte) count(rs9295777:1:0.03);White blood cell count(rs9295777:1:0.02;rs9295777:1:0.02;rs9295777:1:0.03)"	PGBD1(eqtl:0.5:rs9295777);TRIM27(eqtl:0.9:rs9295777);ZFP57(eqtl:0.9:rs9295777);ZKSCAN3(eqtl:0.6:rs9295777);ZKSCAN8(eqtl:0.4:rs9295777);ZKSCAN8P1(eqtl:0.2:rs9295777;sqtl:0.4:rs9295777);ZNF165(eqtl:0.8:rs9295777);ZNF311(eqtl:0.4:rs9295777);ZSCAN16(eqtl:0.3:rs9295777);ZSCAN23(eqtl:0.8:rs9295777);ZSCAN26(eqtl:0.9:rs9295777;sqtl:0.5:rs9295777);ZSCAN31(eqtl:0.9:rs9295777;sqtl:0.5:rs9295777);ZSCAN9(eqtl:1:rs9295777;sqtl:0.7:rs9295777)
6p11.2-2	0	29178514	0.51 0.04 0.38 0.35 0.4	0.0 0.0 0.01 0.1 0.27	228462	228462	29064283	29292745	0.02	0.03	82	135	186	384	5	0	0	0	"""Ankylosing spondylitis, strict definition""(rs2206040:1:-0.43);""Disorders of sclera, cornea, iris and ciliary body""(rs2206040:1:-0.09);""Other predominantly sexually transmitted diseases, not elsewhere classified""(rs2206040:1:-0.15);""Rheumatoid arthritis , including avohilmo""(rs2206040:1:-0.11);""Seropositive rheumatoid arthritis, wide""(rs2206040:1:-0.11);""Type 1 diabetes, strict (exclude DM2)""(rs2206040:1:-0.23);""Type 1 diabetes, strict definition""(rs2206040:1:-0.24);""Type 1 diabetes, strict definition, subgroup 1""(rs2206040:1:-0.25);""Type 1 diabetes, wide definition""(rs2206040:1:-0.12);""Type 1 diabetes, wide definition, subgroup 1""(rs2206040:1:-0.18);""Type1 diabetes, definitions combined""(rs2206040:1:-0.23);Acute and subacute iridocyclitis(rs2206040:1:-0.2);Age started wearing glasses or contact lenses(rs2206040:1:0.23);Alcohol consumption (drinks per week) (MTAG)(rs3117334:0.97:0.01);Ankylosing spondylitis(rs2206040:1:-0.39);Appendicular lean mass(rs2206040:1:0.01;rs2206040:1:0.02);Autoimmune diseases(rs2206040:1:-0.06);Background diabetic retinopathy(rs2206040:1:-0.19);Biological medication for rheuma(rs2206040:1:-0.18);Breast cancer(rs9257408:0.63:NA);Celiac disease(rs2206040:1:-0.45);Coeliac disease(rs2206040:1:-0.2);Comparative height size at age 10(rs2206040:1:0.01);Diabetic background retinopathy(rs2206040:1:-0.18);Diabetic ketoacidosis(rs2206040:1:-0.15);Diabetic retinopathy(rs2206040:1:-0.13);Diastolic blood pressure(rs2206040:1:-0.03);Diseases of the eye and adnexa(rs2206040:1:-0.04);Disorders of iron metabolism(rs2206040:1:0.52);Eosinophil counts(rs2206040:1:0.01;rs2206040:1:0.02);FEV1(rs2206040:1:0.01);Finngen Rheumatological endpoints(rs2206040:1:-0.05);First line medication for Crohns disease(rs2206040:1:-0.05);Forced expiratory volume in 1-second (fev1)(rs2206040:1:0.01);Forced expiratory volume in 1-second (fev1), best measure(rs2206040:1:0.01);Forced expiratory volume in 1-second (fev1), predicted(rs2206040:1:0.01);Forced vital capacity (fvc)(rs2206040:1:0.01);Forced vital capacity (fvc), best measure(rs2206040:1:0.01);General risk tolerance (MTAG)(rs1233508:0.78:-0.01);Granulocyte count(rs2206040:1:0.02);Haematocrit percentage(rs2206040:1:0.06);Haemoglobin concentration(rs2206040:1:0.02);Height(rs3129109:0.75:0.03);Hematocrit(rs2206040:1:0.02;rs2206040:1:0.02;rs2206040:1:0.02);Hemoglobin concentration(rs2206040:1:0.03;rs2206040:1:0.02);Hemoglobin levels(rs209126:0.87:-0.02);Hemoglobin(rs2206040:1:0.03);High light scatter reticulocyte count(rs2206040:1:0.01);High light scatter reticulocyte percentage of red cells(rs2206040:1:0.01);Insulin product | treatment/medication code(rs2206040:1:-0.13);Interstitial lung disease endpoints(rs2206040:1:-0.06);Intestinal malabsorption (non-celiac)(rs2206040:1:-0.4);Iridocyclitis(rs2206040:1:-0.19);KELA_REIMBURSEMENT_202(rs2206040:1:-0.13);Liver iron content(rs2206040:1:0.04);Lymphocyte count(rs2206040:1:0.01);Lymphocyte counts(rs2206040:1:0.03;rs2206040:1:0.03;rs2206040:1:0.03);Malabsorption/coeliac disease | non-cancer illness code, self-reported(rs2206040:1:-0.45);Mean corpuscular haemoglobin(rs2206040:1:0.05);Mean corpuscular hemoglobin concentration(rs2206040:1:-0.03;rs2206040:1:0.01;rs2206040:1:0.01);Mean corpuscular hemoglobin(rs2206040:1:0.03;rs2206040:1:0.03;rs2206040:1:0.03);Mean corpuscular volume(rs9257573:0.84:NA;rs2206040:1:0.11;rs2206040:1:0.03;rs2206040:1:0.02;rs2206040:1:0.02);Mean platelet volume(rs2206040:1:0.01;rs2206040:1:0.01);Mean reticulocyte volume(rs2206040:1:-0.01);Monocyte count(rs2206040:1:0.02;rs2206040:1:0.02);Myeloid white cell count(rs2206040:1:0.02);Neutrophil count(rs2206040:1:0.01;rs2206040:1:0.01;rs2206040:1:0.02);Other systemic involvement of connective tissue (FG)(rs2206040:1:-0.12);Other/unspecified seropositiverheumatoid arthritis(rs2206040:1:-0.11);Peak expiratory flow (pef)(rs2206040:1:1.41);Peak expiratory flow(rs2206040:1:0.02);Platelet-to-lymphocyte ratio(rs9257774:0.72:NA;rs9257774:0.72:NA);Polyarthropathies(rs2206040:1:-0.08);Proliferative diabetic retinopathy(rs2206040:1:-0.23);Red cell distribution width(rs2206040:1:-0.01;rs2206040:1:-0.01;rs2206040:1:0.03);Reticulocyte count(rs2206040:1:0.02);Reticulocyte fraction of red cells(rs2206040:1:0.02);Rheumatoid arthritis(rs2206040:1:-0.12);Second line medication for Crohns disease(rs2206040:1:-0.07);Seropositive rheumatoid arthritis(rs2206040:1:-0.12);Sitting height(rs2206040:1:0.06);Spondyloarthritis(rs2206040:1:-0.23);Spondylopathies (FG)(rs2206040:1:-0.32);Spondylopathies(rs2206040:1:-0.06);Standing height(rs2206040:1:0.14);Sum basophil neutrophil counts(rs2206040:1:0.02);Sum neutrophil eosinophil counts(rs2206040:1:0.02);Trunk fat-free mass(rs2206040:1:0.04);Trunk predicted mass(rs2206040:1:0.04);Type 1 diabetes with coma(rs2206040:1:-0.27);Type 1 diabetes with ketoacidosis(rs2206040:1:-0.28);Type 1 diabetes with ophthalmic complications(rs2206040:1:-0.21);Type 1 diabetes with other specified/multiple/unspecified complications(rs2206040:1:-0.2);Type 1 diabetes without complications(rs2206040:1:-0.19);Type 1 diabetes(rs2206040:1:-0.25;rs2206040:1:-0.15;rs2206040:1:-0.15;rs2206040:1:-0.09);Type 2 diabetes(rs9257408:0.66:NA);Waist circumference adjusted for body mass index(rs2207699:0.76:NA);White blood cell (leukocyte) count(rs2206040:1:0.04);White blood cell count(rs2206040:1:0.02;rs2206040:1:0.03;rs2206040:1:0.02)"	HLA-A(eqtl:0.3:rs2206040);HLA-G(eqtl:0.5:rs2206040);TRIM10(eqtl:0.3:rs2206040);TRIM27(eqtl:1:rs2206040;sqtl:0.1:rs2206040);ZFP57(eqtl:0.8:rs2206040);ZKSCAN3(eqtl:0.5:rs2206040);ZNF311(eqtl:0.5:rs2206040);ZSCAN23(eqtl:0.7:rs2206040);ZSCAN26(eqtl:0.8:rs2206040;sqtl:0.3:rs2206040);ZSCAN31(eqtl:0.9:rs2206040;sqtl:0.5:rs2206040);ZSCAN9(eqtl:0.9:rs2206040;sqtl:0.5:rs2206040)
6p11.2-2	0	35047732	0.48 0.03 0.48 0.26 0.45	0.0 0.01 0.02 0.09 0.29	228462	228462	34933501	35161963	0.02	0.06	38	69	126	211	2	2	0	0	"Apolipoprotein B levels(rs2689094:1:-0.01);Arm fat-free mass (left)(rs2689094:1:0.01);Arm fat-free mass (right)(rs2689094:1:0.01);Arm predicted mass (left)(rs2689094:1:0.01);Arm predicted mass (right)(rs2689094:1:0.01);Basal metabolic rate(rs2689094:1:11.02);Body mass index(rs2762339:0.93:NA);Direct low density lipoprotein cholesterol levels(rs2689094:1:-0.01);Forced expiratory volume in 1-second (fev1), best measure(rs2689094:1:0.01);HDL cholesterol levels(rs2689094:1:-0.01);Height(rs2689094:1:0.01);Low density lipoprotein cholesterol levels(rs2689094:1:-0.01);Lung function (FEV1/FVC)(rs2689094:1:0.02;rs2689094:1:0.02);Serum alkaline phosphatase levels(rs2689094:1:-0.01);Standing height(rs2689094:1:0.09);Total cholesterol levels(rs2689094:1:-0.01);Weight(rs2689094:1:0.19;rs2689094:1:0.19)"	ANKS1A(eqtl:0.2:rs2689094;sqtl:0.9:rs2689094);DEF6(eqtl:0.9:rs2689094);ILRUN(eqtl:0.7:rs2689094);RPL10A(eqtl:0.3:rs2689094);TAF11(eqtl:0.2:rs2689094);TCP11(eqtl:0.4:rs2689094;sqtl:0.4:rs2689094);UHRF1BP1(eqtl:0.3:rs2689094);ZNF76(eqtl:0.4:rs2689094)
6p11.2-2	0	50919411	0.47 0.11 0.32 0.47 0.35	0.0 0.03 0.04 0.13 0.29	228462	228462	50805180	51033642	0.02	0.06	0	0	0	1	1	0	0	0	Cereal intake(rs2746646:0.82:-0.01);Creatinine levels(rs1547211:0.6:-0.02);Cystatin C levels(rs1547211:0.6:-0.02);Eosinophil counts(rs760900:0.83:NA;rs2746646:0.82:0.01;rs2746646:0.82:0.01);Eosinophil percentage of white cells(rs2746646:0.82:0.01);Fresh fruit intake(NA:0.81:0.01;rs578242:1:0.01);Fruit consumption(rs2817399:0.83:NA);Myopia(rs2207136:0.85:NA);Refractive error(rs2076309:0.82:NA);Spherical equivalent(rs2746646:0.82:0.09);Spherical power (left)(rs2207136:0.85:0.1;rs578242:1:-0.1);Spherical power (right)(rs2076309:0.82:-0.09;rs578242:1:-0.09);Vertex-wise sulcal depth(rs571503:1:7.38)	0
6p11.2-2	0	63402075	0.47 0.28 0.41 0.33 0.31	0.0 0.01 0.02 0.09 0.17	228462	228462	63287844	63516306	0.02	0.03	0	0	0	0	0	0	0	0	0	KHDRBS2(eqtl:0.2:rs9343061)
6p11.2-2	0	81233536	0.47 0.36 0.29 0.33 0.33	0.0 0.02 0.03 0.17 0.28	228462	228462	81119305	81347767	0.02	0.07	0	0	0	0	0	0	0	0	"Appendicular lean mass(rs12201782:0.66:0.01;rs504505:1:0.01);Comparative height size at age 10(rs504505:1:0.01);Forced expiratory volume in 1-second (fev1), predicted(rs504505:1:0.01);Height(rs1902070:0.69:-0.02;rs1902070:0.69:NA);Hernia of abodminal wall(rs9449027:0.87:NA;rs504505:1:-0.09);Sitting height(rs658839:0.76:0.08;rs504505:1:0.06);Standing height(rs504505:1:0.12)"	0
6p11.2-2	0	87841511	0.48 0.1 0.35 0.4 0.29	0.0 0.0 0.05 0.19 0.3	228462	228462	87727280	87955742	0.02	0.1	0	0	0	0	2	1	0	0	Atrial fibrillation(rs2031519:1:-0.04);Eosinophil counts(rs2031519:1:0.01;rs2031519:1:0.02);Eosinophil percentage of granulocytes(rs202150775:0.96:0.03;rs2031519:1:0.03);Eosinophil percentage of white cells(rs202150775:0.96:0.03;rs2031519:1:0.02;rs2031519:1:0.02);Eosinophill percentage(rs2031519:1:0.04);Granulocyte count(rs754080897:0.67:-0.03;rs2031519:1:-0.03);Granulocyte percentage of myeloid white cells(rs754080897:0.67:-0.03;rs2031519:1:-0.02);Impedance of leg (left)(rs2031519:1:0.43);Lymphocyte percentage of white cells(rs2031519:1:0.02;rs2031519:1:0.02);Lymphocyte percentage(rs2031519:1:0.13);Mean corpuscular hemoglobin concentration(rs6454582:0.82:-0.01);Mean corpuscular volume(rs6454582:0.82:-0.06;rs6454582:0.82:-0.01;rs6454582:0.82:-0.01;rs2031519:1:-0.01;rs2031519:1:-0.01);Monocyte percentage of white cells(rs2031519:1:0.02;rs2031519:1:0.02);Monocyte percentage(rs2031519:1:0.04);Myeloid white cell count(rs754080897:0.67:-0.03;rs2031519:1:-0.02);Neutrophil count(rs754080897:0.67:-0.03;rs2031519:1:-0.02;rs2031519:1:-0.03;rs2031519:1:-0.03);Neutrophil percentage of granulocytes(rs202150775:0.96:-0.03;rs2031519:1:-0.03);Neutrophil percentage of white cells(rs2031519:1:-0.03;rs2031519:1:-0.03);Neutrophill count(rs2031519:1:-0.03);Neutrophill percentage(rs2031519:1:-0.2);Sum basophil neutrophil counts(rs754080897:0.67:-0.03;rs2031519:1:-0.03);Sum neutrophil eosinophil counts(rs754080897:0.67:-0.03;rs2031519:1:-0.03);White blood cell (leukocyte) count(rs201150852:0.76:-0.03);White blood cell count(rs4574603:0.82:NA;rs754080897:0.67:-0.02;rs2031519:1:-0.02;rs2031519:1:-0.02;rs2031519:1:-0.02)	C6orf163(eqtl:0.9:rs2031519);CFAP206(eqtl:0.1:rs2031519);GJB7(eqtl:0.4:rs2031519);ORC3(sqtl:0.1:rs2031519);RARS2(eqtl:0.6:rs2031519;sqtl:0.6:rs2031519);SLC35A1(eqtl:0.9:rs2031519);SMIM8(eqtl:0.9:rs2031519;sqtl:1:rs2031519);ZNF292(eqtl:0.6:rs2031519)
6p11.2-2	0	115624371	0.44 0.28 0.24 0.29 0.43	0.0 0.01 0.01 0.08 0.21	228462	228462	115510140	115738602	0.02	0.02	0	0	0	0	0	0	0	0	0	0
6p11.2-2	0	126867351	0.52 0.59 0.31 0.03 0.31	0.0 0.0 0.0 0.03 0.24	228462	228462	126753120	126981582	0.02	0	0	0	0	0	2	1	0	0	"Age when periods started (menarche)(rs4380768:1:-0.02);Ankle spacing width(rs4380768:1:0.08);Appendicular lean mass(rs4380768:1:0.05;rs4380768:1:0.04;rs4380768:1:0.04);Arm fat percentage (left)(rs4380768:1:-0.11);Arm fat percentage (right)(rs4380768:1:-0.11);Arm fat-free mass (left)(rs9388490:0.76:0.02;rs4380768:1:0.01);Arm fat-free mass (right)(rs4380768:1:0.01);Arm predicted mass (left)(rs4380768:1:0.01);Arm predicted mass (right)(rs9388490:0.76:0.01;rs4380768:1:0.01);Basal metabolic rate(rs4380768:1:23.87);Body fat percentage(rs4380768:1:-0.09);Brain region volumes [left lateral orbitofrontal](rs17754780:0.8:NA);Comparative height size at age 10(rs4380768:1:0.03);Cortical thickness(rs9388490:0.76:NA);Diabetes or endocrine disease(rs4380768:1:0);Diabetes(rs4380768:1:0);Educational attainment (years of education)(rs9388490:0.76:0.01);FEV1(rs4380768:1:0.01);Feeling nervous(rs6919397:0.79:-0.01);Forced expiratory volume in 1-second (fev1)(rs4380768:1:0.02);Forced expiratory volume in 1-second (fev1), best measure(rs4380768:1:0.02);Forced expiratory volume in 1-second (fev1), predicted(rs4380768:1:0.01);Forced vital capacity (fvc)(rs4380768:1:0.03);Forced vital capacity (fvc), best measure(rs4380768:1:0.03);Haematocrit percentage(rs9375435:0.78:-0.06;rs4380768:1:-0.05);Haemoglobin concentration(rs4380768:1:-0.01);Hematocrit(rs4380768:1:-0.02;rs4380768:1:-0.02;rs4380768:1:-0.02);Hemoglobin concentration(rs4380768:1:-0.02);Hemoglobin(rs4380768:1:-0.02);Hip circumference adjusted for BMI(rs1030807851:0.8:0.03);Impedance of arm (left)(rs35510806:0.71:-0.61);Impedance of arm (right)(rs9388487:0.71:-0.58);Impedance of whole body(rs9398803:0.71:-1.11;rs4380768:1:-0.86);Kidney volume(rs4380768:1:0.05);Leg fat percentage (left)(rs4380768:1:-0.08);Leg fat percentage (right)(rs4380768:1:-0.08);Leg fat-free mass (left)(rs4380768:1:0.03);Leg fat-free mass (right)(rs4380768:1:0.03);Leg predicted mass (left)(rs4380768:1:0.03);Leg predicted mass (right)(rs4380768:1:0.03);Liver volume(rs4380768:1:0.05);Low density lipoprotein cholesterol levels(rs4380768:1:-0.01);Lung function (FEV1/FVC)(rs9398804:0.79:NA);Lung function (FVC)(rs4380768:1:0.02);Male-pattern baldness(rs9398803:0.71:0.12;rs4380768:1:-0.05);Neutrophil count(rs4380768:1:-0.01;rs4380768:1:-0.01);Neutrophill count(rs4380768:1:-0.02);Pattern 1 | hair/balding pattern(rs4380768:1:0.08);Pattern 3 | hair/balding pattern(rs4380768:1:-0.05);Pattern 4 | hair/balding pattern(rs9398803:0.71:NA;rs4380768:1:-0.09);Red blood cell count(rs4380768:1:-0.01;rs4380768:1:-0.01);Salt added to food(rs4380768:1:-0.01);Serum phosphate levels(rs9388489:0.8:0.02);Sex hormone-binding globulin levels adjusted for BMI(rs4380768:1:-0.01;rs4380768:1:-0.01);Sex hormone-binding globulin levels(rs4380768:1:-0.01);Sitting height(rs9388490:0.76:0.17;rs4380768:1:0.16);Standing height(rs4380768:1:0.32);Subcortical volume (MOSTest)(rs9388490:0.76:NA);Trunk fat-free mass(rs4380768:1:0.13);Trunk predicted mass(rs4380768:1:0.12);Type 1 diabetes(rs2045258:0.8:NA;rs9388489:0.8:NA;rs4380768:1:0.09);Type 2 diabetes(rs4380768:1:0.04);Vertex-wise sulcal depth(rs9388490:0.76:NA);Weight(rs4380768:1:0.18);White blood cell (leukocyte) count(rs4380768:1:-0.04);White blood cell count(rs4380768:1:-0.01;rs4380768:1:-0.01);Whole body fat-free mass(rs4380768:1:0.21);Whole body water mass(rs4380768:1:0.15)"	CENPW(eqtl:0.8:rs4380768)
6q11.1	1	62224758	0.17 0.03 0.29 0.08 0.13	0.0 0.0 0.01 0.04 0.1	378909	378908	61992049	62370957	0.03	0.03	0	0	0	0	1	0	0	0	0	KHDRBS2(sqtl:0.6:rs394722;eqtl:0.5:rs177283)
6q11.1	0	26681183	0.21 0.14 0.12 0.09 0.2	0.0 0.01 0.01 0.06 0.29	378909	378909	26491728	26870637	0.03	0.03	76	104	151	207	7	3	0	0	"Arm fat mass (left)(rs12194606:1:-0.01);Arm fat mass (right)(rs12194606:1:-0.01);Arm fat percentage (left)(rs12194606:1:-0.14);Arm fat-free mass (left)(rs12194606:1:-0.01);Arm fat-free mass (right)(rs12194606:1:-0.01);Arm predicted mass (left)(rs12194606:1:-0.01);Arm predicted mass (right)(rs12194606:1:-0.01);Basal metabolic rate(rs12194606:1:-21.22);Body fat percentage(rs12194606:1:-0.15);Comparative height size at age 10(rs12194606:1:-0.01);Forced expiratory volume in 1-second (fev1), predicted(rs12194606:1:-0.01);Hand grip strength(rs12195114:0.61:0);Hemoglobin concentration(rs12194606:1:-0.02);Hip circumference adjusted for BMI(rs61655050:0.81:-0.03);Hip circumference(rs12194606:1:-0.27);Leg fat mass (left)(rs12194606:1:-0.04);Leg fat mass (right)(rs12194606:1:-0.04);Leg fat percentage (left)(rs12194606:1:-0.1);Leg fat percentage (right)(rs12194606:1:-0.1);Leg fat-free mass (left)(rs12194606:1:-0.03);Leg fat-free mass (right)(rs12194606:1:-0.03);Leg predicted mass (left)(rs12194606:1:-0.03);Leg predicted mass (right)(rs12194606:1:-0.03);Mean corpuscular haemoglobin(rs12194606:1:-0.08);Mean corpuscular hemoglobin concentration(rs12194606:1:-0.02;rs12194606:1:-0.02);Mean corpuscular hemoglobin(rs12194606:1:-0.05;rs12194606:1:-0.05;rs12194606:1:-0.05);Mean corpuscular volume(rs1907082:0.62:-0.03;rs12194606:1:-0.05;rs12194606:1:-0.05;rs12194606:1:-0.18;rs12194606:1:-0.04);Mean reticulocyte volume(rs12194606:1:-0.02);Mean sphered cell volume(rs12194606:1:-0.15);Mean spheric corpuscular volume(rs12194606:1:-0.04);Red blood cell count(rs12194606:1:0.02;rs12194606:1:0.02);Red cell distribution width(rs12194606:1:0.02;rs12194606:1:0.02);Sitting height(rs12194606:1:-0.07);Standing height(rs12194606:1:-0.19);Trunk fat mass(rs12194606:1:-0.15);Trunk fat percentage(rs12194606:1:-0.19);Trunk fat-free mass(rs12194606:1:-0.07);Trunk predicted mass(rs12194606:1:-0.06);Waist circumference(rs12194606:1:-0.24);Weight(rs12194606:1:-0.41;rs12194606:1:-0.4);Whole body fat mass(rs12194606:1:-0.25);Whole body fat-free mass(rs12194606:1:-0.15);Whole body water mass(rs12194606:1:-0.11)"	ABT1(eqtl:0.5:rs12194606);BTN2A2(eqtl:0.6:rs12194606);BTN3A1(eqtl:0.8:rs12194606);BTN3A2(eqtl:0.9:rs12194606);H2BC12(eqtl:0.9:rs12194606);H2BC5(eqtl:0.8:rs12194606);H4C8(eqtl:0.5:rs12194606);TRIM38(eqtl:0.4:rs12194606);ZNF322(eqtl:0.4:rs12194606)
6q11.1	0	27855625	0.14 0.2 0.1 0.07 0.15	0.0 0.01 0.02 0.07 0.15	378909	378909	27666170	28045079	0.03	0.06	223	269	301	399	21	0	0	0	"""Diabetes, insuline treatment (Kela reimbursement) (more control exclusions)""(rs200975:1:0.08);""Diabetes, insuline treatment (Kela reimbursement)""(rs200975:1:0.08);""Diabetes, several complications""(rs200975:1:0.2);""Type 1 diabetes, strict (exclude DM2)""(rs200975:1:0.39);""Type 1 diabetes, strict definition""(rs200975:1:0.39);""Type 1 diabetes, strict definition, subgroup 1""(rs200975:1:0.41);""Type 1 diabetes, wide definition""(rs200975:1:0.27);""Type 1 diabetes, wide definition, subgroup 1""(rs200975:1:0.35);""Type1 diabetes, definitions combined""(rs200975:1:0.39);Abdominal hernia(rs200975:1:-0.05);Age started wearing glasses or contact lenses(rs200975:1:-0.37);Autoimmune diseases(rs200975:1:0.11);Background diabetic retinopathy(rs200975:1:0.33);Barrett's esophagus(rs200975:1:-0.11);Cardiovascular disease(rs200975:1:-0.01);Celiac disease(rs200975:1:0.88);Coeliac disease(rs200975:1:0.63);Cognitive performance(rs200975:1:0.02);Comparative body size at age 10(rs200975:1:0.01);Comparative height size at age 10(rs200975:1:-0.01);Dermatitis herpetiformis(rs200975:1:0.72);Diabetes or endocrine disease(rs200975:1:0.01);Diabetic background retinopathy(rs200975:1:0.32);Diabetic ketoacidosis(rs200975:1:0.28);Diabetic maculopathy (more control exclusions)(rs200975:1:0.34);Diabetic maculopathy(rs200975:1:0.32;rs200975:1:0.33);Diabetic retinopathy (more control exclusions)(rs200975:1:0.15);Diabetic retinopathy(rs200975:1:0.15;rs200975:1:0.27);Disorders of choroid and retina(rs200975:1:0.11);Disorders of iron metabolism(rs200975:1:-0.52);Eosinophil counts(rs200975:1:-0.03;rs200975:1:-0.03;rs200975:1:-0.03);Eosinophil percentage of white cells(rs200975:1:-0.02);Eosinophill count(rs200975:1:-0.02);Esophageal disorder(rs200975:1:0);FEV1(rs200975:1:-0.03);Forced expiratory volume in 1-second (fev1)(rs200975:1:-0.02);Forced expiratory volume in 1-second (fev1), best measure(rs200975:1:-0.02);Forced expiratory volume in 1-second (fev1), predicted percentage(rs200975:1:-0.49);Forced vital capacity (fvc)(rs200975:1:-0.02);Forced vital capacity (fvc), best measure(rs200975:1:-0.02);Gastroesophageal reflux disease(rs200975:1:-0.04);Granulocyte count(rs200975:1:-0.03);Haematocrit percentage(rs200975:1:-0.11);Haemoglobin concentration(rs200975:1:-0.05);Hematocrit(rs200975:1:-0.04;rs200975:1:-0.04;rs200975:1:-0.04);Hematuria(rs200975:1:-0.11);Hemoglobin concentration(rs200975:1:-0.05;rs200975:1:-0.05);Hemoglobin(rs200975:1:-0.05);High light scatter reticulocyte count(rs200975:1:0;rs200975:1:-0.03;rs200975:1:-0.03);High light scatter reticulocyte percentage of red cells(rs200975:1:-0.03);Hypertension(rs200975:1:-0.01);Hyperthyroidism or thyrotoxicosis(rs200975:1:0);Hyperthyroidism/thyrotoxicosis | non-cancer illness code, self-reported(rs200975:1:0.25);Inguinal hernia(rs200975:1:-0.1);Insulin product | treatment/medication code(rs200975:1:0.22);Insulin | medication for cholesterol, blood pressure, diabetes, or take exogenous hormones(rs200975:1:0.26);Intestinal malabsorption (non-celiac)(rs200975:1:0.78);Liver iron content(rs200975:1:-0.06);Lung function (FEV1/FVC)(rs200975:1:-0.02);Lung function (FVC)(rs200975:1:-0.02);Lymphocyte count(rs200975:1:-0.02);Lymphocyte counts(rs200975:1:-0.05;rs200975:1:-0.04;rs200975:1:-0.04);Malabsorption/coeliac disease | non-cancer illness code, self-reported(rs200975:1:0.99);Mean corpuscular haemoglobin concentration(rs200975:1:-0.03);Mean corpuscular haemoglobin(rs200975:1:-0.07);Mean corpuscular hemoglobin concentration(rs200975:1:-0.03;rs200975:1:-0.03;rs200975:1:-0.03);Mean corpuscular hemoglobin(rs200975:1:-0.04;rs200975:1:-0.04;rs200975:1:-0.04);Mean corpuscular volume(rs200975:1:-0.03;rs200975:1:-0.03;rs200975:1:-0.14;rs200975:1:-0.03);Mean reticulocyte volume(rs200975:1:0.04;rs200975:1:0.2);Membranous nephropathy(rs200975:1:0.47);Monocyte count(rs200975:1:-0.04;rs200975:1:-0.03;rs200975:1:-0.01);Myeloid white cell count(rs200975:1:-0.03);Neurociticism(rs200975:1:-0.02);Neuroticism score(rs200975:1:-0.06);Neutrophil count(rs200975:1:-0.02;rs200975:1:-0.02;rs200975:1:-0.03);Neutrophil percentage of white cells(rs200975:1:0.02);Neutrophill count(rs200975:1:-0.03);None of the above | medication for pain relief, constipation, heartburn(rs200975:1:0.04);Other diabetic retinopathy(rs200975:1:0.45);Other diseases of the digestive system(rs200975:1:0.22);Other retinal disorders(rs200975:1:0.13);Other type of bread | bread type(rs200975:1:0.08);Paracetamol | medication for pain relief, constipation, heartburn(rs200975:1:-0.04);Peak expiratory flow (pef)(rs200975:1:-2.49);Peak expiratory flow(rs200975:1:-0.04);Proliferative diabetic retinopathy(rs200975:1:0.2;rs200975:1:0.38);Red blood cell (erythrocyte) distribution width(rs200975:1:0.03);Red blood cell count(rs200975:1:-0.02;rs200975:1:-0.02);Red cell distribution width(rs200975:1:0.03;rs200975:1:0.04;rs200975:1:0.04);Reticulocyte count(rs200975:1:0;rs200975:1:-0.04;rs200975:1:-0.04);Reticulocyte fraction of red cells(rs200975:1:-0.04;rs200975:1:-0.04);Sarcoidosis | non-cancer illness code, self-reported(rs200975:1:0.37);Seen a psychiatrist for nerves, anxiety, tension or depression(rs200975:1:-0.06);Seen doctor (gp) for nerves, anxiety, tension or depression(rs200975:1:-0.04);Started insulin within one year diagnosis of diabetes(rs200975:1:0.24);Sum basophil neutrophil counts(rs200975:1:-0.03);Sum eosinophil basophil counts(rs200975:1:-0.03);Sum neutrophil eosinophil counts(rs200975:1:-0.03);Systemic lupus erythematosus(rs200975:1:0.35;rs200975:1:0.35);Thyroid problem (not cancer)(rs200975:1:0);Time to complete round(rs200975:1:-2.16);Type 1 diabetes with coma(rs200975:1:0.48);Type 1 diabetes with ketoacidosis(rs200975:1:0.45);Type 1 diabetes with neurological complications(rs200975:1:0.47);Type 1 diabetes with ophthalmic complications(rs200975:1:0.45);Type 1 diabetes with other specified/multiple/unspecified complications(rs200975:1:0.36);Type 1 diabetes with renal complications(rs200975:1:0.43);Type 1 diabetes without complications(rs200975:1:0.36);Type 1 diabetes(rs200975:1:0.39;rs200975:1:0.31;rs200975:1:0.31;rs200975:1:0.29);Unspecified diabetes(rs200975:1:0.24);Unspecified diabetic retinopathy(rs200975:1:0.33);Varicella zoster virus glycoproteins E and I antibody levels(rs200975:1:0.11);Varicose veins of lower extremity(rs200975:1:-0.09);Varicose veins(rs200975:1:-0.09);White blood cell (leukocyte) count(rs200975:1:-0.06);White blood cell count(rs200975:1:-0.04;rs200975:1:-0.04;rs200975:1:-0.04);Worry(rs200975:1:-0.02)"	H2BC11(eqtl:0.3:rs200975);H2BC12(eqtl:0.9:rs200975);H3C12(eqtl:1:rs200975);H4C13(eqtl:0.8:rs200975);PRSS16(eqtl:0.4:rs200975);ZKSCAN3(eqtl:0.4:rs200975);ZKSCAN4(eqtl:0.5:rs200975;sqtl:0.5:rs200975);ZKSCAN8(eqtl:0.8:rs200975);ZKSCAN8P1(sqtl:0.7:rs200975);ZNF165(eqtl:0.6:rs200975);ZNF184(eqtl:0.3:rs200975);ZNF391(eqtl:0.4:rs200975);ZSCAN16(eqtl:0.6:rs200975);ZSCAN23(eqtl:0.7:rs200975);ZSCAN26(eqtl:0.9:rs200975;sqtl:0.6:rs200975);ZSCAN31(eqtl:0.7:rs200975;sqtl:0.1:rs200975);ZSCAN9(eqtl:0.8:rs200975;sqtl:0.4:rs200975)
6q11.1	0	49107837	0.13 0.11 0.19 0.17 0.09	0.0 0.0 0.01 0.07 0.25	378909	378909	48918382	49297291	0.03	0.05	0	0	0	0	0	0	0	0	0	CENPQ(eqtl:0.7:rs9381738;sqtl:0.5:rs9381738);CRISP2(pqtl:0.2:rs9381738);MMUT(eqtl:0.9:rs9381738)
6q11.1	0	57584723	0.18 0.0 0.28 0.08 0.14	0.0 0.0 0.01 0.06 0.29	378909	378909	57395268	57774177	0.03	0.04	0	0	0	0	1	0	0	0	0	RAB23(eqtl:0.1:rs9800557)
6q11.1	0	58371561	0.17 0.32 0.1 0.07 0.11	0.0 0.01 0.01 0.06 0.11	378909	378909	58182106	58561015	0.03	0.03	0	0	0	0	3	0	0	0	Mean corpuscular hemoglobin(rs57869623:0.82:0.02;rs57869623:0.82:0.02;rs62464127:1:0.02;rs62464127:1:0.02);Mean corpuscular volume(rs57869623:0.82:0.02;rs62464127:1:0.02;rs62464127:1:0.02);Mean reticulocyte volume(rs62464139:0.79:0.02)	0
6q11.1	0	63228037	0.13 0.09 0.05 0.23 0.14	0.01 0.01 0.02 0.08 0.13	378909	378909	63038582	63417491	0.03	0.06	0	0	0	0	0	0	0	0	0	LGSN(eqtl:0.4:rs9350449)
6q11.1	0	86527204	0.22 0.05 0.21 0.11 0.18	0.0 0.0 0.0 0.03 0.25	378909	378909	86337749	86716658	0.03	0.02	0	0	0	0	4	1	0	0	0	NT5E(eqtl:0.6:rs6940692);SNX14(sqtl:0.2:rs6940692)
6q11.1	0	115722700	0.13 0.01 0.12 0.24 0.24	0.0 0.0 0.01 0.06 0.26	378909	378909	115533245	115912154	0.03	0.04	0	0	0	0	0	0	0	0	0	0
6q11.1	0	146356812	0.14 0.06 0.24 0.17 0.09	0.0 0.0 0.0 0.04 0.28	378909	378909	146167357	146546266	0.03	0.04	0	0	0	0	3	1	0	0	0	0
6q14.1	1	78518558	0.1 0.25 0.07 0.37 0.18	0.0 0.01 0.02 0.16 0.45	231753	231752	78400750	78632502	0.04	0.04	0	0	0	0	1	1	1	1	0	0
6q14.1	0	45127152	0.14 0.08 0.21 0.25 0.27	0.0 0.01 0.01 0.06 0.59	231753	231753	45011275	45243028	0.04	0.02	0	0	0	0	2	1	0	0	Estimated glomerular filtration rate(rs720989:0.62:0);Height(rs3799969:0.87:NA);Nose morphology(rs66604011:0.86:NA;rs4714845:0.87:NA;rs12208924:0.87:NA);Pattern 1 | hair/balding pattern(rs1285033:1:-0.09);Pattern 4 | hair/balding pattern(rs1285033:1:0.1);facial morphology traits (multivariate analysis)(rs1852985:0.92:NA);middle facial morphology traits (quantitative measurement) [Nose bridge breadth](rs1852985:0.92:0)	SUPT3H(eqtl:0.9:rs1285033)
6q14.1	0	48781164	0.13 0.29 0.18 0.18 0.11	0.0 0.01 0.01 0.09 0.33	231753	231753	48665287	48897040	0.04	0.04	0	0	0	0	0	0	0	0	0	CENPQ(eqtl:0.3:rs2495867;sqtl:0.1:rs2495867)
6q14.1	0	49293185	0.14 0.27 0.2 0.2 0.1	0.0 0.01 0.02 0.15 0.26	231753	231753	49177308	49409061	0.04	0.04	0	0	0	0	1	0	0	0	0	CENPQ(eqtl:0.8:rs579712);MMUT(eqtl:0.9:rs579712)
6q14.1	0	50808745	0.13 0.22 0.19 0.2 0.14	0.0 0.01 0.02 0.11 0.39	231753	231753	50692868	50924621	0.04	0.03	0	0	0	0	2	0	0	0	Age at first sexual intercourse(rs141547796:0.7:0.04;rs141547796:0.7:0.03;rs1569777:1:0.03;rs1569777:1:0.03);Age first had sexual intercourse(rs901112499:0.77:0.12;rs1569777:1:0.09);Age of smoking initiation (MTAG)(rs141547796:0.7:0.01);Arm fat mass (left)(rs1569777:1:-0.02);Arm fat mass (right)(rs1569777:1:-0.02);Arm fat percentage (left)(rs1569777:1:-0.18);Arm fat percentage (right)(rs1569777:1:-0.18);Arm fat-free mass (left)(rs1569777:1:-0.01);Arm fat-free mass (right)(rs1569777:1:-0.01);Arm predicted mass (left)(rs1569777:1:-0.01);Arm predicted mass (right)(rs1569777:1:-0.01);Attention deficit hyperactivity disorder (MTAG)(rs78648104:0.7:-0.13);Basal metabolic rate(rs1569777:1:-28.02);Body fat percentage(rs1569777:1:-0.14);Body mass index (bmi)(rs1569777:1:-0.15;rs1569777:1:-0.15);Body mass index(rs78648104:0.65:-0.02;rs78648104:0.7:-0.03);Cognitive performance (MTAG) [MTAG](rs78648104:0.7:0.03);Comparative body size at age 10(rs1569777:1:-0.02);Comparative height size at age 10(rs1569777:1:-0.02);Cystatin C levels(rs78648104:0.68:-0.03);Diastolic blood pressure(rs78648104:0.7:0.02;rs78648104:0.7:0.02);Educational attainment (MTAG) [MTAG](rs78648104:0.7:0.02);Educational attainment (years of education)(rs78648104:0.7:0.01);Hand grip strength(rs56068671:0.7:0);Hip circumference(rs1569777:1:-0.27);Impedance of leg (left)(rs1569777:1:0.83);Impedance of leg (right)(rs1569777:1:0.87);Impedance of whole body(rs1569777:1:1.61);Leg fat mass (left)(rs1569777:1:-0.04);Leg fat mass (right)(rs1569777:1:-0.05);Leg fat percentage (left)(rs1569777:1:-0.11);Leg fat-free mass (left)(rs1569777:1:-0.04);Leg fat-free mass (right)(rs1569777:1:-0.04);Leg predicted mass (left)(rs1569777:1:-0.04);Leg predicted mass (right)(rs1569777:1:-0.04);Never | smoking status(rs1569777:1:0.04);Past tobacco smoking(rs1569777:1:0.03);Smoking initiation (ever regular vs never regular) (MTAG)(rs141547796:0.7:-0.01);Systolic blood pressure(rs78648104:0.7:0.48;rs78648104:0.7:0.02;rs78648104:0.7:NA;rs78648104:0.7:0.02);Trunk fat mass(rs1569777:1:-0.15);Trunk fat-free mass(rs1569777:1:-0.09);Trunk predicted mass(rs1569777:1:-0.09);Waist circumference(rs1569777:1:-0.39);Weight(rs1569777:1:-0.48;rs1569777:1:-0.48);Whole body fat mass(rs1569777:1:-0.27);Whole body fat-free mass(rs1569777:1:-0.2);Whole body water mass(rs1569777:1:-0.15)	0
6q14.1	0	82988383	0.13 0.18 0.19 0.27 0.15	0.0 0.02 0.02 0.31 0.59	231753	231753	82872506	83104259	0.04	0.04	0	0	0	0	2	1	0	0	0	IBTK(eqtl:0.4:rs12660548)
6q14.1	0	101280435	0.06 0.34 0.1 0.36 0.14	0.01 0.02 0.03 0.08 0.41	231753	231753	101164558	101396311	0.04	0.04	0	0	0	0	1	1	0	0	0	ASCC3(eqtl:0.9:rs12527901;sqtl:0.2:rs12527901);GRIK2(eqtl:0.6:rs12527901)
6q14.1	0	116441646	0.12 0.28 0.25 0.25 0.11	0.0 0.02 0.03 0.1 0.35	231753	231753	116325769	116557522	0.04	0.04	0	0	0	0	4	1	0	0	Adolescent idiopathic scoliosis(rs482012:0.89:NA);Spherical equivalent(rs2228547:1:NA);Spherical power (left)(rs2228547:1:-0.14;rs2228547:1:-0.14);Spherical power (right)(rs2228547:1:-0.12)	CALHM6(eqtl:0.6:rs2228547);COL10A1(eqtl:0.1:rs2228547);DSE(eqtl:0.7:rs2228547);TSPYL1(eqtl:0.6:rs2228547)
6q14.1	0	127180738	0.09 0.01 0.15 0.45 0.27	0.0 0.0 0.02 0.1 0.36	231753	231753	127064861	127296614	0.04	0.04	0	0	0	0	0	0	0	0	"Diastolic blood pressure(rs1105956:0.73:NA;rs9375476:0.76:0.02);Heel bone mineral density (bmd) t-score, automated(rs12199006:1:0.04);Heel bone mineral density (bmd)(rs12199006:1:0);Heel bone mineral density(rs12199006:1:0.03;rs12199006:1:0.03);Heel broadband ultrasound attenuation, direct entry(rs12199006:1:0.64);Heel quantitative ultrasound index (qui), direct entry(rs12199006:1:0.74);Mean arterial pressure [East Asian](rs1105955:0.64:NA);Mean arterial pressure [Japanese](rs1105956:0.61:0.36);Mean arterial pressure(rs1105956:0.73:NA;rs34370526:0.76:0.02);Medication use (calcium channel blockers)(rs1105956:0.73:0.05);Sex hormone-binding globulin levels adjusted for BMI(rs12199006:1:-0.01);Sitting height(rs12199006:1:0.09);Standing height(rs12199006:1:0.18);Systolic blood pressure(rs34370526:0.76:0.02)"	0
6q14.1	0	146480773	0.1 0.46 0.08 0.12 0.2	0.0 0.0 0.02 0.2 0.4	231753	231753	146364896	146596649	0.04	0.03	0	0	0	0	1	0	0	0	0	0
6q21	1	109913308	0.41 0.17 0.46 0.38 0.41	0.0 0.0 0.01 0.1 0.87	200220	200219	109812089	110012308	0.02	0.02	0	0	0	0	1	1	1	1	"Ankle spacing width(rs10691068:0.84:-0.08);Appendicular lean mass(rs10691068:0.84:-0.02);Arm fat-free mass (left)(rs12529733:0.79:-0.01);Arm predicted mass (left)(rs12529733:0.79:-0.01);Arm predicted mass (right)(rs10691068:0.84:-0.01);Basal metabolic rate(rs10691068:0.84:-19.48);Comparative height size at age 10(rs9386799:0.7:-0.01);Forced expiratory volume in 1-second (fev1)(rs10691068:0.84:-0.01);Forced expiratory volume in 1-second (fev1), best measure(rs10691068:0.84:-0.01);Forced vital capacity (fvc)(rs10691068:0.84:-0.02);Forced vital capacity (fvc), best measure(rs10691068:0.84:-0.02);Granulocyte percentage of myeloid white cells(rs2275652:0.63:0.03);Height(rs1074765:0.84:NA);Monocyte percentage of white cells(rs12528822:0.74:-0.02);Mosaic loss of chromosome Y (Y chromosome dosage)(rs11251:0.69:0.03;rs11251:0.88:-0.01);Neutrophil percentage of white cells(rs13203252:0.63:0.02);Reticulocyte count(rs11153171:0.66:0.02);Reticulocyte fraction of red cells(rs11153171:0.66:0.02);Standing height(rs10691068:0.84:-0.18);Trunk fat-free mass(rs10691068:0.84:-0.08);Trunk predicted mass(rs10691068:0.84:-0.08);Whole body fat-free mass(rs10691068:0.84:-0.16);Whole body water mass(rs10691068:0.84:-0.12)"	AK9(eqtl:0.9:rs1998811;sqtl:0.4:rs1998811);CD164(eqtl:0.9:rs1998811;sqtl:0.8:rs1998811);FIG4(eqtl:1:rs1998811;sqtl:0.1:rs1998811);MICAL1(eqtl:0.9:rs1998811;sqtl:0.9:rs1998811);PPIL6(sqtl:0.2:rs1998811;eqtl:0.2:rs10457192);SMPD2(eqtl:1:rs1998811;sqtl:1:rs1998811);ZBTB24(eqtl:0.9:rs1998811)
6q21	0	33315152	0.43 0.04 0.5 0.34 0.41	0.01 0.02 0.02 0.28 1.06	200220	200220	33215042	33415262	0.02	0.03	17	39	109	500	19	11	0	0	"Coeliac disease(rs583129:1:-0.29);Eosinophil counts(rs583129:1:0.02;rs583129:1:0.02);Eosinophil percentage of white cells(rs583129:1:0.01);Low density lipoprotein cholesterol levels(rs583129:1:0.01);Mean platelet volume(rs583129:1:-0.01);Mean sphered cell volume(rs4484519:0.67:0.07);Mean spheric corpuscular volume(rs4484519:0.67:0.02;rs583129:1:-0.01);None of the above | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor(rs583129:1:0.03);Other diseases of the digestive system(rs583129:1:-0.1);Platelet count(rs583129:1:0.05;rs583129:1:2.59;rs583129:1:0.05;rs583129:1:0.05);Platelet crit(rs583129:1:0);Platelet distribution width(rs583129:1:-0.01;rs583129:1:-0.01);Plateletcrit(rs583129:1:0.05;rs583129:1:0.05);Type 1 diabetes(rs2480487:0.7:NA;rs2772387:0.69:NA;rs583129:1:0.1;rs583129:1:0.18)"	BAK1(eqtl:0.9:rs583129);CUTA(eqtl:0.6:rs583129);DAXX(eqtl:0.9:rs583129;sqtl:0.2:rs583129);HLA-DMA(eqtl:0.2:rs583129);HLA-DOA(eqtl:0.7:rs583129);HLA-DPA1(eqtl:0.3:rs583129);HLA-DPB1(eqtl:0.3:rs583129);HLA-DRB5(eqtl:0.4:rs583129);HSD17B8(eqtl:0.6:rs583129);TAPBP(eqtl:0.7:rs583129;sqtl:0.2:rs583129;pqtl:0.8:rs583129);UQCC2(eqtl:0.4:rs583129);WDR46(eqtl:0.7:rs583129);ZBTB22(eqtl:0.8:rs583129);ZBTB9(eqtl:0.7:rs583129)
6q21	0	66876588	0.44 0.49 0.33 0.34 0.32	0.0 0.02 0.02 0.41 0.79	200220	200220	66776478	66976698	0.02	0.04	0	0	0	0	0	0	0	0	0	0
6q21	0	77684060	0.36 0.3 0.45 0.2 0.44	0.0 0.01 0.01 0.18 0.76	200220	200220	77583950	77784170	0.02	0.02	0	0	0	0	0	0	0	0	0	0
6q21	0	82268753	0.36 0.19 0.32 0.45 0.46	0.0 0.0 0.01 0.29 0.7	200220	200220	82168643	82368863	0.02	0.03	0	0	0	0	0	0	0	0	Breast cancer(rs4448140:1:0.04);Systolic blood pressure(rs9449350:0.84:0.22)	0
6q21	0	88167897	0.45 0.23 0.39 0.47 0.28	0.0 0.02 0.02 0.09 1.02	200220	200220	88067787	88268007	0.02	0.05	0	0	0	0	5	3	0	0	Appendicular lean mass(rs2223880:1:-0.02;rs2223880:1:-0.01);Eosinophil counts(rs2223880:1:0.01;rs2223880:1:0.01);Eosinophil percentage of granulocytes(rs202150775:0.62:0.03;rs2223880:1:0.02);Eosinophil percentage of white cells(rs202150775:0.62:0.03;rs2223880:1:0.02;rs2223880:1:0.02);Eosinophill percentage(rs2223880:1:0.03);Frequency of stair climbing in last 4 weeks(rs10677082:0.65:-0.02);Granulocyte count(rs2223880:1:-0.02);Granulocyte percentage of myeloid white cells(rs2223880:1:-0.03);Impedance of leg (left)(rs2223880:1:0.45);Impedance of leg (right)(rs2223880:1:0.46);Lymphocyte percentage of white cells(rs2223880:1:0.02);Lymphocyte percentage(rs2223880:1:0.13);Mean corpuscular volume(rs2223880:1:-0.01);Monocyte percentage of white cells(rs2223880:1:0.02;rs2223880:1:0.02);Monocyte percentage(rs2223880:1:0.04);Neutrophil count(rs2223880:1:-0.02;rs2223880:1:-0.02;rs2223880:1:-0.02);Neutrophil percentage of granulocytes(rs202150775:0.62:-0.03;rs2223880:1:-0.03);Neutrophil percentage of white cells(rs2223880:1:-0.03;rs2223880:1:-0.03);Neutrophill count(rs2223880:1:-0.03);Neutrophill percentage(rs2223880:1:-0.2);Sum basophil neutrophil counts(rs2223880:1:-0.02);Sum neutrophil eosinophil counts(rs2223880:1:-0.02);White blood cell count(rs2223880:1:-0.02;rs2223880:1:-0.01)	AKIRIN2(eqtl:0.3:rs2223880);C6orf163(eqtl:0.9:rs2223880);CFAP206(eqtl:0.1:rs2223880);GJB7(eqtl:0.3:rs2223880);ORC3(sqtl:0.4:rs2223880);RARS2(eqtl:0.5:rs2223880;sqtl:0.8:rs2223880);SLC35A1(eqtl:0.9:rs2223880);SMIM8(eqtl:0.9:rs2223880;sqtl:0.9:rs2223880);ZNF292(eqtl:0.6:rs2223880)
6q21	0	98463359	0.44 0.36 0.25 0.42 0.34	0.0 0.0 0.01 0.1 0.72	200220	200220	98363249	98563469	0.02	0.03	0	0	0	0	1	0	0	0	A levels/as levels or equivalent | qualifications(rs9388017:1:0.04);Average total household income before tax(rs9388017:1:0.02);Body fat percentage(rs9388017:1:-0.1);Cereal intake(rs9388017:1:0.02);Childhood sunburn occasions(rs9388017:1:0.01);Coffee consumption(rs12189679:0.74:NA);Cognitive performance(rs9388017:1:0.03);College or university degree | qualifications(rs9388017:1:0.05);Dried fruit intake(rs9388017:1:0.01);Fluid intelligence score(rs9388017:1:0.06);Frequency of friend/family visits(rs9388017:1:0.01);Intelligence(rs9388017:1:0.03);Job involves heavy manual or physical work(rs9388017:1:-0.02);Job involves mainly walking or standing(rs9388017:1:-0.02);Leg fat mass (left)(rs9388017:1:-0.02);Leg fat mass (right)(rs9388017:1:-0.02);Leg fat percentage (left)(rs9388017:1:-0.09);Leg fat percentage (right)(rs9388017:1:-0.1);Muesli | cereal type(rs9388017:1:0.04);None of the above | qualifications(rs9388017:1:-0.05);Number of days/week walked 10+ minutes(rs9388017:1:-0.03);Participation in an health questionnaire (not invited vs invited)(rs9388017:1:-0.01);Positional arithmetic | fi4 (rs9388017:1:0.07);Sodium in urine(rs9388017:1:-0.56);Time spend outdoors in summer(rs9388017:1:-0.02);Time spent outdoors in winter(rs9388017:1:-0.01);Time spent using computer(rs9388017:1:0.01);Time spent watching television (tv)(rs9388017:1:-0.01);Trunk fat percentage(rs9388017:1:-0.11);Wholemeal or wholegrain | bread type(rs9388017:1:0.03)	0
6q21	0	105232233	0.37 0.64 0.28 0.26 0.34	0.0 0.01 0.01 0.13 0.7	200220	200220	105132123	105332343	0.02	0.03	0	0	0	0	1	1	0	0	Neuroblastoma(rs4336470:0.85:NA);Weight(rs62419342:0.96:0.02)	HACE1(eqtl:0.8:rs9322817;sqtl:0.4:rs9322817)
6q21	0	122078648	0.43 0.24 0.29 0.46 0.31	0.0 0.01 0.01 0.36 0.72	200220	200220	121978538	122178758	0.02	0.02	0	0	0	4	0	0	0	0	0	0
6q21	0	122635743	0.39 0.54 0.18 0.42 0.28	0.0 0.0 0.02 0.09 0.74	200220	200220	122535633	122735853	0.02	0.04	0	0	0	0	1	0	0	0	Lymphocyte counts(rs9388054:1:-0.01);Monocyte count(rs9388054:1:-0.01);Neurofibrillary tangles (SNP x SNP interaction)(rs472070:0.84:NA);White blood cell count(rs9388054:1:-0.01)	HSF2(eqtl:0.9:rs9388054);PKIB(eqtl:0.5:rs9388054);SERINC1(eqtl:0.6:rs9388054);SMPDL3A(eqtl:0.5:rs9388054)
6q22.31-1	1	118850956	0.53 0.38 0.46 0.27 0.29	0.0 0.0 0.01 0.18 0.43	219046	219045	118748269	118967314	0.01	0.01	0	0	0	0	3	2	0	1	Diastolic blood pressure(rs11153730:0.71:-0.01);Electrocardiogram morphology (amplitude at temporal datapoints) [-10 ms](rs11153730:0.71:0.06);Electrocardiogram morphology (amplitude at temporal datapoints) [-16 ms](rs11153730:0.71:0.08);Electrocardiogram morphology (amplitude at temporal datapoints) [10 ms](rs11153730:0.71:0.07);Electrocardiogram morphology (amplitude at temporal datapoints) [100 ms](rs11153730:0.71:-0.05);Electrocardiogram morphology (amplitude at temporal datapoints) [104 ms](rs11153730:0.71:-0.05);Electrocardiogram morphology (amplitude at temporal datapoints) [108 ms](rs11153730:0.71:-0.05);Electrocardiogram morphology (amplitude at temporal datapoints) [112 ms](rs11153730:0.71:-0.04);Electrocardiogram morphology (amplitude at temporal datapoints) [114 ms](rs11153730:0.71:-0.05);Electrocardiogram morphology (amplitude at temporal datapoints) [118 ms](rs11153730:0.71:-0.05);Electrocardiogram morphology (amplitude at temporal datapoints) [12 ms](rs11153730:0.71:0.07);Electrocardiogram morphology (amplitude at temporal datapoints) [122 ms](rs11153730:0.71:-0.05);Electrocardiogram morphology (amplitude at temporal datapoints) [126 ms](rs11153730:0.71:-0.06);Electrocardiogram morphology (amplitude at temporal datapoints) [128 ms](rs11153730:0.71:-0.06);Electrocardiogram morphology (amplitude at temporal datapoints) [130 ms](rs11153730:0.71:-0.05);Electrocardiogram morphology (amplitude at temporal datapoints) [132 ms](rs11153730:0.71:-0.05);Electrocardiogram morphology (amplitude at temporal datapoints) [134 ms](rs11153730:0.71:-0.05);Electrocardiogram morphology (amplitude at temporal datapoints) [136 ms](rs11153730:0.71:-0.05);Electrocardiogram morphology (amplitude at temporal datapoints) [140 ms](rs11153730:0.71:-0.06);Electrocardiogram morphology (amplitude at temporal datapoints) [142 ms](rs11153730:0.71:-0.06);Electrocardiogram morphology (amplitude at temporal datapoints) [144 ms](rs11153730:0.71:-0.06);Electrocardiogram morphology (amplitude at temporal datapoints) [146 ms](rs11153730:0.71:-0.06);Electrocardiogram morphology (amplitude at temporal datapoints) [156 ms](rs11153730:0.71:-0.05);Electrocardiogram morphology (amplitude at temporal datapoints) [164 ms](rs11153730:0.71:-0.06);Electrocardiogram morphology (amplitude at temporal datapoints) [166 ms](rs11153730:0.71:-0.06);Electrocardiogram morphology (amplitude at temporal datapoints) [168 ms](rs11153730:0.71:-0.05);Electrocardiogram morphology (amplitude at temporal datapoints) [174 ms](rs11153730:0.71:-0.05);Electrocardiogram morphology (amplitude at temporal datapoints) [180 ms](rs11153730:0.71:-0.05);Electrocardiogram morphology (amplitude at temporal datapoints) [188 ms](rs11153730:0.71:-0.05);Electrocardiogram morphology (amplitude at temporal datapoints) [272 ms](rs11153730:0.71:0.05);Electrocardiogram morphology (amplitude at temporal datapoints) [274 ms](rs11153730:0.71:0.05);Electrocardiogram morphology (amplitude at temporal datapoints) [276 ms](rs11153730:0.71:0.05);Electrocardiogram morphology (amplitude at temporal datapoints) [278 ms](rs11153730:0.71:0.05);Electrocardiogram morphology (amplitude at temporal datapoints) [280 ms](rs11153730:0.71:0.06);Electrocardiogram morphology (amplitude at temporal datapoints) [282 ms](rs11153730:0.71:0.06);Electrocardiogram morphology (amplitude at temporal datapoints) [284 ms](rs11153730:0.71:0.06);Electrocardiogram morphology (amplitude at temporal datapoints) [296 ms](rs11153730:0.71:0.07);Electrocardiogram morphology (amplitude at temporal datapoints) [298 ms](rs11153730:0.71:0.08);Electrocardiogram morphology (amplitude at temporal datapoints) [304 ms](rs11153730:0.71:0.07);Electrocardiogram morphology (amplitude at temporal datapoints) [306 ms](rs11153730:0.71:0.08);Electrocardiogram morphology (amplitude at temporal datapoints) [312 ms](rs11153730:0.71:0.08);Electrocardiogram morphology (amplitude at temporal datapoints) [314 ms](rs11153730:0.71:0.08);Electrocardiogram morphology (amplitude at temporal datapoints) [318 ms](rs11153730:0.71:0.08);Electrocardiogram morphology (amplitude at temporal datapoints) [322 ms](rs11153730:0.71:0.07);Electrocardiogram morphology (amplitude at temporal datapoints) [324 ms](rs11153730:0.71:0.07);Electrocardiogram morphology (amplitude at temporal datapoints) [332 ms](rs11153730:0.71:0.07);Electrocardiogram morphology (amplitude at temporal datapoints) [334 ms](rs11153730:0.71:0.07);Electrocardiogram morphology (amplitude at temporal datapoints) [336 ms](rs11153730:0.71:0.07);Electrocardiogram morphology (amplitude at temporal datapoints) [342 ms](rs11153730:0.71:0.06);Electrocardiogram morphology (amplitude at temporal datapoints) [344 ms](rs11153730:0.71:0.06);Electrocardiogram morphology (amplitude at temporal datapoints) [346 ms](rs11153730:0.71:0.05);Electrocardiogram morphology (amplitude at temporal datapoints) [358 ms](rs11153730:0.71:0.04);Electrocardiogram morphology (amplitude at temporal datapoints) [360 ms](rs11153730:0.71:0.04);Electrocardiogram morphology (amplitude at temporal datapoints) [362 ms](rs11153730:0.71:0.04);Electrocardiogram morphology (amplitude at temporal datapoints) [366 ms](rs11153730:0.71:0.03);Electrocardiogram morphology (amplitude at temporal datapoints) [368 ms](rs11153730:0.71:0.03);Electrocardiogram morphology (amplitude at temporal datapoints) [68 ms](rs11153730:0.71:-0.04);Electrocardiogram morphology (amplitude at temporal datapoints) [72 ms](rs11153730:0.71:-0.04);Electrocardiogram morphology (amplitude at temporal datapoints) [76 ms](rs11153730:0.71:-0.04);Electrocardiogram morphology (amplitude at temporal datapoints) [82 ms](rs11153730:0.71:-0.05);Electrocardiogram morphology (amplitude at temporal datapoints) [84 ms](rs11153730:0.71:-0.05);Heart rate(rs11153730:0.67:-0.38);Myocardial fractal dimension (slice 8)(rs283046:0.69:0);PR interval(rs11153730:0.62:-1);QRS duration [EA](rs11153730:0.6:NA);QRS duration(rs11153730:0.71:0.58);QT interval(rs11153730:0.71:1.65;rs11153730:0.71:0.06)	CEP85L(eqtl:0.5:rs12207209);SLC35F1(eqtl:0.5:rs2356176;sqtl:0.8:rs2356176)
6q22.31-1	0	29115748	0.55 0.11 0.51 0.38 0.45	0.0 0.01 0.01 0.09 0.27	219046	219046	29006225	29225271	0.01	0.02	83	128	185	409	7	0	0	0	"""Ankylosing spondylitis, strict definition""(rs3130720:1:-0.48);""Disorders of sclera, cornea, iris and ciliary body""(rs3130720:1:-0.09);""Other predominantly sexually transmitted diseases, not elsewhere classified""(rs3130720:1:-0.14);""Reactive arthropathies, FINNGEN""(rs3130720:1:-0.22);""Rheumatoid arthritis , including avohilmo""(rs3130720:1:-0.11);""Type 1 diabetes, strict (exclude DM2)""(rs3130720:1:-0.26);""Type 1 diabetes, strict definition""(rs3130720:1:-0.27);""Type 1 diabetes, strict definition, subgroup 1""(rs3130720:1:-0.29);""Type 1 diabetes, wide definition""(rs3130720:1:-0.14);""Type 1 diabetes, wide definition, subgroup 1""(rs3130720:1:-0.2);""Type1 diabetes, definitions combined""(rs3130720:1:-0.26);Acute and subacute iridocyclitis(rs3130720:1:-0.21);Adventurousness(rs1884123:0.66:0.01);Alcohol consumption (drinks per week) (MTAG)(rs3117334:0.81:0.01);Ankylosing spondylitis(rs3130720:1:-0.43);Appendicular lean mass(rs3130720:1:0.01);Autoimmune diseases(rs3130720:1:-0.06);Background diabetic retinopathy(rs3130720:1:-0.2);Biological medication for rheuma(rs3130720:1:-0.19);Celiac disease(rs3130720:1:-0.51);Coeliac disease(rs3130720:1:-0.25);Comparative height size at age 10(rs3130720:1:0.01);Diabetes or endocrine disease(rs3130720:1:0);Diabetic background retinopathy(rs3130720:1:-0.19);Diabetic ketoacidosis(rs3130720:1:-0.17);Diabetic retinopathy (more control exclusions)(rs3130720:1:-0.07);Diabetic retinopathy(rs3130720:1:-0.07;rs3130720:1:-0.15);Diseases of the eye and adnexa(rs3130720:1:-0.04);Disorders of choroid and retina(rs3130720:1:-0.06);Disorders of iron metabolism(rs3130720:1:0.54);Eosinophil counts(rs3130720:1:0.01;rs3130720:1:0.01);FEV1(rs3130720:1:0.01);Finngen Rheumatological endpoints(rs3130720:1:-0.06);First line medication for Crohns disease(rs3130720:1:-0.05);Forced expiratory volume in 1-second (fev1)(rs3130720:1:0.01);Forced expiratory volume in 1-second (fev1), best measure(rs3130720:1:0.01);Forced vital capacity (fvc)(rs3130720:1:0.01);General risk tolerance (MTAG)(rs1233508:0.66:-0.01);Haematocrit percentage(rs3130720:1:0.05);Haemoglobin concentration(rs3130720:1:0.02);Height(rs3129109:0.61:0.03);Hematocrit(rs3130720:1:0.02;rs3130720:1:0.02);Hemoglobin concentration(rs3130720:1:0.02;rs3130720:1:0.02);Hemoglobin levels(rs209126:0.76:-0.02);Hemoglobin(rs3130720:1:0.02);High light scatter reticulocyte count(rs3130720:1:0.02);High light scatter reticulocyte percentage of red cells(rs3130720:1:0.01);Hypothyroidism or myxedema(rs3130720:1:0);Insulin product | treatment/medication code(rs3130720:1:-0.16);Interstitial lung disease endpoints(rs3130720:1:-0.06);Intestinal malabsorption (non-celiac)(rs3130720:1:-0.45);Iridocyclitis(rs3130720:1:-0.2);KELA_REIMBURSEMENT_202(rs3130720:1:-0.14);Liver iron content(rs3130720:1:0.04);Lymphocyte counts(rs3130720:1:0.03;rs3130720:1:0.03;rs3130720:1:0.02);Malabsorption/coeliac disease | non-cancer illness code, self-reported(rs3130720:1:-0.52);Mean corpuscular haemoglobin(rs3130720:1:0.04);Mean corpuscular hemoglobin concentration(rs3130720:1:0.01;rs3130720:1:0.01);Mean corpuscular hemoglobin(rs3130720:1:0.02;rs3130720:1:0.02;rs3130720:1:0.02);Mean corpuscular volume(rs9257573:0.96:NA;rs3130720:1:0.02;rs3130720:1:0.02;rs3130720:1:0.08);Mean reticulocyte volume(rs3130720:1:-0.02);Monocyte count(rs3130720:1:0.02;rs3130720:1:0.02);Neutrophil percentage of white cells(rs3130720:1:-0.01);Other diabetic retinopathy(rs3130720:1:-0.24);Other retinal disorders(rs3130720:1:-0.08);Other specified/unspecified inflammatory spondylopathies(rs3130720:1:-0.29);Platelet-to-lymphocyte ratio(rs9257774:0.66:NA;rs9257774:0.66:NA);Polyarthropathies(rs3130720:1:-0.08);Proliferative diabetic retinopathy(rs3130720:1:-0.24);Reactive arthropathies(rs3130720:1:-0.2);Red blood cell (erythrocyte) distribution width(rs3130720:1:-0.01);Red cell distribution width(rs3130720:1:-0.01;rs3130720:1:-0.01);Reticulocyte count(rs3130720:1:0.02);Reticulocyte fraction of red cells(rs3130720:1:0.02);Rheumatoid arthritis(rs3130720:1:-0.12);Risk taking(rs3130720:1:0.03);Second line medication for Crohns disease(rs3130720:1:-0.08);Spondyloarthritis(rs3130720:1:-0.25);Spondylopathies (FG)(rs3130720:1:-0.35);Spondylopathies(rs3130720:1:-0.07);Standing height(rs3130720:1:0.12);Started insulin within one year diagnosis of diabetes(rs3130720:1:-0.19);Thyroid problem (not cancer)(rs3130720:1:0);Trunk fat-free mass(rs3130720:1:0.04);Trunk predicted mass(rs3130720:1:0.04);Type 1 diabetes with coma(rs3130720:1:-0.29);Type 1 diabetes with ketoacidosis(rs3130720:1:-0.33);Type 1 diabetes with ophthalmic complications(rs3130720:1:-0.23);Type 1 diabetes with other specified/multiple/unspecified complications(rs3130720:1:-0.21);Type 1 diabetes without complications(rs3130720:1:-0.21);Type 1 diabetes(rs3130720:1:-0.33;rs3130720:1:-0.24;rs3130720:1:-0.1;rs3130720:1:-0.17;rs3130720:1:-0.14);Unspecified diabetic retinopathy(rs3130720:1:-0.18);Waist circumference adjusted for body mass index(rs2207699:0.63:NA);White blood cell (leukocyte) count(rs3130720:1:0.03);White blood cell count(rs3130720:1:0.02;rs3130720:1:0.02;rs3130720:1:0.02)"	HLA-A(eqtl:0.4:rs3130720);TRIM27(eqtl:0.9:rs3130720);ZFP57(eqtl:0.6:rs3130720);ZKSCAN3(eqtl:0.3:rs3130720);ZKSCAN4(eqtl:0.1:rs3130720);ZKSCAN8P1(sqtl:0.3:rs3130720);ZNF311(eqtl:0.3:rs3130720);ZSCAN23(eqtl:0.4:rs3130720);ZSCAN26(eqtl:0.8:rs3130720;sqtl:0.2:rs3130720);ZSCAN31(eqtl:0.8:rs3130720;sqtl:0.6:rs3130720);ZSCAN9(eqtl:0.9:rs3130720;sqtl:0.1:rs3130720)
6q22.31-1	0	44972209	0.54 0.34 0.33 0.28 0.52	0.0 0.0 0.01 0.05 0.61	219046	219046	44862686	45081732	0.01	0.02	0	0	0	0	1	1	0	0	"Appendicular lean mass(rs1159131:1:-0.02;rs1159131:1:-0.03;rs1159131:1:-0.02);Arm fat-free mass (left)(rs1159131:1:-0.01);Arm fat-free mass (right)(rs1159131:1:-0.01);Arm predicted mass (left)(rs1159131:1:-0.01);Arm predicted mass (right)(rs1159131:1:-0.01);Basal metabolic rate(rs1159131:1:-12.03);Cystatin C levels(rs2038555:0.7:0.01);Glaucoma (multi-trait analysis)(rs2145826:0.66:-0.07);Heel bone mineral density (bmd) (left)(rs1159131:1:0);Heel bone mineral density (bmd) (right)(rs1159131:1:0);Heel bone mineral density (bmd) t-score, automated (right)(rs1159131:1:-0.03);Heel bone mineral density (bmd) t-score, automated(rs149560189:0.69:-0.04;rs1159131:1:-0.03);Heel bone mineral density (bmd)(rs149560189:0.69:0;rs1159131:1:0);Heel bone mineral density T score(rs2038555:0.7:-0.03);Heel bone mineral density(rs764396:0.69:-0.03;rs1159131:1:-0.03;rs1159131:1:-0.03);Heel broadband ultrasound attenuation (right)(rs9717853:0.61:-0.57;rs1159131:1:-0.42);Heel broadband ultrasound attenuation, direct entry(rs149560189:0.69:-0.56;rs1159131:1:-0.46);Heel quantitative ultrasound index (qui), direct entry (right)(rs1159131:1:-0.55);Heel quantitative ultrasound index (qui), direct entry(rs149560189:0.69:-0.66;rs1159131:1:-0.59);Leg fat-free mass (left)(rs1159131:1:-0.02);Leg fat-free mass (right)(rs1159131:1:-0.02);Leg predicted mass (left)(rs1159131:1:-0.01);Leg predicted mass (right)(rs1159131:1:-0.02);Lymphocyte counts(rs9395049:0.64:-0.01;rs1159131:1:0.01);Osteoarthritis (hip)(rs1159131:1:0.07);Otosclerosis(rs1159131:1:0.2);Sitting height(rs1159131:1:-0.09);Standing height(rs1159131:1:-0.1);Trunk fat-free mass(rs1159131:1:-0.05);Trunk predicted mass(rs1159131:1:-0.05);Whole body fat-free mass(rs1159131:1:-0.1);Whole body water mass(rs1159131:1:-0.08)"	CAPN11(sqtl:0.1:rs1159131);RUNX2(eqtl:0.8:rs1159131;sqtl:0.7:rs1159131);SUPT3H(eqtl:1:rs1159131)
6q22.31-1	0	49172864	0.5 0.3 0.48 0.34 0.34	0.0 0.02 0.02 0.08 0.25	219046	219046	49063341	49282387	0.01	0.03	0	0	0	0	0	0	0	0	0	CENPQ(eqtl:0.9:rs990237;sqtl:0.4:rs990237);CRISP2(pqtl:0.5:rs990237);MMUT(eqtl:1:rs990237)
6q22.31-1	0	64362200	0.56 0.05 0.43 0.54 0.37	0.0 0.01 0.01 0.08 0.24	219046	219046	64252677	64471723	0.01	0.02	0	0	0	0	3	1	0	0	Schizophrenia vs Tourette's syndrome and other tic disorders (ordinary least squares (OLS))(rs1884117:0.99:NA);Weight(rs1889096:0.99:-0.02)	LGSN(eqtl:1:rs1212828);PHF3(eqtl:0.4:rs1212828);PTP4A1(eqtl:0.2:rs1212828;sqtl:0.2:rs1212828)
6q22.31-1	0	80816296	0.48 0.59 0.29 0.3 0.33	0.0 0.02 0.04 0.23 0.6	219046	219046	80706773	80925819	0.01	0.04	0	0	0	0	2	2	0	0	"Appendicular lean mass(rs9352808:0.66:-0.04;rs2298307:1:-0.03;rs2298307:1:-0.02;rs2298307:1:-0.02);Arm fat-free mass (left)(rs2298307:1:-0.01);Arm fat-free mass (right)(rs2298307:1:-0.01);Arm predicted mass (left)(rs2298307:1:-0.01);Arm predicted mass (right)(rs2298307:1:-0.01);Basal metabolic rate(rs755039791:0.89:-15.66;rs2298307:1:-14.89);Comparative height size at age 10(rs1359239:0.89:-0.01;rs2298307:1:-0.01);Diastolic blood pressure(rs7753695:0.8:0.1;rs9448894:0.98:0.01);Diastolic blood pressure, automated reading(rs4706113:0.99:0.13);Height(rs2322633:0.99:NA;rs3793000:0.67:-0.03);Joint mobility (Beighton score)(rs4706831:0.67:NA);Leg fat-free mass (left)(rs755039791:0.89:-0.02;rs2298307:1:-0.02);Leg fat-free mass (right)(rs755039791:0.89:-0.02;rs2298307:1:-0.02);Leg predicted mass (left)(rs755039791:0.89:-0.02;rs2298307:1:-0.02);Leg predicted mass (right)(rs755039791:0.89:-0.02;rs2298307:1:-0.02);Sitting height(rs2298307:1:-0.16);Spine bone size(rs9341808:0.91:-0.05);Standing height(rs2298307:1:-0.18);Trunk fat-free mass(rs755039791:0.89:-0.07;rs2298307:1:-0.07);Trunk predicted mass(rs755039791:0.89:-0.07;rs2298307:1:-0.06);Waist circumference adjusted for body mass index(rs10080237:0.75:-0.02);Weight(rs9343974:0.94:-0.18;rs9341808:0.91:-0.18);Whole body fat-free mass(rs2298307:1:-0.12);Whole body water mass(rs2298307:1:-0.09)"	BCKDHB(eqtl:0.8:rs2298307;sqtl:0.2:rs2298307);ELOVL4(eqtl:0.8:rs2298307)
6q22.31-1	0	101263516	0.51 0.23 0.31 0.43 0.52	0.01 0.02 0.03 0.08 0.41	219046	219046	101153993	101373039	0.01	0.04	0	0	0	0	1	1	0	0	Age at first sexual intercourse(rs7740783:1:0.01);Age when periods started (menarche)(rs11458788:0.78:-0.02;rs7740783:1:0.02);Arm fat-free mass (left)(rs11458788:0.78:0.01;rs7740783:1:-0.01);Arm fat-free mass (right)(rs11458788:0.78:0.01;rs7740783:1:-0.01);Arm predicted mass (left)(rs11458788:0.78:0.01;rs7740783:1:-0.01);Arm predicted mass (right)(rs11458788:0.78:0.01;rs7740783:1:-0.01);Basal metabolic rate(rs7740783:1:-11.33);Body mass index (bmi)(rs240764:0.77:0.06);Depression(rs240764:0.77:0.02);Depressive symptoms(rs4461738:0.81:0.01);Impedance of arm (left)(rs11458788:0.78:-0.64;rs7740783:1:0.55);Impedance of arm (right)(rs11458788:0.78:-0.62;rs7740783:1:0.54);Impedance of whole body(rs11458788:0.78:-1.13;rs7740783:1:1.04);Neuroticism(rs240764:0.77:0.03;rs4461738:0.81:0.01);Positive affect(rs4461738:0.81:0.01);Trunk fat-free mass(rs11458788:0.78:0.05;rs7740783:1:-0.05);Trunk predicted mass(rs11458788:0.78:0.05;rs7740783:1:-0.04);Well-being spectrum (multivariate analysis)(rs4461738:0.81:0.01);Whole body fat-free mass(rs11458788:0.78:0.09;rs7740783:1:-0.09);Whole body water mass(rs11458788:0.78:0.07;rs7740783:1:-0.06)	ASCC3(eqtl:0.7:rs7740783;sqtl:0.7:rs7740783);GRIK2(eqtl:0.3:rs7740783)
6q22.31-1	0	111579045	0.48 0.06 0.49 0.42 0.46	0.0 0.01 0.03 0.28 0.51	219046	219046	111469522	111688568	0.01	0.04	0	0	0	0	3	3	0	0	Esophageal varix(rs9487666:0.75:-0.18);Hair color(rs7760535:0.73:NA);Mean corpuscular hemoglobin(rs7774177:1:-0.01;rs7774177:1:-0.01);Mean corpuscular volume(rs7774177:1:-0.01;rs7774177:1:-0.06;rs7774177:1:-0.02);Mean reticulocyte volume(rs7774177:1:-0.01;rs7774177:1:-0.11);Mean sphered cell volume(rs7774177:1:-0.07);Mean spheric corpuscular volume(rs7774177:1:-0.01);Metabolic traits [isoleucine/tyrosine + 10 other traits](rs7760535:0.73:NA);Psoriasis [EA](rs240993:0.62:NA);Psoriasis(rs456865:0.98:NA);Red blood cell count(rs7774177:1:0.01)	MFSD4B(eqtl:0.7:rs7774177);REV3L(eqtl:0.1:rs7774177);TRAF3IP2(eqtl:0.8:rs7774177)
6q22.31-1	0	126683594	0.55 0.73 0.34 0.03 0.32	0.0 0.0 0.01 0.16 0.32	219046	219046	126574071	126793117	0.01	0.02	0	0	0	0	1	1	0	0	"Age when periods started (menarche)(rs9398803:1:-0.02);Ankle spacing width(rs9398803:1:0.08);Appendicular lean mass(rs9388490:0.87:0.05;rs9398803:1:0.05;rs9398803:1:0.05;rs9398803:1:0.04);Arm fat percentage (left)(rs9398803:1:-0.1);Arm fat-free mass (left)(rs9398803:1:0.01);Arm fat-free mass (right)(rs9398803:1:0.01);Arm predicted mass (left)(rs9388490:0.87:0.01;rs9398803:1:0.01);Arm predicted mass (right)(rs9398803:1:0.01);Average total household income before tax(rs9388490:0.87:0.02);Basal metabolic rate(rs9398803:1:25);Bioavailable testosterone levels(rs9398803:1:0.02);Body fat percentage(rs9398803:1:-0.09);Brain region volumes [left lateral orbitofrontal](rs17754780:0.9:NA);Comparative height size at age 10(rs9398803:1:0.03);Coronary artery disease(rs9398803:1:-0.04);Diabetes or endocrine disease(rs9398803:1:0);Diabetes(rs9398803:1:0);Feeling nervous(rs6919397:0.9:-0.01);Forced expiratory volume in 1-second (fev1)(rs9398803:1:0.01);Forced expiratory volume in 1-second (fev1), best measure(rs9398803:1:0.01);Forced expiratory volume in 1-second (fev1), predicted(rs9398803:1:0.01);Forced vital capacity (fvc)(rs9398803:1:0.02);Forced vital capacity (fvc), best measure(rs9398803:1:0.02);Haematocrit percentage(rs9375435:0.89:-0.06;rs9398803:1:-0.05);Haemoglobin concentration(rs9398803:1:-0.02);Hematocrit(rs9398803:1:-0.02;rs9398803:1:-0.02;rs9398803:1:-0.02);Hemoglobin concentration(rs9398803:1:-0.02);Hemoglobin(rs9398803:1:-0.02);Highest math class taken (MTAG) [MTAG](rs9388490:0.87:0.01);Hip circumference adjusted for BMI(rs1030807851:0.9:0.03);Household income (MTAG)(rs9388490:0.87:0.01);Impedance of arm (left)(rs35510806:1:-0.61;rs9398803:1:-0.61);Impedance of arm (right)(rs9388487:1:-0.58;rs9398803:1:-0.58);Impedance of whole body(rs9398803:1:-1.11;rs9398803:1:-1.11);Kidney volume(rs9398803:1:0.04);Leg fat percentage (left)(rs9398803:1:-0.07);Leg fat percentage (right)(rs9398803:1:-0.08);Leg fat-free mass (left)(rs9398803:1:0.03);Leg fat-free mass (right)(rs9398803:1:0.03);Leg predicted mass (left)(rs9388490:0.87:0.03;rs9398803:1:0.03);Leg predicted mass (right)(rs9398803:1:0.03);Low density lipoprotein cholesterol levels(rs9398803:1:-0.01);Lung function (FEV1/FVC)(rs9398804:0.88:NA);Lung function (FVC)(rs9398803:1:0.02);Male-pattern baldness(rs9398803:1:0.12;rs9398803:1:-0.06);Neutrophil count(rs9398803:1:-0.01);Neutrophill count(rs9398803:1:-0.02);Pattern 1 | hair/balding pattern(rs9398803:1:0.08);Pattern 3 | hair/balding pattern(rs9398803:1:-0.05);Pattern 4 | hair/balding pattern(rs9398803:1:NA;rs9398803:1:-0.1);Red blood cell count(rs9398803:1:-0.02;rs9398803:1:-0.02);Serum phosphate levels(rs9388489:0.9:0.02);Sex hormone-binding globulin levels adjusted for BMI(rs9398803:1:-0.01;rs9398803:1:-0.01);Sitting height(rs9398803:1:0.15);Standing height(rs9398803:1:0.31);Trunk fat-free mass(rs9388490:0.87:0.14;rs9398803:1:0.13);Trunk predicted mass(rs9398803:1:0.12);Type 1 diabetes(rs2045258:0.9:NA;rs9388489:0.9:NA;rs9398803:1:0.11;rs9398803:1:0.1;rs9398803:1:0.09);Type 2 diabetes(rs9398803:1:0.04);Weight(rs9398803:1:0.2;rs9398803:1:0.21);White blood cell (leukocyte) count(rs9398803:1:-0.03);White blood cell count(rs9398803:1:-0.01;rs9398803:1:-0.01);Whole body fat-free mass(rs9398803:1:0.22);Whole body water mass(rs9398803:1:0.16)"	CENPW(eqtl:0.9:rs9398803)
6q22.31-1	0	145920732	0.51 0.02 0.37 0.51 0.54	0.0 0.01 0.01 0.1 0.36	219046	219046	145811209	146030255	0.01	0.02	0	0	0	0	1	1	0	0	Appendicular lean mass(rs6570699:1:-0.01;rs6570699:1:-0.02);Heel bone mineral density(rs1355146:0.96:NA);Lobe attachment (rater-scored or self-reported)(rs375873:0.92:NA;rs1292335:1:NA;rs6570726:0.97:NA;rs2814864:0.65:NA)	EPM2A(eqtl:0.9:rs6570699;sqtl:0.8:rs6570699);FBXO30(eqtl:0.2:rs6570699);SHPRH(eqtl:0.7:rs6570699)
6q22.31-2	1	121514401	0.81 0.11 0.81 0.69 0.49	0.0 0.01 0.02 0.21 0.67	148323	148322	121380134	121528456	0.02	0.02	0	0	0	0	1	1	0	0	0	TBC1D32(sqtl:0.9:rs1846865)
6q22.31-2	0	54282223	0.79 0.55 0.71 0.42 0.53	0.0 0.04 0.06 0.25 0.69	148323	148323	54208061	54356384	0.02	0.06	0	0	0	0	1	0	0	0	0	TINAG(eqtl:0.7:rs2397158)
6q22.31-2	0	65397011	0.76 0.37 0.74 0.41 0.66	0.0 0.04 0.05 0.3 0.61	148323	148323	65322849	65471172	0.02	0.06	0	0	0	0	1	0	0	0	0	0
6q22.31-2	0	66308325	0.78 0.55 0.53 0.4 0.61	0.02 0.03 0.06 0.22 0.49	148323	148323	66234163	66382486	0.02	0.07	0	0	0	0	1	0	0	0	0	0
6q22.31-2	0	97751525	0.82 0.7 0.63 0.16 0.57	0.01 0.05 0.05 0.2 0.56	148323	148323	97677363	97825686	0.02	0.05	59	103	144	149	2	1	0	0	Well-being spectrum (multivariate analysis)(rs6931902:0.7:NA)	MMS22L(eqtl:0.6:rs9387231)
6q22.31-2	0	119772827	0.83 0.32 0.8 0.39 0.53	0.0 0.02 0.02 0.2 0.5	148323	148323	119698665	119846988	0.02	0.03	0	0	0	0	1	0	0	0	0	MAN1A1(eqtl:0.1:rs12204367)
6q22.31-2	0	129038275	0.82 0.13 0.79 0.48 0.61	0.0 0.01 0.06 0.31 0.56	148323	148323	128964113	129112436	0.02	0.07	0	0	0	0	0	0	0	0	0	0
6q22.31-2	0	133594176	0.81 0.41 0.64 0.51 0.6	0.0 0.03 0.05 0.27 0.66	148323	148323	133520014	133668337	0.02	0.07	0	0	0	0	1	0	0	0	"Heel bone mineral density (bmd) (right)(rs754997:1:0);Heel bone mineral density (bmd) t-score, automated (right)(rs754997:1:-0.04);Heel bone mineral density (bmd)(rs754997:1:0);Heel bone mineral density(rs754997:1:-0.03);Heel broadband ultrasound attenuation (right)(rs754997:1:-0.57);Heel broadband ultrasound attenuation, direct entry(rs754997:1:-0.44);Heel quantitative ultrasound index (qui), direct entry (right)(rs754997:1:-0.65)"	SLC18B1(eqtl:0.3:rs754997);VNN2(eqtl:0.5:rs754997)
6q22.31-2	0	146834145	0.78 0.58 0.48 0.26 0.75	0.01 0.03 0.04 0.54 0.81	148323	148323	146759983	146908306	0.02	0.08	0	0	0	0	1	1	0	0	0	0
6q22.31-2	0	149754677	0.85 0.73 0.6 0.23 0.59	0.0 0.02 0.05 0.31 0.72	148323	148323	149680515	149828838	0.02	0.08	0	0	0	0	4	2	0	0	0	GINM1(eqtl:0.5:rs1934117);NUP43(eqtl:0.4:rs1934117);ZC3H12D(eqtl:0.1:rs1934117)
7q11.21	1	66191599	0.13 0.06 0.12 0.21 0.14	0.0 0.0 0.0 0.04 0.12	445555	445554	65986450	66432004	0.02	0.02	0	0	0	0	8	2	0	0	0	ASL(sqtl:0.9:rs145710538;eqtl:0.3:rs145998666);CRCP(eqtl:0.8:rs145710538;sqtl:0.9:rs145710538);KCTD7(eqtl:0.8:rs3962133);RABGEF1(sqtl:0.4:rs145710538;eqtl:0.7:rs145998666);TMEM248(eqtl:0.5:rs145710538;sqtl:0.8:rs145710538);TPST1(eqtl:0.7:rs10081172;pqtl:0.2:rs6964080);TYW1(eqtl:0.1:rs10081172)
7q11.21	0	56171760	0.15 0.21 0.09 0.02 0.16	0.0 0.01 0.01 0.1 0.31	445555	445555	55948982	56394537	0.02	0.09	0	0	0	0	11	7	0	0	0	CCT6A(eqtl:0.7:rs6593298);CHCHD2(eqtl:1:rs6593298);NIPSNAP2(eqtl:0.7:rs6593298;sqtl:0.2:rs6593298);NUPR2(eqtl:0.9:rs6593298;sqtl:0.5:rs6593298);PHKG1(eqtl:1:rs6593298);PSPH(sqtl:0.5:rs6593298);SUMF2(eqtl:0.5:rs6593298);ZNF713(eqtl:0.8:rs6593298)
7q11.21	0	62491454	0.11 0.19 0.08 0.1 0.15	0.0 0.0 0.01 0.09 0.13	445555	445555	62268676	62714231	0.02	0.09	0	0	0	0	0	0	0	0	0	0
7q11.21	0	63632543	0.09 0.27 0.07 0.13 0.11	0.0 0.01 0.01 0.09 0.31	445555	445555	63409765	63855320	0.02	0.08	0	0	0	0	6	2	0	0	0	ERV3-1(eqtl:0.8:rs10277428);ZNF107(eqtl:0.2:rs10277428);ZNF680(eqtl:0.5:rs10277428);ZNF736(eqtl:0.1:rs10277428)
7q11.21	0	64784025	0.14 0.03 0.15 0.28 0.09	0.0 0.01 0.02 0.06 0.12	445555	445555	64561247	65006802	0.02	0.05	0	0	0	0	3	1	0	0	0	ERV3-1(eqtl:1:rs12668603);GUSB(eqtl:0.4:rs12668603);ZNF117(eqtl:0.3:rs12668603)
7q11.21	0	65305632	0.11 0.06 0.2 0.14 0.21	0.0 0.0 0.0 0.03 0.08	445555	445555	65082854	65528409	0.02	0.02	0	0	0	0	7	2	0	0	Lymphocyte percentage of white cells(rs1404147:0.99:0.02;rs3813708:1:-0.02);Lymphocyte percentage(rs1404147:0.99:0.17;rs3813708:1:-0.16);Monocyte percentage of white cells(rs3813708:1:-0.02);Neutrophil count(rs13235246:0.94:0.03;rs4718273:0.99:-0.03;NA:1:-0.03;rs427044:0.95:NA;rs3813708:1:0.03;rs3813708:1:0.03);Neutrophil percentage of white cells(NA:0.89:0.03;rs3813708:1:0.03);Neutrophill count(rs3813708:1:0.03);Neutrophill percentage(rs3813708:1:0.22);White blood cell count(rs35631459:0.85:0.02;rs3813708:1:0.02)	ASL(eqtl:1:rs3813708);CRCP(eqtl:0.4:rs3813708;sqtl:0.2:rs3813708);ERV3-1(eqtl:0.9:rs3813708);GUSB(eqtl:1:rs3813708);KCTD7(eqtl:0.8:rs3813708);RABGEF1(sqtl:0.1:rs3813708);TPST1(eqtl:0.9:rs3813708);VKORC1L1(eqtl:1:rs3813708);ZNF117(eqtl:0.5:rs3813708)
7q11.21	0	69210740	0.17 0.05 0.15 0.07 0.23	0.0 0.0 0.01 0.03 0.27	445555	445555	68987962	69433517	0.02	0.03	0	0	0	0	2	1	0	0	Pattern 1 | hair/balding pattern(rs10260553:1:-0.06);Response to serotonin reuptake inhibitors in non-psychotic unipolar depression(rs7785360:0.68:NA)	AUTS2(eqtl:0.1:rs10260553)
7q11.21	0	86073449	0.12 0.23 0.03 0.06 0.13	0.0 0.01 0.02 0.11 0.29	445555	445555	85850671	86296226	0.02	0.1	0	0	0	0	1	0	0	0	0	GRM3(eqtl:0.7:rs113970552)
7q11.21	0	118872938	0.17 0.02 0.1 0.24 0.11	0.0 0.0 0.01 0.12 0.18	445555	445555	118650160	119095715	0.02	0.1	0	0	0	0	0	0	0	0	0	0
7q11.21	0	119398753	0.15 0.05 0.08 0.3 0.12	0.0 0.0 0.0 0.1 0.28	445555	445555	119175975	119621530	0.02	0.1	0	0	0	0	1	0	0	0	0	0
7q11.21-2	1	66600219	0.78 0.52 0.69 0.93 0.8	0.0 0.01 0.02 0.16 0.35	64833	64832	66568235	66633067	0.02	0.02	0	0	0	0	2	1	0	0	0	KCTD7(eqtl:0.1:rs1815098);SBDS(eqtl:0.2:rs11769928);TPST1(eqtl:0.9:rs10236844);TYW1(eqtl:1:rs10236844;sqtl:1:rs113111427)
7q11.21-2	0	56241800	0.76 0.8 0.67 0.75 0.72	0.0 0.01 0.02 0.08 0.25	64833	64833	56209383	56274216	0.02	0.01	0	0	0	0	0	0	0	0	0	CCT6A(eqtl:0.7:rs2110260);CHCHD2(eqtl:0.8:rs2110260);NIPSNAP2(eqtl:0.6:rs2110260);NUPR2(sqtl:0.5:rs2110260);PSPH(sqtl:0.5:rs2110260);SUMF2(eqtl:0.7:rs2110260);ZNF713(eqtl:0.8:rs2110260)
7q11.21-2	0	62660735	0.8 0.47 0.85 0.89 0.8	0.01 0.01 0.02 0.1 0.15	64833	64833	62628318	62693151	0.02	0.01	0	0	0	0	0	0	0	0	0	0
7q11.21-2	0	99552892	0.8 0.33 0.87 0.88 0.77	0.0 0.01 0.03 0.15 0.18	64833	64833	99520475	99585308	0.02	0.01	0	0	0	0	3	1	0	0	Arm fat-free mass (left)(rs10243988:0.74:-0.01;rs13223723:1:-0.01);Arm fat-free mass (right)(rs10243988:0.74:-0.01;rs13223723:1:-0.01);Arm predicted mass (left)(rs10243988:0.74:-0.01;rs13223723:1:-0.01);Arm predicted mass (right)(rs10243988:0.74:-0.01;rs13223723:1:-0.01);Basal metabolic rate(rs10243988:0.74:-14.76;rs13223723:1:-13.06);Haematocrit percentage(rs13223723:1:0.05);Height(rs13223723:1:-0.01);Hematocrit(rs13223723:1:0.02;rs13223723:1:0.02);Hemoglobin concentration(rs13223723:1:0.02);Hemoglobin levels(rs13223723:1:0.02);Hemoglobin(rs13223723:1:0.02);Mean corpuscular hemoglobin concentration(rs13223723:1:-0.02);Mean corpuscular hemoglobin(rs13223723:1:-0.02;rs13223723:1:-0.02);Mean corpuscular volume(rs13223723:1:-0.02;rs13223723:1:-0.02;rs13223723:1:-0.02);Paired immunoglobulin-like type 2 receptor beta levels(rs13223723:1:0.33);Platelet count(rs13223723:1:-0.02;rs13223723:1:-0.02;rs13223723:1:-1.05;rs13223723:1:-0.02);Platelet distribution width(rs13223723:1:0.02);Plateletcrit(rs13223723:1:-0.01);Red blood cell (erythrocyte) count(rs13223723:1:0.01);Red blood cell count(rs13223723:1:0.03;rs13223723:1:0.03;rs13223723:1:0.03;rs13223723:1:0.03);Total testosterone levels(rs13223723:1:0.02;rs13223723:1:0.01);Trunk fat-free mass(rs10243988:0.74:-0.06;rs13223723:1:-0.05);Trunk predicted mass(rs10243988:0.74:-0.06;rs13223723:1:-0.05);Whole body fat-free mass(rs10243988:0.74:-0.11;rs13223723:1:-0.1);Whole body water mass(rs10243988:0.74:-0.09;rs13223723:1:-0.07)	AP4M1(eqtl:0.6:rs13223723);COPS6(eqtl:0.4:rs13223723);EPHB4(eqtl:0.6:rs13223723);GAL3ST4(eqtl:0.4:rs13223723);GIGYF1(eqtl:0.1:rs13223723);GPC2(eqtl:0.2:rs13223723);LAMTOR4(eqtl:0.6:rs13223723;sqtl:0.3:rs13223723);MBLAC1(eqtl:0.4:rs13223723);MEPCE(eqtl:0.2:rs13223723);MOSPD3(eqtl:0.3:rs13223723);PILRB(eqtl:0.8:rs13223723);PVRIG(eqtl:0.6:rs13223723);STAG3(eqtl:0.2:rs13223723;sqtl:0.6:rs13223723);TRAPPC14(eqtl:0.8:rs13223723);TRIM4(eqtl:0.9:rs13223723;sqtl:0.6:rs13223723);UFSP1(eqtl:0.5:rs13223723);ZCWPW1(eqtl:0.5:rs13223723);ZKSCAN1(eqtl:0.5:rs13223723);ZKSCAN5(eqtl:0.2:rs13223723)
7q11.21-2	0	100256228	0.78 0.85 0.84 0.78 0.55	0.01 0.01 0.03 0.21 0.41	64833	64833	100223811	100288644	0.02	0.02	0	0	0	0	5	0	0	0	"Haematocrit percentage(rs6952341:1:0.09);Haemoglobin concentration(rs6952341:1:0.02);Hematocrit(rs6952341:1:0.03;rs6952341:1:0.04;rs6952341:1:0.04);Hemoglobin concentration(rs6952341:1:0.03);Hemoglobin(rs6952341:1:0.03);High light scatter reticulocyte percentage of red cells(rs564636753:0.79:-0.03;rs6952341:1:-0.02;rs6952341:1:-0.03);Immature fraction of reticulocytes(rs564636753:0.79:-0.03;rs6952341:1:-0.02);Immature reticulocyte fraction(rs73156234:0.85:0);Low density lipoprotein cholesterol levels(rs6952341:1:-0.02);Mean corpuscular haemoglobin concentration(rs6952341:1:-0.03);Mean corpuscular haemoglobin(rs6952341:1:-0.11);Mean corpuscular hemoglobin concentration(rs6952341:1:-0.03;rs6952341:1:-0.03;rs6952341:1:-0.03);Mean corpuscular hemoglobin(rs6952341:1:-0.07;rs6952341:1:-0.07;rs6952341:1:-0.07);Mean corpuscular volume(rs6952341:1:-0.06;rs6952341:1:-0.23;rs6952341:1:-0.06;rs6952341:1:-0.06);Mean platelet (thrombocyte) volume(rs6952341:1:0.02);Mean platelet volume(rs62482252:0.63:0.03;rs4729607:0.62:0.02;rs6952341:1:0.02;rs6952341:1:0.02);Mean reticulocyte volume(rs6952341:1:-0.02);Mean sphered cell volume(rs6952341:1:-0.13);Mean spheric corpuscular volume(rs6952341:1:-0.04);Monocyte count(rs6952341:1:0.01);Other erythrocyte phenotypes [RBC](rs2075671:0.7:0);Platelet count(rs6952341:1:-1.61;rs6952341:1:-0.02;rs6952341:1:-0.02;rs6952341:1:-0.02);Platelet crit(rs6952341:1:0);Plateletcrit(rs6952341:1:-0.02);Pulse rate, automated reading(rs6952341:1:-0.24);Red blood cell (erythrocyte) count(rs6952341:1:0.02);Red blood cell (erythrocyte) distribution width(rs6952341:1:0.03);Red blood cell count(rs6952341:1:0.07;rs6952341:1:0.07;rs6952341:1:0.07);Red cell distribution width(rs6952341:1:0.04;rs6952341:1:0.03;rs6952341:1:0.04;rs6952341:1:0.03);Reticulocyte fraction of red cells(rs6952341:1:-0.02;rs6952341:1:-0.03);Vertex-wise cortical surface area(rs11770534:0.87:6.44)"	AP4M1(eqtl:0.5:rs6952341);EPHB4(eqtl:1:rs6952341);FIS1(eqtl:0.3:rs6952341);GIGYF1(eqtl:0.8:rs6952341);GNB2(sqtl:0.9:rs6952341);LRCH4(eqtl:0.1:rs6952341;sqtl:0.5:rs6952341);MOSPD3(eqtl:0.9:rs6952341);PCOLCE(eqtl:0.5:rs6952341;pqtl:0.4:rs6952341);PVRIG(eqtl:0.2:rs6952341);SLC12A9(eqtl:0.2:rs6952341;sqtl:0.3:rs6952341);TFR2(eqtl:0.7:rs6952341);TRAPPC14(eqtl:0.7:rs6952341);UFSP1(eqtl:0.8:rs6952341);ZAN(eqtl:0.9:rs6952341)
7q11.21-2	0	102503186	0.76 0.73 0.73 0.73 0.81	0.01 0.01 0.02 0.12 0.26	64833	64833	102470769	102535602	0.02	0.01	0	0	0	0	2	1	0	0	Haemorrhoidal disease(rs12530741:1:0.03)	FAM185A(eqtl:0.4:rs12530741);FBXL13(eqtl:0.5:rs12530741);LRWD1(eqtl:0.1:rs12530741);POLR2J2(eqtl:0.5:rs12530741);POLR2J3(eqtl:0.7:rs12530741;sqtl:0.5:rs12530741);SPDYE2(eqtl:0.7:rs12530741);SPDYE2B(eqtl:0.2:rs12530741)
7q11.21-2	0	104516230	0.78 0.67 0.84 0.57 0.79	0.01 0.02 0.04 0.2 0.51	64833	64833	104483813	104548646	0.02	0.02	0	0	0	0	2	0	0	0	Educational attainment (years of education)(rs10258340:0.72:NA);Regular attendance at a religious group(rs10085831:0.71:NA);Type 2 diabetes(rs73184014:0.83:-0.03)	PUS7(eqtl:0.7:rs35894637)
7q11.21-2	0	110733717	0.82 0.38 0.78 0.87 0.83	0.0 0.01 0.06 0.23 0.53	64833	64833	110701300	110766133	0.02	0.01	0	0	0	0	2	1	0	0	0	IMMP2L(eqtl:0.9:rs2107147;sqtl:0.3:rs2107147)
7q11.21-2	0	120409658	0.82 0.32 0.9 0.93 0.82	0.01 0.02 0.04 0.17 0.4	64833	64833	120377241	120442074	0.02	0.02	0	0	0	0	2	0	0	0	0	CPED1(eqtl:0.9:rs73425863);ING3(eqtl:0.6:rs73425863);TSPAN12(eqtl:0.8:rs73425863)
7q11.21-2	0	123227469	0.79 0.84 0.67 0.63 0.8	0.0 0.01 0.02 0.13 0.32	64833	64833	123195052	123259885	0.02	0.02	0	0	0	0	3	1	0	0	0	ASB15(eqtl:0.2:rs1090540);IQUB(eqtl:0.5:rs1090540);NDUFA5(sqtl:0.9:rs1090540);WASL(eqtl:0.1:rs1090540)
8p11.22	1	39389416	0.26 0.02 0.3 0.14 0.3	0.0 0.01 0.02 0.2 0.55	217905	217904	39223634	39441538	0.09	0.09	0	0	0	0	3	0	0	0	0	IDO1(eqtl:0.6:rs56316550)
8p11.22	0	31594948	0.25 0.05 0.22 0.24 0.26	0.0 0.01 0.02 0.22 0.72	217905	217905	31485995	31703900	0.09	0.08	0	0	0	0	1	1	0	0	0	0
8p11.22	0	36520156	0.3 0.39 0.17 0.04 0.16	0.03 0.06 0.07 0.18 0.4	217905	217905	36411203	36629108	0.09	0.08	0	0	0	0	0	0	0	0	0	0
8p11.22	0	57201675	0.23 0.4 0.12 0.16 0.16	0.01 0.06 0.08 0.35 0.73	217905	217905	57092722	57310627	0.09	0.11	0	0	0	0	4	2	0	0	"Ankle spacing width(rs62515458:1:0.08);Appendicular lean mass(rs62515454:0.66:0.04;rs62515458:1:0.03;rs62515458:1:0.04;rs62515458:1:0.04);Arm fat-free mass (left)(rs62515458:1:0.01);Arm fat-free mass (right)(rs62515458:1:0.01);Arm predicted mass (left)(rs62515458:1:0.01);Arm predicted mass (right)(rs62515458:1:0.01);Basal metabolic rate(rs62515458:1:22.79);Comparative height size at age 10(rs62515458:1:0.02);Cortical surface area(rs62515449:0.97:NA);Cortical thickness(rs62515456:0.98:NA);Forced expiratory volume in 1-second (fev1)(rs62515458:1:0.01);Forced expiratory volume in 1-second (fev1), best measure(rs62515458:1:0.01);Forced expiratory volume in 1-second (fev1), predicted(rs75201573:0.9:0.01;rs62515458:1:0.01);Forced vital capacity (fvc)(rs62515458:1:0.02);Forced vital capacity (fvc), best measure(rs62515458:1:0.02);Heel bone mineral density T score(rs10958476:0.61:-0.02);Height [Conditioned on rs7460090](rs10958476:0.61:NA);Height(rs10958476:0.61:0.05;rs10958476:0.61:0.04;rs62515432:0.75:0.05);Hip circumference adjusted for BMI(rs62515433:0.86:NA);Leg fat-free mass (left)(rs62515437:0.96:0.03;rs62515458:1:0.03);Leg fat-free mass (right)(rs62515458:1:0.03);Leg predicted mass (left)(rs62515437:0.96:0.03;rs62515458:1:0.03);Leg predicted mass (right)(rs62515458:1:0.03);Sitting height(rs62515432:0.75:0.18;rs62515458:1:0.17);Standing height(rs62515435:0.9:0.3;rs62515458:1:0.3);Trunk fat-free mass(rs62515458:1:0.1);Trunk predicted mass(rs62515458:1:0.1);Vertex-wise cortical surface area(rs13207748:0.97:7.55);Vertex-wise cortical thickness(rs13207748:0.97:5.67);Vertex-wise sulcal depth(rs62515456:0.98:9.19);Weight(rs62515458:1:0.24;rs62515458:1:0.24);Whole body fat-free mass(rs62515458:1:0.19);Whole body water mass(rs62515458:1:0.14)"	CHCHD7(eqtl:0.4:rs62515458);PENK(pqtl:0.6:rs62515458);TGS1(eqtl:0.2:rs62515458)
8p11.22	0	63789571	0.27 0.05 0.3 0.13 0.19	0.0 0.02 0.03 0.16 0.5	217905	217905	63680618	63898523	0.09	0.1	0	0	0	0	1	0	0	0	Gamma-glutamyl hydrolase measurement(rs719235:0.65:-0.41;rs11775329:1:-0.34);Serum levels of protein GGH(rs719235:0.65:-0.4)	GGH(eqtl:0.7:rs11775329;pqtl:0.9:rs11775329);NKAIN3(eqtl:0.1:rs11775329);TTPA(eqtl:0.5:rs11775329);YTHDF3(eqtl:0.4:rs11775329)
8p11.22	0	64431242	0.22 0.12 0.41 0.17 0.2	0.01 0.02 0.04 0.32 0.47	217905	217905	64322289	64540194	0.09	0.11	0	0	0	0	1	0	0	0	0	0
8p11.22	0	87106149	0.28 0.49 0.11 0.02 0.2	0.0 0.02 0.05 0.27 0.39	217905	217905	86997196	87215101	0.09	0.09	0	30	51	87	2	0	0	0	0	CA2(eqtl:0.6:rs28613013);RBIS(eqtl:0.1:rs28613013)
8p11.22	0	91203075	0.22 0.08 0.24 0.33 0.19	0.0 0.04 0.05 0.16 0.38	217905	217905	91094122	91312027	0.09	0.09	0	0	0	0	2	0	0	0	0	NBN(eqtl:0.5:rs12679473);OSGIN2(eqtl:0.3:rs12679473)
8p11.22	0	105207142	0.29 0.34 0.19 0.05 0.17	0.0 0.03 0.05 0.26 0.37	217905	217905	105098189	105316094	0.09	0.08	0	0	0	0	1	1	0	0	0	DCSTAMP(eqtl:0.3:rs2441901);FZD6(eqtl:0.3:rs2441901);RIMS2(eqtl:0.7:rs2441901)
8p11.22	0	115789416	0.22 0.14 0.26 0.24 0.23	0.0 0.02 0.02 0.15 0.56	217905	217905	115680463	115898368	0.09	0.09	0	0	0	0	0	0	0	0	Educational attainment (MTAG) [MTAG](rs72672052:0.68:NA);Educational attainment (years of education)(rs72672052:0.68:NA)	0
8q13.3	1	71784981	0.32 0.24 0.58 0.62 0.24	0.0 0.0 0.0 0.22 1.08	335082	335081	71585912	71920993	0.03	0.03	0	0	0	0	1	1	0	0	"Cortical surface area [Pars Opercularis](rs441890:0.66:-5.9);Haemorrhoidal disease(rs13252808:0.74:NA);Heel bone mineral density (bmd) (left)(rs7838421:0.74:0);Heel bone mineral density (bmd) t-score, automated (left)(rs7838421:0.74:-0.03);Heel bone mineral density(rs7003794:0.74:-0.03);Heel quantitative ultrasound index (qui), direct entry (left)(rs7838421:0.74:-0.52);Waist-hip ratio(rs1481801:0.66:NA);Waist-to-hip ratio adjusted for BMI(rs12675159:1:0.01)"	LACTB2(eqtl:0.9:rs268642);TRAM1(eqtl:0.8:rs268642);XKR9(eqtl:1:rs268642;sqtl:0.8:rs268642)
8q13.3	0	9543651	0.28 0.41 0.42 0.55 0.42	0.0 0.01 0.02 0.28 1.08	335082	335082	9376110	9711192	0.03	0.16	110	142	159	186	2	1	0	0	"Age at first birth(rs11249939:0.65:0.06;rs13270801:1:0.06;rs13270801:1:0.06);Age at first sexual intercourse(rs13270801:1:0.01);Age first had sexual intercourse(rs13270801:1:0.07);Alanine aminotransferase levels(rs33994795:0.69:-0.02);Aspartate aminotransferase levels(rs33994795:0.69:-0.02);Barrett's esophagus(rs10104032:0.65:NA);Blood pressure medication | medication for cholesterol, blood pressure, diabetes, or take exogenous hormones(rs13270801:1:-0.05);Body fat percentage(rs33994795:0.69:-0.01);Cortical surface area [Superior Temporal](rs4840425:0.62:12.02);Educational attainment (years of education)(rs11249939:0.65:NA);Heel bone mineral density (bmd) t-score, automated(rs11249939:0.65:-0.02);Heel bone mineral density (bmd)(rs11249939:0.65:0);Heel bone mineral density(rs7001832:0.68:-0.02;rs13270801:1:-0.02);Heel broadband ultrasound attenuation (right)(rs13270801:1:-0.47);Heel broadband ultrasound attenuation, direct entry(rs13270801:1:-0.34);Heel quantitative ultrasound index (qui), direct entry(rs11249939:0.65:-0.37);High blood pressure | vascular/heart problems diagnosed by doctor(rs13270801:1:-0.04);Hypertension | non-cancer illness code, self-reported(rs13270801:1:-0.04);Liver enzyme levels (alanine transaminase)(rs13270801:1:0);Mean platelet volume(rs57453266:0.61:-0.02);Metabolic biomarkers (multivariate analysis)(rs33994795:0.69:NA);None of the above | vascular/heart problems diagnosed by doctor(rs13270801:1:0.03);Platelet distribution width(rs13270801:1:-0.01;rs13270801:1:-0.02);Red cell distribution width(rs13270801:1:-0.02;rs13270801:1:-0.02);Triglycerides(rs33994795:0.69:0.02);White blood cell count(rs4075359:0.66:0.01)"	ERI1(eqtl:0.4:rs13270801;sqtl:0.1:rs13270801);MFHAS1(eqtl:0.7:rs13270801);MSRA(eqtl:0.9:rs13270801);TNKS(eqtl:0.3:rs13270801;sqtl:0.8:rs13270801)
8q13.3	0	31311783	0.35 0.28 0.47 0.43 0.38	0.0 0.02 0.05 0.71 0.99	335082	335082	31144242	31479324	0.03	0.2	0	0	0	0	0	0	0	0	0	0
8q13.3	0	93183772	0.36 0.12 0.48 0.56 0.49	0.12 0.13 0.14 0.3 1.06	335082	335082	93016231	93351313	0.03	0.2	0	0	0	0	1	0	0	0	0	0
8q13.3	0	94648694	0.3 0.64 0.37 0.32 0.31	0.0 0.02 0.03 0.09 0.97	335082	335082	94481153	94816235	0.03	0.06	0	0	0	0	5	2	0	0	0	CIBAR1(sqtl:0.1:rs11998599);PDP1(eqtl:0.3:rs11998599)
8q13.3	0	97922382	0.32 0.31 0.51 0.51 0.37	0.01 0.01 0.02 0.2 1.18	335082	335082	97754841	98089923	0.03	0.07	0	0	0	0	2	1	0	0	0	SDC2(eqtl:0.4:rs12547542)
8q13.3	0	101141867	0.36 0.39 0.29 0.52 0.43	0.01 0.01 0.04 0.24 1.15	335082	335082	100974326	101309408	0.03	0.17	0	0	0	0	6	5	0	0	Basal cell carcinoma(rs2514686:1:0.08);Basophil count(rs7014862:0.65:0.01)	FBXO43(eqtl:0.9:rs2514686);RNF19A(eqtl:0.2:rs2514686);SPAG1(eqtl:1:rs2514686;sqtl:0.9:rs2514686)
8q13.3	0	106231172	0.36 0.17 0.27 0.63 0.52	0.01 0.04 0.05 0.28 1.0	335082	335082	106063631	106398713	0.03	0.16	0	0	0	0	1	1	0	0	Lymphocyte counts(rs1350723:1:-0.01;rs1350723:1:-0.01);White blood cell (leukocyte) count(rs5893737:0.98:-0.03;rs1350723:1:-0.03);White blood cell count(rs1350723:1:NA;rs1350723:1:-0.01;rs1350723:1:-0.01)	0
8q13.3	0	119977337	0.32 0.49 0.43 0.52 0.25	0.01 0.02 0.05 0.39 0.99	335082	335082	119809796	120144878	0.03	0.16	0	0	0	0	3	0	0	0	Autoimmune traits(rs1032129:0.81:NA);Diabetes or endocrine disease(rs1032129:0.81:NA;rs12679857:1:0);Eosinophil counts(rs12681644:0.65:NA;rs12681644:0.65:-0.02;rs12679857:1:-0.01;rs12679857:1:-0.01;rs12679857:1:-0.01);Eosinophil percentage of white cells(rs12679857:1:-0.02);Hypothyroidism or myxedema(rs1032129:0.81:NA;rs12679857:1:0);Hypothyroidism(rs1032129:0.81:NA);Medication use (thyroid preparations)(rs1032129:0.81:-0.06;rs12679857:1:-0.06);Serum alkaline phosphatase levels(rs12679857:1:0.02);Thyroid problem (not cancer)(rs1032129:0.81:NA;rs12679857:1:0)	SAMD12(eqtl:0.3:rs12679857);TNFRSF11B(eqtl:0.2:rs12679857;sqtl:0.1:rs12679857)
8q13.3	0	131084728	0.31 0.17 0.53 0.68 0.31	0.0 0.0 0.01 0.19 1.04	335082	335082	130917187	131252269	0.03	0.14	0	0	0	0	4	0	0	0	Appendicular lean mass(rs4733768:0.63:0.01;rs62524625:1:0.01);Mean corpuscular volume(rs62524625:1:-0.01;rs62524625:1:-0.01);Mean platelet (thrombocyte) volume(rs62524625:1:-0.03);Mean platelet volume(rs62524625:1:-0.03;rs62524625:1:-0.03;rs62524625:1:-0.02);Mean sphered cell volume(rs62524625:1:-0.08);Mean spheric corpuscular volume(rs62524625:1:-0.02)	ASAP1(eqtl:0.9:rs62524625;sqtl:0.1:rs62524625)
9p21.1-1	1	30599424	0.64 0.05 0.56 0.27 0.58	0.0 0.0 0.02 0.14 0.32	268946	268945	30465021	30733966	0.04	0.04	0	0	0	0	0	0	0	0	0	0
9p21.1-1	0	11608697	0.62 0.61 0.3 0.25 0.41	0.0 0.02 0.03 0.16 0.48	268946	268946	11474224	11743170	0.04	0.08	0	0	0	0	0	0	0	0	0	0
9p21.1-1	0	34266323	0.62 0.11 0.62 0.36 0.5	0.0 0.01 0.01 0.12 0.33	268946	268946	34131850	34400796	0.04	0.09	0	0	0	0	6	5	0	0	0	C9orf24(sqtl:0.1:rs10972030);DCAF12(eqtl:0.6:rs10972030);DNAI1(sqtl:0.2:rs10972030);GALT(eqtl:0.1:rs10972030);KIF24(eqtl:0.1:rs10972030;sqtl:0.5:rs10972030);MYORG(pqtl:0.8:rs10972030);NUDT2(eqtl:0.8:rs10972030;sqtl:0.3:rs10972030);UBAP1(eqtl:0.7:rs10972030;sqtl:0.4:rs10972030)
9p21.1-1	0	34773049	0.66 0.18 0.44 0.3 0.6	0.02 0.02 0.03 0.29 0.49	268946	268946	34638576	34907522	0.04	0.16	0	0	0	0	9	4	0	0	Eosinophil counts(rs7018860:0.83:-0.01;rs112103921:0.75:0.01;rs12339911:0.68:NA;rs12339911:0.82:-0.01);Eosinophil percentage of white cells(rs112103921:0.75:0.01);Eosinophill count(rs7018860:0.82:-0.01)	DCTN3(eqtl:0.5:rs277578);DNAJB5(eqtl:0.6:rs277578);FAM205C(eqtl:0.4:rs277578);IL11RA(eqtl:0.7:rs277578);NUDT2(eqtl:0.8:rs277578);PHF24(sqtl:0.6:rs277578);PIGO(eqtl:0.8:rs277578);RPP25L(eqtl:0.6:rs277578);VCP(eqtl:0.7:rs277578)
9p21.1-1	0	75652050	0.6 0.11 0.53 0.38 0.59	0.0 0.01 0.02 0.36 0.43	268946	268946	75517577	75786523	0.04	0.24	0	0	0	0	2	0	0	0	0	ALDH1A1(eqtl:0.7:rs11143441);ZFAND5(eqtl:0.2:rs11143441)
9p21.1-1	0	94866040	0.65 0.08 0.53 0.55 0.39	0.0 0.02 0.03 0.25 0.52	268946	268946	94731567	95000513	0.04	0.2	0	0	0	0	4	1	0	0	0	ROR2(eqtl:0.6:rs7037848;pqtl:0.2:rs7037848;sqtl:0.7:rs7037848);SPTLC1(eqtl:0.9:rs7037848;sqtl:0.8:rs7037848);SUSD3(eqtl:0.1:rs7037848)
9p21.1-1	0	102632235	0.61 0.51 0.24 0.34 0.45	0.0 0.01 0.03 0.05 0.2	268946	268946	102497762	102766708	0.04	0.04	0	0	0	0	5	2	0	0	Height(rs7023690:0.85:NA)	INVS(eqtl:0.2:rs2416878)
9p21.1-2	1	32022393	0.38 0.56 0.64 0.56 0.43	0.0 0.01 0.02 0.51 0.98	132362	132361	31941622	32073983	0.03	0.03	228	378	386	386	0	0	0	0	0	0
9p21.1-2	0	6465465	0.39 0.75 0.41 0.39 0.54	0.0 0.02 0.03 0.63 1.11	132362	132362	6399284	6531646	0.03	0.04	0	0	0	0	1	1	0	0	"Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor(rs541378:1:0.05);Asthma | non-cancer illness code, self-reported(rs541378:1:0.05);Asthma(rs541378:1:0);Eosinophil counts(rs541378:1:0.03;rs541378:1:0.03;rs541378:1:0.03);Eosinophil percentage of granulocytes(rs541378:1:0.02);Eosinophil percentage of white cells(rs541378:1:0.03;rs541378:1:0.02);Eosinophill count(rs541378:1:0.02);Eosinophill percentage(rs541378:1:0.04);Neutrophil percentage of granulocytes(rs541378:1:-0.02);Respiratory or ear-nose-throat disease(rs541378:1:0.01);Sum eosinophil basophil counts(rs541378:1:0.02)"	GLDC(sqtl:0.2:rs541378)
9p21.1-2	0	74750768	0.37 0.45 0.59 0.77 0.39	0.0 0.02 0.04 0.53 1.07	132362	132362	74684587	74816949	0.03	0.06	0	0	0	0	1	0	0	0	0	GDA(eqtl:0.3:rs4434678)
9p21.1-2	0	76652191	0.38 0.77 0.51 0.52 0.5	0.0 0.01 0.02 0.37 0.91	132362	132362	76586010	76718372	0.03	0.06	0	0	0	0	0	0	0	0	Advanced age-related macular degeneration [EA](rs10781182:0.83:NA);Height(rs13302616:0.73:NA;rs7020553:0.72:-0.01);Standing height(rs10869321:0.72:-0.09)	0
9p21.1-2	0	84791337	0.36 0.87 0.33 0.67 0.38	0.0 0.0 0.01 0.05 0.93	132362	132362	84725156	84857518	0.03	0.03	0	0	0	0	0	0	0	0	Autism spectrum disorder or schizophrenia(rs2767713:0.64:NA);Lung function (FEV1/FVC)(rs6559650:0.68:-0.01);Mean corpuscular hemoglobin(rs2767717:1:0.01;rs2767717:1:0.01);Mean corpuscular volume(rs2767717:1:0.01;rs2767717:1:0.01);Schizophrenia(rs1319017:0.68:NA;rs11139497:0.63:NA;rs11139497:0.64:NA;rs11139497:0.64:NA;rs2767713:0.73:NA;rs2767713:0.75:NA;rs2767713:0.76:NA)	0
9p21.1-2	0	91477889	0.41 0.47 0.5 0.74 0.49	0.0 0.02 0.05 0.85 1.11	132362	132362	91411708	91544070	0.03	0.07	0	0	0	0	0	0	0	0	Monocyte count(rs6559299:0.86:0;rs10867125:1:0.02);Monocyte percentage of white cells(rs10867125:1:0.02);Platelet count(rs2316806:0.76:NA)	S1PR3(eqtl:0.6:rs10867125)
9p21.1-2	0	96352311	0.34 0.56 0.68 0.54 0.5	0.0 0.02 0.05 0.25 0.96	132362	132362	96286130	96418492	0.03	0.05	0	0	0	0	3	2	0	0	Appendicular lean mass(rs1041500:1:-0.01);Comparative body size at age 10(rs1041500:1:-0.01);Impedance of leg (left)(rs62574545:0.69:0.6;rs1041500:1:0.55);Impedance of leg (right)(rs62574545:0.69:0.62;rs1041500:1:0.57);Leg fat-free mass (right)(rs62574545:0.69:-0.02;rs1041500:1:-0.02);Leg predicted mass (right)(rs62574545:0.69:-0.02;rs1041500:1:-0.02)	CARD19(eqtl:0.6:rs1041500);FAM120A(eqtl:0.3:rs1041500);FAM120AOS(eqtl:0.4:rs1041500);PHF2(eqtl:0.3:rs1041500);WNK2(eqtl:0.3:rs1041500)
9p21.1-2	0	114287607	0.42 0.45 0.53 0.58 0.63	0.0 0.02 0.03 0.3 0.98	132362	132362	114221426	114353788	0.03	0.06	0	0	0	0	3	2	0	0	Height(rs10980926:0.8:NA;rs10980926:0.8:-0.02);Menarche (age at onset) [EA](rs10441737:0.8:-2.78);Menarche (age at onset)(rs10980926:0.8:-2.5;rs10217747:0.75:NA);Standing height(rs10817185:0.82:-0.11;rs10980924:1:-0.09)	ECPAS(eqtl:0.8:rs10980924);ZNF483(eqtl:0.5:rs10980924)
9p21.1-2	0	118343415	0.38 0.73 0.36 0.72 0.41	0.0 0.01 0.02 0.35 1.02	132362	132362	118277234	118409596	0.03	0.04	0	0	0	0	0	0	0	0	Osteoarthritis (hip)(rs7862601:0.99:NA);Varicose veins of lower extremity(rs4979558:1:0.08);Varicose veins(rs4979558:1:0.08)	0
9p21.1-2	0	121103251	0.4 0.74 0.48 0.5 0.38	0.0 0.01 0.04 0.6 1.16	132362	132362	121037070	121169432	0.03	0.05	0	0	0	0	0	0	0	0	0	0
10p11.22	1	32903978	0.47 0.02 0.3 0.1 0.32	0.0 0.0 0.0 0.09 0.43	453464	453463	32715818	33169281	0.03	0.03	0	0	0	0	2	1	1	1	0	CCDC7(eqtl:0.7:rs2490490;sqtl:0.6:rs2490490);ITGB1(eqtl:0.4:rs2490490;sqtl:0.4:rs2243926)
10p11.22	0	35031758	0.46 0.09 0.15 0.17 0.38	0.0 0.01 0.02 0.22 0.31	453464	453464	34805026	35258490	0.03	0.21	0	0	0	0	2	0	0	0	Estimated glomerular filtration rate(rs7072591:0.8:0)	PARD3(eqtl:0.6:rs17493513;sqtl:0.2:rs17493513)
10p11.22	0	63136622	0.45 0.02 0.29 0.09 0.35	0.0 0.03 0.05 0.19 0.61	453464	453464	62909890	63363354	0.03	0.17	0	0	0	0	2	1	0	0	Salt added to food(rs4948275:1:0.02)	TMEM26(eqtl:0.7:rs4948275)
10p11.22	0	69166348	0.42 0.05 0.27 0.2 0.36	0.0 0.01 0.01 0.19 0.45	453464	453464	68939616	69393080	0.03	0.18	0	0	0	0	2	1	0	0	0	SIRT1(eqtl:0.8:rs9415879)
10p11.22	0	93583154	0.43 0.17 0.13 0.11 0.26	0.0 0.0 0.01 0.31 0.51	453464	453464	93356422	93809886	0.03	0.12	0	0	0	0	7	3	0	0	Bioavailable testosterone levels(rs2421701:1:0.01);Liver enzyme levels (alkaline phosphatase)(rs1890896:0.66:0);Liver volume(rs10881959:0.87:0.05;rs2421701:1:0.04);Mean corpuscular volume(rs2421704:0.94:0.01;rs2421701:1:0.01);Serum alkaline phosphatase levels(rs1772182:0.68:0.02);Sex hormone-binding globulin levels adjusted for BMI(rs1772179:0.68:-0.01;rs34370527:0.68:-0.01;rs11186721:0.66:0.01;rs2421701:1:-0.01;rs2421701:1:-0.01;rs2421701:1:-0.01);Sex hormone-binding globulin levels(rs1772183:0.68:-0.03;rs1772183:0.68:-0.01;rs34370527:0.68:-0.01;rs11186721:0.66:0.01;rs2421701:1:-0.01;rs2421701:1:-0.01;rs2421701:1:-0.01);Total PHF-tau (SNP x SNP interaction)(rs12248932:0.83:NA);Total testosterone levels(rs3802650:0.68:-0.02);Urate levels(rs2994394:0.9:0.01)	PPP1R3C(eqtl:0.4:rs2421701)
10p11.22	0	94089160	0.47 0.04 0.21 0.14 0.28	0.0 0.0 0.01 0.15 0.44	453464	453464	93862428	94315892	0.03	0.15	0	0	0	0	4	2	0	0	Creatinine levels(rs11186923:1:-0.01);Mean platelet volume(rs11186923:1:0.01;rs11186923:1:0.01;rs11186923:1:0.01);Platelet count(rs11186923:1:-0.01);Sex hormone-binding globulin levels adjusted for BMI(rs11186923:1:0);Sex hormone-binding globulin levels(rs11186923:1:-0.01);Waist-hip ratio(rs7091853:0.61:NA;rs950732:0.62:0.01);Waist-to-hip ratio adjusted for BMI(rs7091853:0.61:NA)	CPEB3(eqtl:0.6:rs11186923;sqtl:0.4:rs11186923);HHEX(eqtl:0.2:rs11186923);MARCHF5(eqtl:0.5:rs11186923;sqtl:0.3:rs11186923)
10p11.22	0	111502210	0.47 0.04 0.18 0.26 0.31	0.0 0.01 0.02 0.19 0.37	453464	453464	111275478	111728942	0.03	0.18	0	0	0	0	2	0	0	0	0	ADD3(eqtl:0.6:rs12767383);MXI1(eqtl:0.1:rs12767383);XPNPEP1(eqtl:0.9:rs12767383;sqtl:0.4:rs12767383)
10p11.22	0	117226375	0.47 0.06 0.3 0.04 0.29	0.0 0.01 0.02 0.07 0.41	453464	453464	116999643	117453107	0.03	0.07	0	0	0	0	1	1	0	0	0	0
10q22.3	1	81631742	0.88 0.79 0.77 0.98 0.83	0.0 0.0 0.0 0.11 0.88	762273	762272	81263542	82025814	0.34	0.34	0	0	0	0	19	2	0	0	Blood protein levels [SFTPD](rs2146192:0.67:NA);Cystatin C levels(rs55855057:0.64:0.02);Haematocrit percentage(rs61859980:0.98:-0.09);Haemoglobin concentration(rs61859980:0.98:-0.03);Hemoglobin(rs61863508:1:-0.02);Serum urea levels(rs17678338:0.6:0.03);Urate levels(rs55838345:0.62:NA;rs17678338:0.6:0.02);Urea levels(rs36073865:1:0.02)	ANXA11(sqtl:0.9:rs36023925;eqtl:1:rs35180576);DYDC2(sqtl:0.2:rs12416199;eqtl:0.6:rs12412999);NUTM2B(eqtl:0.9:rs61859793);NUTM2E(eqtl:0.2:rs1051246);PLAC9(eqtl:0.8:rs61860481);PRXL2A(eqtl:0.5:rs723191;sqtl:0.6:rs12416199);SFTPA1(sqtl:0.5:rs17881607);SFTPA2(sqtl:0.7:rs61860481);SFTPD(eqtl:0.7:rs61860992);TMEM254(sqtl:0.8:rs17886234;eqtl:0.9:rs55835350);TSPAN14(eqtl:0.7:rs17881607)
10q22.3	0	23197428	0.89 0.5 0.95 1.0 0.91	0.0 0.03 0.05 0.37 0.83	762273	762273	22816291	23578564	0.34	0.49	0	0	0	0	5	2	0	0	0	ARMC3(eqtl:0.6:rs10828372)
10q22.3	0	27304609	0.93 0.81 0.76 0.73 0.94	0.0 0.01 0.03 0.19 0.98	762273	762273	26923472	27685745	0.34	0.45	0	0	0	0	10	4	0	0	0	ANKRD26(eqtl:0.9:rs3781098);MASTL(eqtl:1:rs3781098);YME1L1(eqtl:0.7:rs3781098)
10q22.3	0	28214488	0.91 0.7 0.87 0.82 0.86	0.0 0.01 0.03 0.26 0.72	762273	762273	27833351	28595624	0.34	0.41	0	0	0	0	6	1	0	0	0	MASTL(eqtl:0.3:rs7071570)
10q22.3	0	31386479	0.91 0.75 0.83 0.92 0.83	0.01 0.04 0.07 0.24 0.87	762273	762273	31005342	31767615	0.34	0.45	1	1	1	1	6	2	0	0	0	ZNF438(eqtl:0.4:rs11008345)
10q22.3	0	63300506	0.88 0.92 0.84 0.74 0.79	0.0 0.01 0.02 0.16 0.72	762273	762273	62919369	63681642	0.34	0.43	0	0	0	0	4	2	0	0	0	CABCOCO1(eqtl:0.9:rs16916259)
10q22.3	0	70400209	0.87 0.78 0.8 0.88 0.89	0.01 0.03 0.06 0.22 0.68	762273	762273	70019072	70781345	0.34	0.29	0	0	0	0	12	6	0	0	Height(rs12221107:0.65:-0.04);Sitting height(rs35787829:0.66:-0.13);Waist circumference adjusted for body mass index(rs12221107:0.65:NA)	DNA2(eqtl:0.1:rs7084598);SLC25A16(eqtl:0.4:rs7084598);SRGN(eqtl:0.6:rs7084598);STOX1(eqtl:1:rs7084598);SUPV3L1(eqtl:0.4:rs7084598)
10q22.3	0	86383024	0.9 0.9 0.92 0.82 0.82	0.0 0.01 0.06 0.34 0.72	762273	762273	86001887	86764160	0.34	0.46	0	0	0	0	3	1	0	0	0	0
10q22.3	0	106584326	0.87 0.92 0.73 0.87 0.89	0.0 0.02 0.04 0.22 0.73	762273	762273	106203189	106965462	0.34	0.48	0	0	0	0	4	1	0	0	0	0
10q22.3	0	110707825	0.84 0.65 0.98 1.0 0.88	0.0 0.0 0.01 0.22 0.72	762273	762273	110326688	111088961	0.34	0.45	0	0	0	0	0	0	0	0	Alcohol consumption (drinks per week)(rs142488468:0.98:NA)	0
10q23.33	1	96918336	0.44 0.52 0.55 0.95 0.62	0.0 0.0 0.02 0.44 0.78	135325	135324	96856007	96991331	0.02	0.02	0	0	0	0	1	0	0	0	Serum metabolite levels [3-hydroxy-2-ethylpropionate](rs632113:0.97:0.15;rs632113:0.94:0.15);Urinary metabolite levels in chronic kidney disease [dimethylmalonic acid](rs685607:0.98:-0.14)	CYP2C8(eqtl:0.5:rs676501;sqtl:0.6:rs676501);NOC3L(eqtl:0.5:rs676501);PDLIM1(eqtl:0.8:rs676501;sqtl:0.5:rs676501)
10q23.33	0	23480318	0.47 0.61 0.51 0.84 0.64	0.0 0.02 0.04 0.42 0.72	135325	135325	23412655	23547980	0.02	0.04	0	0	0	0	2	1	0	0	Brain region volumes [cerebellar vermal lobules VIII X](rs1886764:0.98:NA);Heel bone mineral density(rs6415968:0.73:0.01;rs35943195:0.7:NA)	ARMC3(eqtl:0.2:rs12415184);C10orf67(eqtl:0.5:rs12415184)
10q23.33	0	33213837	0.42 0.85 0.63 0.74 0.42	0.0 0.01 0.02 0.21 0.76	135325	135325	33146174	33281499	0.02	0.04	0	0	0	0	3	1	0	0	Platelet distribution width(rs2503996:1:0.02)	CCDC7(eqtl:0.6:rs2503996);ITGB1(sqtl:0.2:rs2503996)
10q23.33	0	67192833	0.46 0.49 0.49 0.98 0.68	0.0 0.04 0.06 0.29 0.69	135325	135325	67125170	67260495	0.02	0.06	0	0	0	0	0	0	0	0	Bioavailable testosterone levels(rs7914750:1:0.01;rs7914750:1:0.02);Total testosterone levels(rs7914750:1:0.02)	0
10q23.33	0	68813266	0.48 0.61 0.49 0.79 0.63	0.0 0.02 0.02 0.48 0.91	135325	135325	68745603	68880928	0.02	0.08	0	0	0	0	3	1	0	0	Essential tremor(rs12764057:0.61:NA)	LRRTM3(eqtl:0.3:rs7904053;sqtl:0.8:rs7904053)
10q23.33	0	69559722	0.42 0.73 0.59 0.86 0.52	0.01 0.02 0.05 0.12 0.6	135325	135325	69492059	69627384	0.02	0.05	0	0	0	0	1	1	0	0	Mean platelet volume(rs10997819:0.63:-0.02;rs10997819:0.63:-0.01);Neutrophil count(rs10997815:1:-0.01);Platelet count(rs10997819:0.68:0.01);Sex hormone-binding globulin levels adjusted for BMI(rs10997815:1:0.01;rs10997815:1:0);Sex hormone-binding globulin levels(rs10997815:1:0.01);Systolic blood pressure(rs2236318:0.73:-0.02;rs545435:0.71:NA);White blood cell count(rs10997815:1:-0.01)	SIRT1(eqtl:1:rs10997815)
10q23.33	0	81577042	0.41 0.79 0.63 0.7 0.53	0.0 0.0 0.0 0.09 0.89	135325	135325	81509379	81644704	0.02	0	0	0	0	0	3	0	0	0	0	ANXA11(eqtl:0.4:rs4933793);NUTM2B(eqtl:1:rs4933793);NUTM2E(eqtl:1:rs4933793);SFTPA2(sqtl:0.6:rs4933793);SFTPD(eqtl:0.7:rs4933793)
10q23.33	0	93443076	0.42 0.52 0.76 0.81 0.63	0.02 0.02 0.03 0.41 0.79	135325	135325	93375413	93510738	0.02	0.04	0	0	0	0	1	0	0	0	Arm fat percentage (left)(rs1313566680:0.79:-0.1);Arm fat percentage (right)(rs76313529:1:-0.1);College or university degree | qualifications(rs34190234:1:NA;rs76313529:1:0.03);Sex hormone-binding globulin levels adjusted for BMI(rs76313529:1:-0.01);Sitting height(NA:0.96:0.06;rs76313529:1:0.06)	PPP1R3C(eqtl:0.5:rs76313529);TNKS2(eqtl:0.4:rs76313529;sqtl:0.2:rs76313529)
10q23.33	0	97734022	0.47 0.66 0.73 0.91 0.41	0.01 0.05 0.07 0.14 0.87	135325	135325	97666359	97801684	0.02	0.07	0	0	0	0	2	1	1	1	0	ALDH18A1(eqtl:0.7:rs10509696);ENTPD1(eqtl:0.9:rs10509696;sqtl:0.5:rs10509696);TCTN3(eqtl:0.5:rs10509696)
10q23.33	0	110149976	0.42 0.59 0.62 0.86 0.65	0.0 0.02 0.03 0.51 0.71	135325	135325	110082313	110217638	0.02	0.04	0	0	0	0	0	0	0	0	0	0
11p11.12	1	49779252	0.94 0.95 0.97 1.0 0.97	0.0 0.0 0.0 0.02 0.05	973894	973893	49400370	50374263	0.04	0.04	0	0	0	0	5	0	0	0	"Blood protein levels [FOLH1, 5478_50_2](rs148966811:0.77:0.71);Serum levels of protein FOLH1(rs7946236:0.75:0.71);Serum metabolite levels [N-acetyl-aspartyl-glutamate (NAAG](rs61885293:0.67:-0.93;rs61885293:0.7:-0.93);Urinary metabolite levels in chronic kidney disease [N-acetyl-aspartyl-glutamate (NAAG](rs55728336:0.75:-0.68)"	FOLH1(eqtl:0.6:rs61885348;sqtl:0.9:rs61885348)
11p11.12	0	46742249	0.92 0.98 0.93 1.0 0.97	0.0 0.0 0.01 0.03 0.18	973894	973894	46255302	47229196	0.04	0.16	0	0	0	0	22	6	0	0	Apolipoprotein A1 levels(rs3136434:1:-0.02);HDL cholesterol levels(rs3136434:1:-0.02);Heel bone mineral density T score(rs3136434:1:0.03);Heel bone mineral density(rs3136434:1:0.03);Lymphocyte counts(rs61899280:0.66:0.02;rs3136434:1:0.03;rs3136434:1:0.03;rs3136434:1:0.02);Monocyte percentage of white cells(rs3136434:1:-0.02);Oily fish intake(rs3136469:0.99:0.02;rs3136434:1:0.02);Schizophrenia(rs10838634:0.81:NA)	ACP2(eqtl:0.6:rs3136434);ARFGAP2(eqtl:0.6:rs3136434);ARHGAP1(eqtl:0.4:rs3136434);C1QTNF4(eqtl:0.8:rs3136434);CKAP5(eqtl:0.2:rs3136434;sqtl:0.9:rs3136434);CSTPP1(eqtl:0.6:rs3136434);DGKZ(sqtl:0.8:rs3136434);F2(sqtl:0.8:rs3136434);HARBI1(eqtl:0.5:rs3136434);LARGE2(eqtl:0.3:rs3136434);LRP4(eqtl:0.2:rs3136434);MDK(sqtl:0.3:rs3136434);MTCH2(eqtl:0.1:rs3136434);MYBPC3(eqtl:0.2:rs3136434);NR1H3(eqtl:0.9:rs3136434);PACSIN3(eqtl:0.4:rs3136434);PHF21A(eqtl:0.5:rs3136434);SPI1(eqtl:0.7:rs3136434)
11p11.12	0	47262592	0.96 0.99 0.86 0.95 0.99	0.0 0.01 0.02 0.06 0.08	973894	973894	46775645	47749539	0.04	0.08	0	0	0	0	28	12	0	0	0	ACP2(eqtl:0.9:rs11039143);DDB2(eqtl:0.1:rs11039143);MTCH2(eqtl:0.3:rs11039143);MYBPC3(eqtl:0.9:rs11039143;sqtl:0.9:rs11039143);NR1H3(eqtl:0.3:rs11039143)
11p11.12	0	48086151	0.96 0.84 0.97 1.0 0.96	0.0 0.01 0.02 0.07 0.09	973894	973894	47599204	48573098	0.04	0.09	0	0	0	1	17	5	0	0	Mean platelet (thrombocyte) volume(rs1569171:1:0.04);Mean platelet volume(rs1569171:1:NA;rs73464876:1:0.03;rs61914727:1:0.04;rs61915913:0.97:0.04)	0
11p11.12	0	48941767	0.95 1.0 0.97 1.0 0.97	0.0 0.0 0.0 0.01 0.04	973894	973894	48454820	49428714	0.04	0.03	1	1	1	1	5	0	0	0	"Blood protein levels [FOLH1, 5478_50_2](rs148966811:0.88:0.71);Platelet distribution width(rs4367948:1:0.03);Serum levels of protein FOLH1(rs7946236:0.9:0.71);Serum metabolite levels [N-acetyl-aspartyl-glutamate (NAAG](rs61885293:0.67:-0.93;rs61885293:0.74:-0.93);Urinary metabolite levels in chronic kidney disease [N-acetyl-aspartyl-glutamate (NAAG](rs55728336:0.9:-0.68)"	FOLH1(eqtl:0.5:rs4367948;sqtl:0.9:rs4367948)
11p11.12	0	50288759	0.94 0.9 0.97 1.0 0.96	0.0 0.0 0.0 0.02 0.03	973894	973894	49801812	50775706	0.04	0.03	0	0	0	0	5	0	0	0	Platelet distribution width(rs61893102:1:0.03)	0
11p11.12	0	55247690	0.94 0.93 0.96 1.0 0.97	0.0 0.0 0.0 0.04 0.08	973894	973894	54760743	55734637	0.04	0.08	0	0	0	0	21	0	0	0	Adolescent idiopathic scoliosis(rs17599071:0.63:NA);Eosinophil counts(rs17500359:0.95:NA);Platelet distribution width(rs61894894:0.9:0.03;rs61918003:1:0.03);Urinary metabolite levels in chronic kidney disease [N-acetyl-aspartyl-glutamate (NAAG](rs61898064:0.72:-0.62)	0
11p11.12	0	55748099	0.91 0.99 0.95 1.0 0.96	0.0 0.0 0.01 0.06 0.11	973894	973894	55261152	56235046	0.04	0.11	0	0	0	0	38	0	0	0	Adolescent idiopathic scoliosis(rs17599071:1:NA);Eosinophil counts(rs17500359:0.66:NA);Platelet distribution width(rs61896257:1:0.03)	0
11p11.12	0	56257588	0.91 0.99 0.95 1.0 0.96	0.0 0.01 0.01 0.07 0.17	973894	973894	55770641	56744535	0.04	0.17	0	0	0	0	30	0	0	0	Platelet distribution width(rs61902886:1:0.03)	0
11p11.12	0	85120950	0.96 0.99 0.98 1.0 0.95	0.0 0.0 0.01 0.07 0.23	973894	973894	84634003	85607897	0.04	0.2	0	0	0	0	7	6	0	0	Age at first sexual intercourse(rs7942847:0.85:0.05;rs1848766:1:0.04)	DLG2(eqtl:0.4:rs1848766);SYTL2(eqtl:0.3:rs1848766);TMEM126A(sqtl:0.2:rs1848766)
11q11	1	55312683	0.66 0.79 0.73 0.61 0.64	0.0 0.0 0.01 0.05 0.08	548475	548474	55035854	55584328	0.05	0.05	0	0	0	0	14	0	0	0	"Apolipoprotein A1 levels(rs11228871:0.97:0.03;rs2212339:1:0.03);C-reactive protein levels(rs28872512:1:-0.02;rs2212339:1:-0.02;rs11229252:0.88:-0.03);Cardiovascular disease(rs74966104:0.84:NA);Diastolic blood pressure(rs28872512:1:-0.02;rs12419022:0.99:-0.02);Eosinophil counts(rs1425193:1:-0.01);Glaucoma (multi-trait analysis)(rs11229165:0.96:0.1);HDL cholesterol levels(rs11228871:0.97:0.04);HDL cholesterol(rs28872512:1:0.04;rs12226802:1:0.03);Heel bone mineral density(rs2177349:0.77:-0.02);High blood pressure | vascular/heart problems diagnosed by doctor(rs11246486:0.95:NA);High density lipoprotein cholesterol levels(rs2212339:1:0.04);Hypertension | non-cancer illness code, self-reported(rs11246486:0.95:NA);Hypertension(rs11229165:0.96:NA);Insulin-like growth factor 1 levels(rs28872512:1:0.03;rs11230983:1:0.03);Intra-ocular pressure, goldmann-correlated (left)(rs10431123:0.99:0.16);Intraocular pressure(rs28872512:1:0.14;rs4102526:1:0.32;rs7936821:0.95:NA;rs11229165:0.96:NA);Lymphocyte counts(rs11227435:0.93:NA;rs12221645:0.99:-0.03;rs28872512:1:-0.03);Mean arterial pressure(rs28807461:1:-0.02);Mean corpuscular hemoglobin concentration(rs76154806:1:-0.02);Mean corpuscular volume(rs2212339:1:-0.02);Mean platelet volume(rs1587335:0.78:NA);Medication use (diuretics)(rs11534520:0.98:-0.07;rs11229252:0.88:-0.07);Menarche (age at onset)(rs568442:1:NA);None of the above | vascular/heart problems diagnosed by doctor(rs11246486:0.95:NA);Pulse pressure(rs7928221:1:-0.02);Systolic blood pressure(rs28872512:1:-0.03;rs11525445:1:-0.02;rs7928221:1:-0.02;rs74237369:0.95:-0.32;rs11525445:0.61:NA)"	OR4C6(eqtl:0.7:rs10896987);TRIM48(eqtl:0.6:rs1036357)
11q11	0	31397702	0.62 0.51 0.71 0.93 0.59	0.0 0.0 0.01 0.03 0.26	548475	548475	31123464	31671939	0.05	0.04	0	0	0	0	4	4	0	0	"Brain morphology (MOSTest)(rs1964699:0.65:NA);Cigarettes smoked per day (MTAG)(rs10128753:0.84:-0.01);Diastolic blood pressure(rs919045:0.65:-0.12);Diastolic blood pressure, automated reading(rs61878204:0.65:-0.14);Hematocrit(rs479005:1:0.02;rs479005:1:0.01);Hemoglobin concentration(rs479005:1:0.01);Hemoglobin(rs479005:1:0.01);Lateral thalamic nuclei volume(rs2774406:0.73:-0.07);Red blood cell count(rs479005:1:0.02;rs479005:1:0.02)"	DCDC1(eqtl:1:rs479005;sqtl:0.3:rs479005);DNAJC24(eqtl:0.7:rs479005;sqtl:0.6:rs479005);ELP4(eqtl:0.4:rs479005);IMMP1L(eqtl:0.2:rs479005)
11q11	0	47374998	0.69 0.84 0.68 0.72 0.58	0.01 0.02 0.02 0.06 0.08	548475	548475	47100760	47649235	0.05	0.06	0	0	0	0	22	9	0	0	"Alcohol consumption (drinks per week)(rs56030824:0.92:-0.01);Alcohol consumption(rs2071305:0.68:-0.01);Appendicular lean mass(rs2856661:1:0.02;rs2856661:1:0.03);Arm fat mass (left)(rs2856661:1:-0.01);Arm fat mass (right)(rs2856661:1:-0.01);Arm fat percentage (left)(rs2856661:1:-0.21);Arm fat percentage (right)(rs2856661:1:-0.2);Body fat percentage(rs2856661:1:-0.16);Body mass index (bmi)(rs2856661:1:-0.11;rs2856661:1:-0.1);Cognitive aspects of educational attainment(rs7105851:0.94:0.04);Comparative body size at age 10(rs2856661:1:-0.01);Forced expiratory volume in 1-second (fev1)(rs2856661:1:0.01);Forced expiratory volume in 1-second (fev1), best measure(rs2856661:1:0.01);Forced expiratory volume in 1-second (fev1), predicted(rs2856661:1:0.01);Forced vital capacity (fvc)(rs2856661:1:0.01);Forced vital capacity (fvc), best measure(rs2856661:1:0.02);Full cream | milk type used(rs2856661:1:0.06);Glaucoma (multi-trait analysis)(rs2856661:1:0.07);Hand grip strength (left)(rs2856661:1:0.11);Hematocrit(rs2856661:1:-0.01;rs2856661:1:-0.02);Hemoglobin concentration(rs2856661:1:-0.01);Hemoglobin(rs2856661:1:-0.02);Hip circumference(rs2856661:1:-0.15);Leg fat mass (left)(rs2856661:1:-0.03);Leg fat mass (right)(rs2856661:1:-0.02);Leg fat percentage (left)(rs2856661:1:-0.12);Leg fat percentage (right)(rs2856661:1:-0.12);Lymphocyte counts(rs2856661:1:-0.01;rs2856661:1:-0.01);Mean corpuscular hemoglobin(rs2856661:1:-0.01);Mean corpuscular volume(rs2856661:1:-0.01;rs2856661:1:-0.01);Mean platelet (thrombocyte) volume(rs2856661:1:-0.02);Mean platelet volume(rs2856650:0.68:0.02;rs2856650:0.68:0.02;rs1542321:0.99:NA;rs2856661:1:-0.02;rs2856661:1:-0.02);Neutrophil count(rs935914:0.91:-0.02;rs55876153:0.9:0.02;rs2856661:1:-0.02;rs2856661:1:-0.02);Neutrophill count(rs35996350:0.91:0.03;rs2856661:1:-0.03);Noncognitive aspects of educational attainment(rs12146565:0.92:0.05);Platelet count(rs2856661:1:0.02;rs2856661:1:0.02;rs2856661:1:0.02;rs2856661:1:0.99);Platelet distribution width(rs2856661:1:0.01);Plateletcrit(rs2856661:1:0.01);Refractive error(rs7928419:0.92:NA);Serum alkaline phosphatase levels(rs11570094:0.65:-0.02);Serum total protein level(rs3740688:0.66:0.02);Sitting height(rs2856661:1:0.08);Spherical equivalent(rs2856661:1:-0.07);Standing height(rs2856661:1:0.17);Suffer from 'nerves'(rs2856661:1:0.04);Trunk fat mass(rs2856661:1:-0.1);Trunk fat percentage(rs2856661:1:-0.18);Usual walking pace(rs2856661:1:0.01);Waist circumference(rs2856661:1:-0.21);White blood cell (leukocyte) count(rs2856661:1:-0.04);White blood cell count(rs2856661:1:-0.02;rs2856661:1:-0.02);Whole body fat mass(rs2856661:1:-0.17)"	ACP2(eqtl:0.9:rs2856661);C1QTNF4(eqtl:1:rs2856661);CELF1(eqtl:0.1:rs2856661);DDB2(eqtl:0.4:rs2856661);FAM180B(eqtl:0.6:rs2856661);FNBP4(eqtl:0.5:rs2856661);LRP4(eqtl:0.3:rs2856661);MADD(eqtl:0.2:rs2856661);MTCH2(eqtl:0.9:rs2856661;sqtl:0.9:rs2856661);MYBPC3(eqtl:1:rs2856661);NDUFS3(eqtl:0.7:rs2856661);NR1H3(eqtl:0.9:rs2856661);NUP160(eqtl:0.5:rs2856661);PSMC3(eqtl:0.7:rs2856661);PTPMT1(eqtl:0.2:rs2856661);PTPRJ(eqtl:0.5:rs2856661);RAPSN(eqtl:0.5:rs2856661);SLC39A13(eqtl:0.5:rs2856661;sqtl:0.9:rs2856661);SPI1(eqtl:1:rs2856661)
11q11	0	49111407	0.67 0.34 0.81 0.76 0.77	0.0 0.0 0.0 0.02 0.04	548475	548475	48837169	49385644	0.05	0.02	0	0	1	1	4	0	0	0	"Body size at age 10(rs11040333:0.83:0.01);High blood pressure | vascular/heart problems diagnosed by doctor(rs2727020:1:-0.04);Hypertension | non-cancer illness code, self-reported(rs2727020:1:-0.04);Hypertension(rs2727020:1:-0.01);None of the above | vascular/heart problems diagnosed by doctor(rs2727020:1:0.03)"	FOLH1(eqtl:0.7:rs2727020;sqtl:0.1:rs2727020)
11q11	0	49802934	0.68 0.46 0.78 0.72 0.78	0.0 0.0 0.0 0.02 0.05	548475	548475	49528696	50077171	0.05	0.02	0	0	0	0	3	0	0	0	"High blood pressure | vascular/heart problems diagnosed by doctor(rs10769615:1:-0.04);Hypertension | non-cancer illness code, self-reported(rs10769615:1:-0.04);Hypertension(rs10769615:1:-0.01);Insulin-like growth factor 1 levels(rs10769621:1:0.02);Mean corpuscular volume(rs10769595:0.79:0.01);None of the above | vascular/heart problems diagnosed by doctor(rs10769615:1:0.03);Platelet distribution width(rs7396359:0.61:0.01;rs10769615:1:-0.02)"	0
11q11	0	50368338	0.65 0.52 0.77 0.78 0.78	0.0 0.0 0.0 0.02 0.03	548475	548475	50094100	50642575	0.05	0.02	0	0	0	0	2	0	0	0	"Depressed affect(rs11826064:0.76:-0.02);Fed-up feelings(rs8189285:0.76:NA;rs534142:1:0.03);Feeling fed-up(rs11532157:0.76:-0.02;rs534142:1:0.01);High blood pressure | vascular/heart problems diagnosed by doctor(rs534142:1:0.03);Hypertension | non-cancer illness code, self-reported(rs534142:1:0.03);Hypertension(rs534142:1:0.01);Insulin-related traits (multivariate analysis)(rs10901988:0.97:NA);None of the above | vascular/heart problems diagnosed by doctor(rs534142:1:-0.03);Platelet distribution width(rs534142:1:0.02);Systolic blood pressure, automated reading(rs35290086:0.76:-0.31;rs534142:1:0.28)"	0
11q11	0	56143977	0.64 0.45 0.78 0.86 0.76	0.0 0.01 0.01 0.05 0.17	548475	548475	55869739	56418214	0.05	0.05	0	0	0	0	23	0	0	0	0	0
11q11	0	66167585	0.67 0.53 0.83 0.58 0.77	0.0 0.02 0.02 0.12 0.2	548475	548475	65893347	66441822	0.05	0.12	0	0	0	0	27	18	0	0	C-reactive protein levels(rs1784029:0.94:-0.01);Cycle | types of transport used (excluding work)(rs71045941:0.76:NA;rs7939111:1:-0.06);Urate levels(rs7107191:0.98:-0.01)	ACTN3(eqtl:0.8:rs7939111;sqtl:0.3:rs7939111);B4GAT1(eqtl:0.4:rs7939111);BBS1(eqtl:0.1:rs7939111);BRMS1(sqtl:0.1:rs7939111);CCS(eqtl:0.8:rs7939111);CTSF(eqtl:1:rs7939111);CTSW(eqtl:0.5:rs7939111);DPP3(eqtl:0.2:rs7939111;sqtl:0.4:rs7939111);LRFN4(eqtl:0.8:rs7939111);MAP3K11(eqtl:0.1:rs7939111);MRPL11(sqtl:0.8:rs7939111);RCE1(eqtl:0.4:rs7939111);RIN1(eqtl:0.9:rs7939111);SIPA1(sqtl:0.1:rs7939111);SLC29A2(eqtl:0.2:rs7939111;sqtl:1:rs7939111);YIF1A(eqtl:0.1:rs7939111)
11q11	0	85398998	0.69 0.92 0.59 0.71 0.61	0.0 0.01 0.02 0.11 0.27	548475	548475	85124760	85673235	0.05	0.13	0	0	0	0	8	7	0	0	0	PICALM(eqtl:0.4:rs2467059);SYTL2(eqtl:0.9:rs2467059;sqtl:0.8:rs2467059);TMEM126A(eqtl:0.7:rs2467059)
11q11	0	90071907	0.67 0.68 0.57 0.78 0.71	0.0 0.01 0.04 0.14 0.27	548475	548475	89797669	90346144	0.05	0.14	13	13	13	13	5	2	0	0	0	0
11q12.1	1	56050916	0.09 0.01 0.06 0.0 0.04	0.0 0.0 0.01 0.05 0.12	375024	375023	55822789	56197812	0.03	0.03	0	0	0	0	17	0	0	0	Adolescent idiopathic scoliosis(rs17599071:1:NA);Eosinophil counts(rs17500359:0.66:NA)	0
11q12.1	0	14553094	0.07 0.0 0.03 0.12 0.05	0.0 0.01 0.01 0.03 0.32	375024	375024	14365582	14740606	0.03	0.03	0	0	0	0	4	3	0	0	Serum 25-Hydroxyvitamin D levels(rs7110118:1:-0.1;rs7110118:1:-0.1;rs7110118:1:-0.11;rs7110118:1:-0.11;rs7110118:1:-0.11;rs7110118:1:-0.11)	COPB1(eqtl:0.9:rs7110118);SPON1(eqtl:0.2:rs7110118)
11q12.1	0	28293590	0.09 0.01 0.01 0.0 0.05	0.0 0.0 0.0 0.03 0.22	375024	375024	28106078	28481102	0.03	0.02	0	0	0	0	2	2	0	0	0	0
11q12.1	0	46831556	0.06 0.0 0.01 0.0 0.04	0.0 0.0 0.0 0.03 0.08	375024	375024	46644044	47019068	0.03	0.03	0	0	0	0	10	3	0	0	0	ACP2(eqtl:0.5:rs12796154);C1QTNF4(eqtl:0.6:rs12796154);MYBPC3(eqtl:0.8:rs12796154);NR1H3(eqtl:0.4:rs12796154)
11q12.1	0	47354905	0.1 0.01 0.02 0.0 0.05	0.0 0.02 0.02 0.06 0.08	375024	375024	47167393	47542417	0.03	0.05	0	0	0	0	16	6	0	0	Arm fat percentage (left)(rs11570115:1:-0.18);Arm fat percentage (right)(rs11570115:1:-0.16);Blood glucose levels(rs11570115:1:-0.04;rs11570115:1:-0.04);Body fat percentage(rs11570115:1:-0.14);Body mass index(rs11570115:1:-0.02);Comparative body size at age 10(rs11570115:1:-0.02);Fasting blood glucose(rs11570115:1:-0.03);Glycated hemoglobin levels(rs11570115:1:-0.03);Hemoglobin A1c levels(rs11570115:1:-0.03);Insulin-like growth factor 1 levels(rs11570115:1:-0.02;rs11570115:1:-0.02);Proinsulin levels(rs11570115:1:-0.13);Trunk fat percentage(rs11570115:1:-0.18)	ACP2(eqtl:0.7:rs11570115);ARHGAP1(eqtl:0.2:rs11570115);C1QTNF4(eqtl:0.7:rs11570115);FNBP4(eqtl:0.4:rs11570115);LRP4(eqtl:0.2:rs11570115);MADD(eqtl:0.9:rs11570115;sqtl:0.4:rs11570115);MYBPC3(eqtl:0.7:rs11570115);NUP160(eqtl:0.1:rs11570115);SLC39A13(sqtl:0.8:rs11570115)
11q12.1	0	47861857	0.06 0.0 0.02 0.0 0.04	0.0 0.0 0.01 0.05 0.1	375024	375024	47674345	48049369	0.03	0.03	0	0	0	0	4	3	0	0	Lectin-like oxidized LDL receptor 1 levels(rs74873109:1:-0.12);Sex hormone-binding globulin levels(rs74873109:1:0.01)	ARFGAP2(eqtl:0.3:rs74873109);C1QTNF4(eqtl:0.7:rs74873109);DDB2(eqtl:0.1:rs74873109);FNBP4(eqtl:0.2:rs74873109;sqtl:0.2:rs74873109);MADD(eqtl:0.8:rs74873109);MTCH2(eqtl:0.1:rs74873109);MYBPC3(eqtl:0.7:rs74873109);NR1H3(eqtl:0.6:rs74873109);NUP160(eqtl:0.1:rs74873109);PACSIN3(eqtl:0.6:rs74873109;sqtl:0.9:rs74873109);PSMC3(eqtl:0.5:rs74873109)
11q12.1	0	48363082	0.08 0.06 0.04 0.06 0.05	0.0 0.01 0.01 0.04 0.09	375024	375024	48175570	48550594	0.03	0.03	0	0	0	0	8	0	0	0	0	0
11q12.1	0	49428865	0.09 0.01 0.01 0.0 0.04	0.0 0.0 0.01 0.03 0.05	375024	375024	49241353	49616377	0.03	0.03	0	0	0	0	1	0	0	0	0	0
11q12.1	0	50065237	0.06 0.0 0.03 0.0 0.03	0.0 0.0 0.0 0.02 0.04	375024	375024	49877725	50252749	0.03	0.01	0	0	0	0	3	0	0	0	Platelet distribution width(rs7937964:1:0.03)	FOLH1(eqtl:0.5:rs7937964;sqtl:0.9:rs7937964)
11q12.1	0	89746146	0.05 0.0 0.04 0.0 0.03	0.0 0.0 0.0 0.08 0.23	375024	375024	89558634	89933658	0.03	0.05	5	6	6	10	11	2	0	0	0	NAALAD2(eqtl:0.2:rs76083228);TRIM64B(eqtl:0.7:rs76083228)
12p13.2	1	11207864	0.49 0.64 0.74 0.81 0.53	0.0 0.0 0.0 0.4 1.28	194523	194522	11128832	11323354	0.07	0.07	0	0	0	0	10	1	0	1	Bitter taste perception (multivariate analysis) [quinine and caffeine](rs10772420:1:NA);Bitter taste perception (multivariate analysis) [quinine and denatonium benzoate](rs10772420:1:NA);Bitter taste perception (multivariate analysis) [quinine and sucrose octaacetate](rs10772420:1:NA);Bitter taste perception [Quinine](rs1031391:1:NA);Bitter taste perception [quinine](rs10772420:1:NA);Serum levels of protein AMY1A(rs2123007:1:-0.14)	PRB3(eqtl:0.1:rs10772419);PRH1(eqtl:0.9:rs4763602;sqtl:1:rs4763602);PRR4(eqtl:0.9:rs4763602;sqtl:1:rs4763602);SMIM10L1(eqtl:0.6:rs4763602);TAS2R10(eqtl:0.3:rs4763602);TAS2R14(eqtl:0.9:rs4763602);TAS2R19(eqtl:0.7:rs4763602);TAS2R20(eqtl:0.8:rs4763602);TAS2R31(eqtl:0.7:rs4763602);TAS2R43(eqtl:1:rs4763602);TAS2R46(eqtl:0.9:rs4763602);TAS2R50(eqtl:0.4:rs4763602);TAS2R8(eqtl:0.2:rs2599414);YBX3(eqtl:0.1:rs10772420)
12p13.2	0	13752145	0.47 0.63 0.7 0.98 0.5	0.0 0.03 0.05 0.69 1.42	194523	194523	13654883	13849406	0.07	0.14	0	0	0	0	1	1	0	0	0	0
12p13.2	0	17077669	0.54 0.87 0.61 0.67 0.62	0.0 0.1 0.11 0.42 1.14	194523	194523	16980407	17174930	0.07	0.12	0	0	0	0	1	0	0	0	Morning person(rs1601409:0.92:NA);Tea intake(rs1601409:0.92:0.04)	0
12p13.2	0	19601137	0.45 0.77 0.67 0.68 0.67	0.0 0.01 0.03 0.39 1.15	194523	194523	19503875	19698398	0.07	0.06	0	0	0	0	2	1	0	0	Diastolic blood pressure(rs61912333:0.67:NA)	AEBP2(eqtl:0.5:rs7309303;sqtl:0.1:rs7309303);PLEKHA5(eqtl:0.5:rs7309303)
12p13.2	0	31251544	0.44 0.71 0.57 0.81 0.61	0.0 0.03 0.06 0.76 1.12	194523	194523	31154282	31348805	0.07	0.16	0	0	0	0	3	0	0	0	Mean reticulocyte volume(rs80318075:0.92:0.01;rs7966523:0.97:0.01;rs4931431:1:0.1;rs4931431:1:0.01;rs4931431:1:0.01)	DDX11(eqtl:1:rs4931431;sqtl:1:rs4931431)
12p13.2	0	63557914	0.53 0.87 0.7 0.46 0.65	0.0 0.01 0.05 0.42 1.17	194523	194523	63460652	63655175	0.07	0.15	0	0	0	0	1	0	0	0	Chronotype(rs10877962:0.84:NA);Cystatin C levels(rs1042615:0.98:0.01);Insulin-like growth factor 1 levels(rs4547160:0.65:0;rs35575064:0.64:0.02;rs1042615:0.98:-0.01);Morning person(rs10877962:0.84:NA);Morningness(rs7138306:0.84:-0.01)	AVPR1A(eqtl:0.2:rs7307997)
12p13.2	0	69926704	0.5 0.88 0.66 0.6 0.51	0.0 0.0 0.01 0.49 1.36	194523	194523	69829442	70023965	0.07	0.19	0	0	3	3	6	1	0	0	Standing height(rs472197:1:0.1)	CCT2(eqtl:0.8:rs472197;sqtl:0.2:rs472197);FRS2(eqtl:0.6:rs472197;sqtl:0.7:rs472197);LYZ(eqtl:0.7:rs472197);YEATS4(eqtl:0.7:rs472197)
12p13.2	0	83746006	0.52 0.82 0.54 0.68 0.66	0.0 0.04 0.06 0.53 1.13	194523	194523	83648744	83843267	0.07	0.08	0	0	0	0	0	0	0	0	0	0
12p13.2	0	101211766	0.53 0.65 0.65 0.71 0.68	0.04 0.07 0.08 0.59 1.12	194523	194523	101114504	101309027	0.07	0.18	0	0	0	0	1	0	0	0	0	0
12p13.2	0	105445559	0.52 0.87 0.5 0.61 0.64	0.09 0.1 0.12 0.21 1.35	194523	194523	105348297	105542820	0.07	0.13	0	0	0	0	5	3	0	0	Serum albumin levels(rs2440717:0.63:-0.02)	ALDH1L2(eqtl:0.5:rs11611857);APPL2(eqtl:1:rs11611857);C12orf75(eqtl:0.8:rs11611857)
12p11.21	1	31647305	0.42 0.22 0.47 0.57 0.62	0.0 0.0 0.01 0.42 1.04	175629	175628	31560063	31735691	0.02	0.02	0	0	0	0	1	1	1	1	Refractive error(rs7311970:0.88:NA);Total PHF-tau (SNP x SNP interaction)(rs2568901:0.72:NA)	DENND5B(eqtl:0.9:rs7313889);RESF1(eqtl:0.4:rs7313889)
12p11.21	0	29246064	0.45 0.37 0.55 0.56 0.39	0.0 0.02 0.04 0.56 1.13	175629	175629	29158249	29333878	0.02	0.05	0	0	0	0	1	1	0	0	Mean platelet (thrombocyte) volume(rs2099529:1:-0.04);Mean platelet volume(rs2099529:1:-0.03;rs2099529:1:-0.03;rs2099529:1:-0.03);Pattern 4 | hair/balding pattern(rs2099529:1:0.06);Platelet count(rs2099529:1:0.02;rs2099529:1:0.02;rs2099529:1:1.03);Platelet distribution width(rs2099529:1:-0.01;rs2099529:1:-0.01);Standing height(rs2099529:1:-0.09)	FAR2(eqtl:0.5:rs2099529);TMTC1(eqtl:0.3:rs2099529)
12p11.21	0	50578705	0.38 0.48 0.58 0.55 0.38	0.0 0.01 0.01 0.42 0.9	175629	175629	50490890	50666519	0.02	0.03	0	0	0	0	6	4	0	0	Colorectal cancer(rs34245511:0.91:NA);Heel bone mineral density T score(rs9364:0.91:0.01);Heel bone mineral density(rs7964698:0.79:NA;rs11169302:1:-0.01;rs11169302:1:-0.01);Impedance of leg (left)(rs11169302:1:-0.5);Impedance of leg (right)(rs11169302:1:-0.43);Impedance of whole body(rs11169302:1:-0.89);Liver enzyme levels (alanine transaminase)(rs11169302:1:0);Lymphocyte counts(rs7964698:0.79:0.01;rs7964698:0.79:0.01;rs3184122:0.75:0.01;rs9364:0.91:-0.01;rs11169302:1:0.01;rs11169302:1:0.01);Mean corpuscular volume(rs11169302:1:0.01);Neutrophil count(rs11169302:1:0.02;rs11169315:0.72:0.02;rs6580736:0.71:NA;rs11169302:1:0.02;rs11169302:1:0.02);Neutrophill count(rs7398356:0.71:-0.03;rs11169302:1:0.03);Platelet count(rs11169302:1:0.01);Platelet crit(rs11169302:1:0);Red blood cell (erythrocyte) distribution width(rs11169302:1:0.01);Red cell distribution width(rs11169302:1:0.02;rs11169302:1:0.02);Sex hormone-binding globulin levels adjusted for BMI(rs11169302:1:0.01;rs11169302:1:0.01);Sex hormone-binding globulin levels(rs11169302:1:0.01;rs11169302:1:0.01);Vertex-wise sulcal depth(rs2302900:0.69:6.52);White blood cell (leukocyte) count(rs7398356:0.71:-0.05;rs11169302:1:0.04);White blood cell count(rs11169302:1:0.02;rs11169302:1:NA;rs11169315:0.72:0.02;rs2302900:0.69:NA;rs11169302:1:0.02;rs11169302:1:0.02)	ASIC1(eqtl:0.3:rs11169302);ATF1(eqtl:0.7:rs11169302;sqtl:0.4:rs11169302);CERS5(eqtl:1:rs11169302;sqtl:1:rs11169302);COX14(eqtl:0.9:rs11169302;sqtl:0.6:rs11169302);DIP2B(eqtl:0.8:rs11169302);FAM186A(sqtl:1:rs11169302);LIMA1(eqtl:1:rs11169302);METTL7A(eqtl:0.8:rs11169302);SMARCD1(eqtl:0.7:rs11169302;sqtl:0.8:rs11169302);TFCP2(eqtl:0.5:rs11169302)
12p11.21	0	62101898	0.45 0.6 0.36 0.41 0.44	0.0 0.01 0.02 0.42 0.95	175629	175629	62014083	62189712	0.02	0.03	0	0	0	0	1	0	0	0	0	0
12p11.21	0	65780013	0.39 0.26 0.61 0.58 0.48	0.0 0.01 0.02 0.29 1.04	175629	175629	65692198	65867827	0.02	0.03	0	0	0	0	2	0	0	1	"FEV1(rs12825748:0.68:0.02;rs11175741:1:0.02);Forced expiratory volume in 1-second (fev1), best measure(rs11175741:1:0.01);Forced vital capacity (fvc), best measure(rs11175741:1:0.01);Lung function (FEV1)(rs1494502:0.98:0.03);Lung function (FVC)(rs12825748:0.68:0.02;rs1494508:0.99:-0.02;rs11175741:1:0.02);Temporal lobe volume(rs7301260:1:0.69)"	LEMD3(eqtl:0.9:rs11175741);MSRB3(sqtl:0.6:rs11175741)
12p11.21	0	70602404	0.45 0.62 0.46 0.26 0.45	0.0 0.0 0.01 0.26 0.98	175629	175629	70514589	70690218	0.02	0.03	0	0	0	0	2	0	0	0	Eosinophil counts(rs7299446:0.74:-0.01;rs6581928:0.74:NA);Eosinophil percentage of white cells(rs35731285:0.74:-0.01)	CNOT2(sqtl:0.8:rs7978426);KCNMB4(eqtl:0.9:rs7978426);MYRFL(eqtl:0.4:rs7978426)
12p11.21	0	97282058	0.45 0.45 0.54 0.47 0.44	0.01 0.02 0.03 0.36 0.99	175629	175629	97194243	97369872	0.02	0.05	0	0	0	0	2	2	0	0	0	NEDD1(eqtl:1:rs252185)
12p11.21	0	98410613	0.38 0.3 0.57 0.53 0.48	0.0 0.02 0.04 0.49 0.95	175629	175629	98322798	98498427	0.02	0.05	0	0	0	0	2	0	0	0	0	0
12p11.21	0	102710684	0.46 0.47 0.53 0.41 0.38	0.0 0.0 0.01 0.14 1.02	175629	175629	102622869	102798498	0.02	0.03	0	3	3	3	1	0	0	0	0	WASHC3(eqtl:0.2:rs1113483)
12p11.21	0	121343893	0.43 0.52 0.37 0.56 0.34	0.0 0.01 0.03 0.26 0.95	175629	175629	121256078	121431707	0.02	0.06	0	0	0	0	4	1	0	0	"Age asthma diagnosed(rs35604151:0.62:0.77);Allergic disease (asthma, hay fever and/or eczema) (age of onset)(rs9431:0.76:0.03);Allergic disease (asthma, hay fever and/or eczema) (multivariate analysis)(rs9431:0.76:0.03);Allergic disease (asthma, hay fever or eczema)(rs2393717:0.85:NA;rs1718188:1:0.04);Allergic rhinitis(rs2461475:0.75:NA);Anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, or Tourette syndrome (pleiotropy)(rs2047568:0.67:NA);Appendicular lean mass(rs200192701:0.71:0.01;rs1718188:1:0.01);Asthma(rs625228:0.99:NA);Depression(rs3213572:0.67:NA);Depressive symptoms(rs11611087:0.68:0.01);Eczema(rs3213567:0.85:NA);Educational attainment (MTAG) [MTAG](rs660549:0.97:0.01);Eosinophil counts(rs1718188:1:0.02;rs1718188:1:0.02);Eosinophill count(rs1718188:1:0.01);Hay fever and/or eczema(rs2393717:0.85:NA);Hayfever, allergic rhinitis or eczema | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor(rs3213567:0.85:NA;rs1718188:1:0.03);Height(rs7137504:0.65:-0.01);Low density lipoprotein cholesterol levels(rs1718188:1:-0.01);Major depressive disorder(rs35905305:0.68:NA);None of the above | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor(rs1718188:1:-0.03);Platelet count(rs1718188:1:0.01);Plateletcrit(rs1718188:1:0.02);Red cell distribution width(rs1718188:1:-0.01);Relative age of first facial hair(rs1221386678:0.63:-0.01;rs1718188:1:0.01);Serum metabolite levels [butyrylcarnitine](rs4454799:0.66:NA);Sex hormone-binding globulin levels adjusted for BMI(rs1718188:1:0.01;rs1718188:1:0.01);Sex hormone-binding globulin levels(rs1718188:1:0.01;rs1718188:1:0.01);Standing height(rs1718188:1:0.09);White blood cell count(rs1718188:1:0.01;rs1718188:1:0.01)"	ACADS(eqtl:0.8:rs1718188);CAMKK2(eqtl:0.4:rs1718188);COQ5(eqtl:0.1:rs1718188);OASL(eqtl:0.6:rs1718188);P2RX4(eqtl:0.7:rs1718188);P2RX7(eqtl:0.1:rs1718188);SPPL3(eqtl:0.9:rs1718188)
12p11.1	1	33989289	0.41 0.17 0.28 0.08 0.4	0.0 0.01 0.02 0.1 0.25	172490	172489	33907109	34079598	0.03	0.03	0	0	0	0	0	0	0	0	Heart rate response to recovery post exercise [females](rs1384590:0.8:-0.69);Heart rate response to recovery post exercise [males](rs1384590:0.8:-0.5);Heart rate response to recovery post exercise(rs2218650:0.79:-0.6);Morning person(rs1906136:0.61:NA);Serum 25-Hydroxyvitamin D levels(rs7306334:0.81:0.01);Snoring [adjusted for BMI](rs10844664:0.93:NA);Waist-hip index(rs34353125:0.71:NA);Waist-hip ratio(rs10844642:0.82:NA;rs2200155:0.8:-0.01);Waist-to-hip ratio adjusted for BMI(rs10844642:0.82:-0.01;rs7308214:0.81:NA;rs11053221:0.81:-0.01;rs34353125:0.71:NA)	ALG10(eqtl:0.8:rs11052901)
12p11.1	0	38514547	0.38 0.11 0.29 0.17 0.31	0.0 0.01 0.01 0.05 0.09	172490	172490	38428302	38600792	0.03	0.02	0	0	0	0	0	0	0	0	0	0
12p11.1	0	39028239	0.45 0.1 0.34 0.23 0.31	0.0 0.01 0.01 0.06 0.15	172490	172490	38941994	39114484	0.03	0.02	0	0	0	0	1	1	0	0	"Alcohol consumption (drinks per week) (MTAG)(rs9325144:0.68:-0.01);Chronotype(rs1843888:0.88:NA);Daytime nap(rs34565156:1:-0.01);Getting up in morning(rs34565156:1:-0.01);Heart rate(rs826838:0.66:-0.23);Insulin-like growth factor 1 levels(rs6582630:0.89:0.02);Morning person(rs1843888:0.88:NA;rs7313852:0.93:NA);Morning vs. evening chronotype(rs6582618:0.82:NA);Morning/evening person (chronotype)(rs34565156:1:0.02);Morningness(rs7313852:0.93:-0.03);Pulse rate, automated reading(rs34565156:1:-0.21);Serum 25-Hydroxyvitamin D levels(rs9668081:0.66:0.01;rs7955128:0.8:0.01;rs10880925:0.84:0.01;rs34565156:1:-0.01;rs34565156:1:-0.01;rs34565156:1:-0.01;rs34565156:1:-0.01)"	ALG10B(eqtl:0.8:rs34565156)
12p11.1	0	39848960	0.45 0.12 0.3 0.16 0.3	0.0 0.0 0.01 0.11 0.29	172490	172490	39762715	39935205	0.03	0.01	0	0	0	0	1	1	0	0	0	ABCD2(eqtl:0.6:rs4628717);CPNE8(eqtl:0.4:rs4628717);LRRK2(eqtl:0.4:rs4628717)
12p11.1	0	61001481	0.39 0.02 0.34 0.22 0.4	0.0 0.01 0.02 0.11 0.22	172490	172490	60915236	61087726	0.03	0.03	0	0	0	0	0	0	0	0	0	0
12p11.1	0	73776884	0.39 0.22 0.34 0.09 0.22	0.0 0.02 0.03 0.14 0.33	172490	172490	73690639	73863129	0.03	0.04	0	0	0	0	0	0	0	0	0	0
12p11.1	0	74595877	0.43 0.17 0.28 0.16 0.27	0.0 0.01 0.03 0.11 0.3	172490	172490	74509632	74682122	0.03	0.04	0	0	0	0	1	0	0	1	0	0
12p11.1	0	81978026	0.4 0.19 0.26 0.13 0.37	0.0 0.02 0.03 0.18 0.44	172490	172490	81891781	82064271	0.03	0.04	0	0	0	0	1	1	0	0	0	0
12p11.1	0	84084693	0.4 0.18 0.3 0.12 0.39	0.0 0.0 0.02 0.21 0.39	172490	172490	83998448	84170938	0.03	0.04	0	0	0	0	0	0	0	0	College or university degree | qualifications(rs4882469:1:-0.03);Cortical thickness(rs324766:0.92:NA);Glaucoma (multi-trait analysis)(rs324762:0.88:0.07;rs4882469:1:-0.07);Glaucoma (primary open-angle)(rs324788:0.92:0.09);Optic cup area(rs482507:0.89:0.02;rs324775:0.88:NA;rs4882469:1:-0.02);Optic disc area(rs442376:0.92:0.03;rs2667477:0.92:0.03;rs4882469:1:-0.03);Vertex-wise cortical surface area(rs11115937:0.92:7.44);Vertex-wise cortical thickness(rs324766:0.92:-6.71);Vertex-wise sulcal depth(rs11115937:0.92:8.89);Vertical cup-disc ratio (adjusted for vertical disc diameter)(rs63092660:0.88:0.01);Vertical cup-disc ratio (multi-trait analysis)(rs324780:0.88:0.02);Vertical cup-disc ratio(rs324776:0.88:0.01;rs324780:0.89:0.01;rs4882469:1:-0.01)	0
12p11.1	0	84698651	0.41 0.11 0.27 0.29 0.26	0.0 0.01 0.02 0.11 0.37	172490	172490	84612406	84784896	0.03	0.03	0	0	0	0	0	0	0	0	0	0
12q14.1	1	62745268	0.18 0.34 0.25 0.13 0.15	0.0 0.0 0.01 0.14 1.17	181440	181439	62646745	62828184	0.02	0.02	0	0	0	0	2	1	1	1	Educational attainment (years of education)(rs11174399:1:0.01)	TAFA2(eqtl:0.9:rs7298827);USP15(eqtl:0.9:rs7298827;sqtl:0.4:rs12315645)
12q14.1	0	48595245	0.23 0.26 0.21 0.13 0.13	0.01 0.01 0.02 0.19 1.05	181440	181440	48504525	48685965	0.02	0.03	0	0	0	0	5	3	0	0	Mean corpuscular volume(rs11168458:1:-0.01)	ASB8(eqtl:0.4:rs11168458);CCDC184(eqtl:0.7:rs11168458);H1-7(eqtl:0.8:rs11168458);KANSL2(eqtl:0.7:rs11168458);OR10AD1(eqtl:0.1:rs11168458);PFKM(eqtl:0.5:rs11168458);SENP1(sqtl:0.1:rs11168458);TMEM106C(eqtl:0.8:rs11168458);ZNF641(eqtl:1:rs11168458;sqtl:0.4:rs11168458)
12q14.1	0	53733283	0.18 0.2 0.19 0.18 0.21	0.0 0.01 0.01 0.31 0.98	181440	181440	53642563	53824003	0.02	0.03	78	78	78	78	8	4	0	0	Apolipoprotein A1 levels(rs11170517:0.73:-0.02);HDL cholesterol levels(rs11170516:0.81:-0.02);Hypospadias (moderate to severe)(rs11170516:0.99:NA);Low density lipoprotein cholesterol levels(rs11829355:1:0.02);Mean corpuscular haemoglobin(rs11829355:1:-0.04);Mean corpuscular hemoglobin(rs11170516:0.99:-0.04;rs11170516:0.99:NA;rs11170516:0.91:-0.03;rs12582170:0.79:0.03;rs12582170:0.79:0.04;rs11829355:1:-0.03;rs11829355:1:-0.03;rs11829355:1:-0.03);Mean corpuscular volume(rs4759113:0.92:0.04;rs11170509:0.91:-0.04;rs12582170:0.72:NA;rs12582170:0.79:0.04;rs12582170:0.79:0.16;rs12582170:0.79:0.04;rs12582170:0.79:0.15;rs12582170:0.79:0.05;rs11829355:1:-0.03;rs11829355:1:-0.04;rs11829355:1:-0.12;rs11829355:1:-0.03);Mean platelet volume(rs11829355:1:-0.01);Mean reticulocyte volume(rs12582170:0.79:0.24;rs11829355:1:-0.18;rs11829355:1:-0.03);Mean sphered cell volume(rs12582170:0.79:0.18;rs11829355:1:-0.14);Mean spheric corpuscular volume(rs11829355:1:-0.03);Monocyte count(rs11829355:1:-0.02);Monocyte percentage of white cells(rs71068111:1:-0.02;rs11829355:1:-0.02);Red blood cell (erythrocyte) count(rs11829355:1:0.01);Red blood cell count(rs11829355:1:0.03;rs11829355:1:0.02);Reticulocyte count(rs11829355:1:0.02);Sex hormone-binding globulin levels adjusted for BMI(rs11829355:1:-0.01);Sex hormone-binding globulin levels(rs11829355:1:-0.01)	AMHR2(sqtl:0.9:rs11829355);ATP5MC2(eqtl:0.7:rs11829355;sqtl:0.6:rs11829355);MAP3K12(eqtl:0.6:rs11829355;sqtl:0.1:rs11829355);PCBP2(eqtl:0.2:rs11829355);PRR13(eqtl:1:rs11829355);SP1(eqtl:0.9:rs11829355;sqtl:0.3:rs11829355);TARBP2(eqtl:0.4:rs11829355)
12q14.1	0	70639854	0.14 0.09 0.22 0.2 0.37	0.0 0.01 0.01 0.28 1.03	181440	181440	70549134	70730574	0.02	0.03	0	0	0	0	2	0	0	0	0	KCNMB4(eqtl:0.9:rs74716820;sqtl:0.2:rs74716820);RAB3IP(sqtl:0.3:rs74716820)
12q14.1	0	72116782	0.14 0.22 0.2 0.3 0.16	0.01 0.03 0.03 0.34 1.03	181440	181440	72026062	72207502	0.02	0.06	0	0	0	0	4	4	0	0	0	0
12q14.1	0	75771295	0.14 0.21 0.2 0.12 0.3	0.01 0.01 0.01 0.34 1.12	181440	181440	75680575	75862015	0.02	0.03	0	0	0	0	3	3	0	0	0	CAPS2(eqtl:0.6:rs12424057;sqtl:0.6:rs12424057);GLIPR1(eqtl:1:rs12424057;sqtl:0.5:rs12424057);GLIPR1L1(eqtl:0.2:rs12424057);GLIPR1L2(eqtl:0.7:rs12424057);KRR1(eqtl:0.9:rs12424057)
12q14.1	0	96921405	0.23 0.08 0.37 0.2 0.16	0.0 0.0 0.02 0.34 1.34	181440	181440	96830685	97012125	0.02	0.04	0	0	0	0	1	1	0	0	0	NEDD1(eqtl:0.2:rs12814453)
12q14.1	0	101732904	0.21 0.05 0.22 0.37 0.28	0.0 0.01 0.02 0.83 1.34	181440	181440	101642184	101823624	0.02	0.04	0	0	0	0	2	2	0	0	Alcohol dependence (age at onset)(rs57083693:0.95:NA)	UTP20(eqtl:0.4:rs112875290)
12q14.1	0	102786072	0.2 0.32 0.15 0.17 0.13	0.0 0.01 0.02 0.32 1.02	181440	181440	102695352	102876792	0.02	0.05	3	3	3	3	1	0	0	0	Sitting height(rs10860862:1:0.07);Standing height(rs10860862:1:0.11)	PARPBP(eqtl:0.1:rs10860862);WASHC3(sqtl:0.1:rs10860862)
12q14.1	0	108373127	0.16 0.12 0.32 0.35 0.18	0.0 0.01 0.02 0.63 1.26	181440	181440	108282407	108463847	0.02	0.05	0	0	0	0	1	0	0	0	Daytime nap(rs60222088:0.76:-0.01);Nap during day(rs60222088:0.76:-0.01);Sleep duration(rs4402351:0.76:-0.98)	BTBD11(eqtl:0.2:rs7953269);WSCD2(eqtl:0.6:rs7953269)
12q24.11	1	110918673	0.88 0.69 0.9 0.99 0.92	0.0 0.01 0.01 0.04 0.26	343030	343029	110747511	111090540	0.03	0.03	9	12	17	28	10	10	0	0	Automobile speeding propensity(rs61106808:0.8:NA);Cognitive performance (MTAG) [MTAG](rs148526428:0.79:0.02);Composite immunoglobulin trait (IgA/IgG)(rs28720928:0.83:-0.12);Headache | pain type(s) experienced in last month(rs112961098:0.78:NA);Headache(rs7300001:0.78:-0.01);Intelligence (MTAG)(rs12313068:0.64:0.02)	ANAPC7(sqtl:0.4:rs7960988;eqtl:0.5:rs61117387);ANKRD13A(sqtl:0.2:rs7960988);ARPC3(eqtl:0.7:rs7960988;sqtl:0.5:rs7960988);ATP2A2(eqtl:0.1:rs7960988);C12orf76(eqtl:0.5:rs7960988;sqtl:0.3:rs7960988);FAM216A(eqtl:1:rs73206895);GLTP(sqtl:0.9:rs7960988);GPN3(eqtl:1:rs7960988);HVCN1(eqtl:0.9:rs7960988);PPP1CC(eqtl:0.8:rs7960988);PPTC7(eqtl:0.8:rs7960988);RAD9B(eqtl:0.5:rs7960988);TCHP(eqtl:0.4:rs73206857);TCTN1(eqtl:0.3:rs7960988);VPS29(eqtl:0.4:rs7960988)
12q24.11	0	33575678	0.89 0.79 0.89 0.94 0.78	0.0 0.02 0.04 0.17 0.44	343030	343030	33404163	33747193	0.03	0.12	0	0	0	0	1	0	0	0	"Pulse rate, automated reading(rs1994166:1:-0.26)"	SYT10(eqtl:1:rs1994166)
12q24.11	0	39277118	0.92 0.79 0.88 0.85 0.92	0.0 0.01 0.01 0.1 0.21	343030	343030	39105603	39448633	0.03	0.07	0	0	0	0	1	1	0	0	0	CPNE8(eqtl:0.3:rs78667616)
12q24.11	0	39864880	0.88 0.82 0.88 0.86 0.93	0.0 0.0 0.0 0.1 0.31	343030	343030	39693365	40036395	0.03	0.05	0	0	0	0	3	2	0	0	0	ABCD2(eqtl:0.8:rs146270702);LRRK2(eqtl:0.1:rs146270702)
12q24.11	0	51240780	0.92 0.6 0.89 0.97 0.91	0.01 0.03 0.03 0.11 0.38	343030	343030	51069265	51412295	0.03	0.09	0	0	0	0	6	5	0	0	Neutrophil count(rs12317842:1:0.02);White blood cell count(rs12317842:1:0.02)	ATF1(eqtl:0.2:rs12317842);CERS5(eqtl:0.7:rs12317842);LETMD1(eqtl:0.7:rs12317842);LIMA1(eqtl:0.6:rs12317842);METTL7A(eqtl:0.5:rs12317842);SLC11A2(eqtl:0.8:rs12317842);TFCP2(eqtl:0.6:rs12317842)
12q24.11	0	73931715	0.88 0.67 0.91 0.94 0.9	0.0 0.01 0.02 0.12 0.31	343030	343030	73760200	74103230	0.03	0.08	0	0	0	0	0	0	0	0	0	0
12q24.11	0	74466625	0.88 0.66 0.9 0.98 0.93	0.0 0.01 0.01 0.08 0.24	343030	343030	74295110	74638140	0.03	0.05	0	0	0	0	1	0	0	0	0	0
12q24.11	0	84439577	0.9 0.74 0.96 0.97 0.9	0.0 0.01 0.02 0.13 0.27	343030	343030	84268062	84611092	0.03	0.09	0	0	0	0	0	0	0	0	0	0
12q24.11	0	86407902	0.86 0.71 0.95 0.95 0.89	0.0 0.0 0.02 0.14 0.26	343030	343030	86236387	86579417	0.03	0.1	0	0	0	0	2	1	0	0	Hair color(rs7299005:0.69:NA)	MGAT4C(eqtl:0.4:rs61931073)
12q24.11	0	86951340	0.88 0.69 0.94 0.97 0.9	0.0 0.01 0.01 0.06 0.17	343030	343030	86779825	87122855	0.03	0.03	0	0	0	1	1	1	0	0	0	0
13q14.2	1	49016644	0.96 0.22 0.9 0.89 0.9	0.0 0.0 0.01 0.1 0.73	251267	251266	48892086	49143352	0.02	0.02	0	0	0	0	4	3	0	0	0	LPAR6(eqtl:0.3:rs415160);RCBTB2(eqtl:0.4:rs2854348)
13q14.2	0	19994310	0.94 0.22 0.83 0.93 0.89	0.0 0.02 0.07 0.17 0.61	251267	251267	19868676	20119943	0.02	0.1	0	0	0	0	3	1	0	0	0	MPHOSPH8(eqtl:0.3:rs4771230);TPTE2(eqtl:0.1:rs4771230;sqtl:0.2:rs4771230)
13q14.2	0	50478732	0.95 0.97 0.81 0.42 0.82	0.02 0.04 0.05 0.14 0.56	251267	251267	50353098	50604365	0.02	0.1	0	0	0	0	7	3	0	0	0	CAB39L(sqtl:0.4:rs75389624);EBPL(eqtl:0.1:rs75389624);KCNRG(eqtl:0.2:rs75389624);RCBTB1(eqtl:0.4:rs75389624);SPRYD7(eqtl:0.7:rs75389624)
13q14.2	0	67329549	0.92 0.34 0.93 0.85 0.9	0.0 0.05 0.07 0.3 0.71	251267	251267	67203915	67455182	0.02	0.13	0	0	0	0	2	0	0	0	0	0
13q14.2	0	68177973	0.91 0.57 0.88 0.7 0.78	0.0 0.06 0.08 0.26 0.89	251267	251267	68052339	68303606	0.02	0.12	0	0	0	0	0	0	0	0	0	0
13q14.2	0	80925733	0.95 0.51 0.66 0.83 0.89	0.02 0.05 0.08 0.38 0.81	251267	251267	80800099	81051366	0.02	0.14	0	0	0	0	1	0	0	0	0	0
13q14.2	0	82160891	0.92 0.76 0.61 0.66 0.85	0.0 0.02 0.04 0.26 0.85	251267	251267	82035257	82286524	0.02	0.12	0	0	0	0	0	0	0	0	0	0
13q14.2	0	84735533	0.92 0.58 0.92 0.75 0.77	0.0 0.02 0.03 0.22 0.58	251267	251267	84609899	84861166	0.02	0.09	0	0	0	0	1	0	0	0	0	0
13q14.2	0	93457534	0.93 0.62 0.79 0.68 0.85	0.0 0.01 0.03 0.4 0.91	251267	251267	93331900	93583167	0.02	0.08	0	0	0	0	2	0	0	0	Biological sex(rs9556218:0.75:0.02)	0
13q14.2	0	97929154	0.93 0.4 0.81 0.91 0.84	0.01 0.06 0.08 0.22 0.78	251267	251267	97803520	98054787	0.02	0.14	0	0	0	0	2	0	0	1	0	MBNL2(eqtl:0.1:rs7320723)
15q21.3	1	57363575	0.52 0.02 0.44 0.36 0.32	0.0 0.01 0.01 0.1 1.15	269922	269921	57217167	57487088	0.03	0.03	0	0	0	0	1	1	0	0	"""Primary open-angle glaucoma, strict""(rs715338:0.8:NA);Bioavailable testosterone levels(rs7496293:0.92:0.02;rs7496293:0.92:0.01);Body mass index [Japanese](rs2593235:0.93:-0.02);HDL cholesterol levels(rs2920265:0.78:-0.01);Insomnia [Female](rs715338:0.8:NA);Insomnia(rs715338:0.8:NA);Intraocular pressure(rs715338:0.8:-0.08);Juvenile Open Angle Glaucoma(rs715338:0.8:NA);Pattern 2 | hair/balding pattern(rs1378597254:0.69:NA);Primary open-angle glaucoma(rs715338:0.8:NA);Total testosterone levels(rs11071293:0.62:-0.02);Type 2 diabetes [conditional](rs2585088:0.78:NA);Type 2 diabetes(rs2435907:0.78:-0.03)"	TCF12(eqtl:0.8:rs62025331;sqtl:0.3:rs62025331);ZNF280D(eqtl:0.4:rs2111891)
15q21.3	0	31843528	0.53 0.05 0.61 0.1 0.36	0.01 0.06 0.08 0.36 1.32	269922	269922	31708567	31978489	0.03	0.18	0	0	0	0	2	0	0	0	Body mass index(rs4284600:1:NA;rs11630385:1:0.01;rs1471212:0.98:NA)	0
15q21.3	0	40062086	0.49 0.22 0.27 0.18 0.53	0.0 0.01 0.05 0.34 1.31	269922	269922	39927125	40197047	0.03	0.13	0	0	0	0	3	1	0	0	0	EIF2AK4(eqtl:0.3:rs1021411);SRP14(eqtl:0.2:rs1021411);THBS1(eqtl:0.1:rs1021411)
15q21.3	0	40741973	0.5 0.18 0.39 0.2 0.37	0.01 0.09 0.1 0.78 1.27	269922	269922	40607012	40876934	0.03	0.19	0	0	0	0	11	7	0	0	Lymphocyte counts(rs4244580:1:-0.01;rs4244580:1:-0.01);Red cell distribution width(rs4244580:1:-0.01;rs4244580:1:-0.01);Triglyceride levels(rs3803357:0.92:-0.01)	BAHD1(eqtl:0.7:rs4244580);CCDC32(eqtl:1:rs4244580;sqtl:0.9:rs4244580);CHST14(eqtl:0.5:rs4244580);DNAJC17(eqtl:0.2:rs4244580);GCHFR(eqtl:0.5:rs4244580);INAFM2(eqtl:0.5:rs4244580);IVD(eqtl:0.4:rs4244580;sqtl:0.6:rs4244580);KNSTRN(eqtl:0.9:rs4244580);RMDN3(eqtl:0.8:rs4244580);ZFYVE19(eqtl:0.9:rs4244580;sqtl:0.8:rs4244580)
15q21.3	0	45808928	0.49 0.25 0.36 0.2 0.29	0.0 0.0 0.0 0.34 1.28	269922	269922	45673967	45943889	0.03	0.05	0	0	0	0	9	6	0	0	Appendicular lean mass(rs3120975:0.74:0.01;rs11070460:1:-0.01);Glomerular filtration rate (creatinine)(rs11070460:1:0.01);Glomerular filtration rate in non diabetics (creatinine)(rs11070460:1:0.01)	BLOC1S6(eqtl:0.4:rs11070460);DUOX1(eqtl:0.3:rs11070460);GATM(eqtl:1:rs11070460;sqtl:0.1:rs11070460);SLC28A2(eqtl:0.9:rs11070460);SPATA5L1(eqtl:1:rs11070460)
15q21.3	0	47143731	0.49 0.1 0.51 0.15 0.4	0.01 0.08 0.09 0.24 1.03	269922	269922	47008770	47278692	0.03	0.12	0	0	0	0	0	0	0	0	0	0
15q21.3	0	47754027	0.52 0.19 0.55 0.12 0.33	0.01 0.02 0.05 0.43 1.04	269922	269922	47619066	47888988	0.03	0.15	0	0	0	0	1	0	0	0	Age at first sexual intercourse(rs12900091:0.69:0.02;rs281323:1:-0.01;rs281323:1:-0.02);Attention deficit hyperactivity disorder [males](rs8039398:0.88:NA;rs281323:1:0.09);Attention deficit hyperactivity disorder or cannabis use(rs8039398:0.88:NA);Attention deficit hyperactivity disorder or intracranial volume (pleiotropy)(rs281320:0.99:6.47);Attention deficit hyperactivity disorder or putamen volume (pleiotropy)(rs281323:1:5.9);Attention deficit hyperactivity disorder(rs281324:1:NA);Educational attainment (years of education)(rs281323:1:NA);Gamma glutamyl transferase levels(rs4775699:0.69:-0.01);Major depressive disorder vs ADHD (ordinary least squares (OLS))(rs8039398:0.88:NA);Oily fish consumption(rs28533540:0.76:NA);Oily fish intake(rs28533540:0.76:0.02);Platelet count(rs8027136:0.65:-0.01);Pork consumption(rs28533540:0.76:NA)	SEMA6D(eqtl:1:rs281323)
15q21.3	0	63451563	0.52 0.18 0.35 0.35 0.28	0.0 0.01 0.03 0.69 1.25	269922	269922	63316602	63586524	0.03	0.15	0	0	0	0	6	4	0	0	Blood metabolite levels [succinylcarnitine](rs1472631:0.78:-0.04);Creatinine levels(rs2053633:0.76:-0.02);Cystatin C levels(rs2053633:0.76:-0.02);Estimated glomerular filtration rate(rs11071738:0.61:0);Mean platelet (thrombocyte) volume(rs55862039:1:-0.02);Mean platelet volume(rs55862039:1:-0.02;rs55862039:1:-0.02;rs55862039:1:-0.02);Metabolic traits [succinylcarnitine](rs2652822:0.77:-0.09);Platelet count(rs55862039:1:0.01;rs55862039:1:0.01);Serum metabolite levels [succinylcarnitine (C4-DC](rs1126308:0.88:-0.41);Serum metabolite levels [succinylcarnitine](rs2652822:0.77:NA);Urinary metabolite levels in chronic kidney disease [succinylcarnitine (C4-DC](rs11071733:0.63:-0.14)	APH1B(eqtl:0.7:rs55862039);LACTB(eqtl:0.9:rs55862039);RAB8B(sqtl:0.9:rs55862039);RPS27L(eqtl:0.7:rs55862039);TPM1(eqtl:0.7:rs55862039)
15q21.3	0	78234455	0.5 0.38 0.3 0.27 0.28	0.01 0.02 0.06 0.35 1.11	269922	269922	78099494	78369416	0.03	0.16	0	0	0	0	5	1	0	0	Serum albumin levels(rs62008592:1:-0.02);Serum total protein level(rs62008592:1:-0.01)	ADAMTS7(sqtl:0.8:rs62008592);DNAJA4(eqtl:0.6:rs62008592);TBC1D2B(eqtl:0.6:rs62008592)
15q21.3	0	90862093	0.53 0.2 0.43 0.2 0.33	0.01 0.04 0.08 0.47 1.35	269922	269922	90727132	90997054	0.03	0.17	0	0	0	0	8	6	0	0	Basophil count(rs9944274:1:-0.02;rs9944274:1:-0.01);Basophil percentage of white cells(rs9944274:1:-0.02);Basophill percentage(rs9944274:1:-0.01);Heel bone mineral density(rs9944274:1:-0.02;rs9944274:1:-0.02);Lymphocyte counts(rs9944274:1:0.02;rs9944274:1:0.02);Lymphocyte percentage of white cells(rs9944274:1:0.01)	BLM(eqtl:0.2:rs9944274);CIB1(eqtl:0.7:rs9944274);CRTC3(eqtl:0.7:rs9944274);GDPGP1(eqtl:0.7:rs9944274);IQGAP1(eqtl:1:rs9944274;sqtl:0.5:rs9944274);NGRN(eqtl:0.1:rs9944274);ZNF774(eqtl:0.8:rs9944274;sqtl:0.3:rs9944274)
17q21.31	1	43968572	0.24 0.02 0.06 0.0 0.16	0.0 0.01 0.13 0.37 0.49	796440	796439	43572888	44369327	0.46	0.46	100	101	107	107	13	2	0	0	"Accelerometer-based physical activity measurement (average acceleration)(rs55657917:0.99:0.3);Alcohol consumption (drinks per week)(rs62055691:0.99:-0.03);Alcohol consumption (heavy vs. light/non-drinkers)(rs1635291:0.87:5.8);Aspartate aminotransferase levels(rs112275793:0.99:-0.03);Bitter alcoholic beverage consumption(rs1724409:0.82:0.01);Brain region volumes [right lingual](rs1388368194:0.99:NA);Brain region volumes [right pallidum](rs2106786:0.96:NA);Breast cancer(rs2463523:0.91:NA);Cancer (pleiotropy)(rs3072094:0.98:NA);Cardiorespiratory fitness (vo2 max)(rs527325496:0.78:0.04);Chronic obstructive pulmonary disease(rs12373142:1:NA);Cognitive aspects of educational attainment(rs113322852:0.77:NA;rs4327090:0.8:-0.05);Cognitive performance (MTAG) [MTAG](rs62065449:0.77:-0.03);Cognitive performance(rs62065449:0.77:-0.03);College or university degree | qualifications(rs1428201696:0.99:NA);Cortical surface area (global PC1)(rs62054807:0.64:NA;rs56168933:0.76:NA);Cortical surface area [Fusiform](rs62057070:0.98:-17.64);Cortical surface area [total](rs79600142:0.99:-1414.63);Cortical volume [Global](rs149366495:0.69:NA);Corticobasal degeneration(rs393152:0.99:NA);Daytime nap(rs385199:0.99:-0.02);Depressed affect(rs62057061:0.99:0.03);Drive faster than motorway speed limit(rs973104925:0.81:-0.02);Educational attainment (MTAG) [MTAG](rs62057107:1:-0.02);Educational attainment (years of education) [conditional-joint](rs56192752:0.76:-0.02);Educational attainment (years of education)(rs56319902:0.99:-0.02;rs417968:0.82:NA);Eosinophil counts(rs142955985:0.85:-0.02);Eosinophil percentage of white cells(rs9906974:0.98:-0.04);Eosinophill percentage(rs62065453:0.98:-0.07);Epithelial ovarian cancer(rs1879586:0.76:NA);Experiencing mood swings(rs55657917:0.99:0.03);Feeling guilty(rs77804065:0.93:0.02);Feeling hurt(rs55657917:0.99:0.03);General cognitive ability(rs242559:0.94:7.43);General factor of neuroticism(rs62064598:0.73:NA;rs113434679:0.76:-0.02);Guilty feelings(rs1724414:0.94:NA);Haematocrit percentage(NA:0.94:0.13);Haemoglobin concentration(NA:0.94:0.05);Headache | pain type(s) experienced in last month(rs549494279:0.83:NA);Headache(rs77804065:0.93:0.01);Heel bone mineral density(rs56303031:0.99:NA);Height(rs62053939:0.99:-0.02;rs7207400:0.77:NA);Hematocrit(rs62055888:1:0.04;rs62054395:0.99:0.05;rs187569028:0.67:0.07);Hemoglobin A1c levels(rs62063281:0.98:-0.02);Hemoglobin concentration(rs4471726:0.99:0.04);Hemoglobin levels(rs12949256:0.76:0.04);High-grade serous ovarian cancer(rs1879586:0.76:NA);Highest math class taken (MTAG) [MTAG](rs62057107:1:-0.02);Highest math class taken(rs4327090:0.8:-0.02);Hip circumference adjusted for BMI(rs3072094:0.98:0.02);Household income (MTAG)(rs16940672:0.96:-0.02);Hypertrophic cardiomyopathy (sarcomere negative)(rs28768976:0.87:0.27);Hypertrophic cardiomyopathy(rs28768976:0.95:0.26);Impedance of whole body(rs1724409:0.82:1.38);Intelligence (MTAG)(rs17426174:0.99:NA);Interstitial lung disease(rs2957316:0.94:-0.26);Invasive epithelial ovarian cancer(rs1879586:0.76:NA);Joint mobility (Beighton score)(rs113518470:0.99:NA);Left-handedness(rs55974014:0.94:NA);Liver enzyme levels (alkaline phosphatase)(rs62065453:0.98:0);Lumbar spine bone mineral density(rs1864325:0.82:-0.04);Lung function (FEV1) [EA](rs444967:1:-30.58;rs199525:0.69:-19.16);Lung function (FEV1)(rs199525:0.69:-18.85);Lung function (FVC)(rs199525:0.69:-20.32;rs62057101:1:-0.04);Lymphocyte counts(rs58089049:0.78:0.02);Lymphocyte percentage(rs1364364714:0.65:0.18);Macular thickness(rs62064364:0.96:NA);Maximum habitual alcohol consumption [EA](rs77804065:0.91:-0.07);Medication use (anilides)(rs78929339:1:0.06);Medication use (antithrombotic agents)(rs56214516:1:0.05;rs56214516:0.78:0.05);Menarche (age at onset)(rs241036:0.99:NA);Monobrow(rs1243275519:0.98:NA);Neuroticism conditioned on Townsend deprivation index (multi-trait conditioning and joint analysis)(rs56192752:0.76:NA);Neuroticism conditioned on average household income before tax (multi-trait conditioning and joint analysis)(rs56192752:0.76:NA);Neuroticism conditioned on cognitive performance (multi-trait conditioning and joint analysis)(rs34465449:0.76:NA);Neuroticism conditioned on educational attainment (multi-trait conditioning and joint analysis)(rs56192752:0.76:NA);Neuroticism conditioned on highest math class (multi-trait conditioning and joint analysis)(rs35354512:0.75:NA);Neuroticism conditioned on self-rated math ability (multi-trait conditioning and joint analysis)(rs35354512:0.75:NA);Neuroticism score(rs2693353:0.94:0.1);Neuroticism(rs111433752:0.97:0.12;rs34465449:0.76:0.01;rs77804065:0.93:11.69;rs77804065:0.93:0.06;rs113322852:0.77:NA;rs1724414:0.94:0.03);Neutrophil count(rs71375338:0.95:NA;rs675600:0.85:0.03);Non-albumin protein levels(rs62062137:0.97:-0.02);Number of sexual partners(rs62063281:0.98:-0.02);Osteoarthritis (hip)(rs62063281:0.98:NA);Osteoarthritis; localized(rs62063281:0.98:NA);Osteoarthrosis (time to event)(rs62063281:0.98:NA);Ovarian cancer in BRCA1 mutation carriers(rs17631303:0.76:NA);Parkinson's disease or first degree relation to individual with Parkinson's disease(rs62053943:0.65:-0.27);Parkinson's disease(rs62053943:0.65:-0.3;rs365825:0.99:NA;rs2942168:1:NA;rs393152:0.99:NA;rs113434679:0.76:-0.31);Peak expiratory flow (pef)(rs1428201696:0.99:-3.06);Physical activity (overall physical activity time)(rs55657917:0.99:0.04);Pulmonary fibrosis(rs2957316:0.94:-0.28);Red blood cell count(rs2106786:0.84:0.05;rs12150672:0.99:NA;rs372494195:0.67:0.08;rs190958065:0.67:0.07);Remission after SSRI treatment in MDD or neuroticism(rs9899111:0.76:NA);Reticulocyte fraction of red cells(rs7219532:0.78:0.03);Right-handed | handedness (chirality/laterality)(rs1615553:0.73:NA);Schizophrenia(rs1635298:0.7:NA);Self-reported math ability (MTAG) [MTAG](rs62065449:0.77:-0.02);Self-reported math ability(rs112010353:0.98:-0.01);Serous invasive ovarian cancer(rs1879586:0.76:NA);Serum albumin levels(rs62062137:0.97:-0.03);Serum phosphate levels(rs1876829:0.96:-0.03;rs62062137:0.97:-0.03);Serum total protein level(rs62062137:0.97:-0.04);Sex hormone-binding globulin levels adjusted for BMI(rs79724577:0.72:0.01);Spherical equivalent(rs12936645:0.73:NA);Subcortical brain region volumes [Intracranial volume, EA](rs17689882:0.99:-13460.47;rs8072451:1:NA);Sum basophil neutrophil counts(rs675600:0.85:0.03);Systolic blood pressure(rs16940672:0.96:-0.02);Testosterone levels(rs1635288:0.87:-0.01);Trouble falling asleep(NA:0.85:NA);Type 1 diabetes(rs35327136:0.74:NA);Vertex-wise cortical surface area(rs62056934:0.98:NA;rs62056934:0.98:25.21);Vertex-wise cortical thickness(rs62056934:0.98:30.42);Vertex-wise sulcal depth(rs56319902:0.99:NA;rs56319902:0.99:32.43);Waist-hip ratio(rs1876829:0.96:NA);Waist-to-hip ratio adjusted for BMI(rs1876829:0.96:0.02;rs3072094:0.98:-0.02);White blood cell (leukocyte) count(rs373607110:0.68:0.04);White blood cell count(rs62064598:0.73:0.02;rs62064641:0.74:NA);White matter microstructure (axial diusivities) [External capsule ](rs62064364:0.96:NA);White matter microstructure (axial diusivities) [Superior longitudinal fasciculus](rs4763:0.7:NA);White matter microstructure (fractional anisotropy) [Anterior limb of internal capsule](rs62062797:1:NA);Worry too long after an embarrassing experience(rs75022332:0.99:0.02);Worry(rs7207400:0.77:0.02)"	ACBD4(eqtl:0.3:rs3087534);ARHGAP27(eqtl:1:rs62065453;sqtl:0.7:rs62065453);ARL17A(eqtl:1:rs440778;sqtl:0.8:rs74918686);ARL17B(eqtl:0.9:rs62065453);CRHR1(eqtl:0.8:rs62065453;sqtl:0.9:rs62065453);DCAKD(eqtl:0.6:rs17574040);EFTUD2(eqtl:0.3:rs62055716);FMNL1(eqtl:0.9:rs62065453);HEXIM2(eqtl:0.2:rs643024);KANSL1(eqtl:1:rs62065453;sqtl:1:rs62065453);LRRC37A(eqtl:1:rs62065453;sqtl:0.5:rs62065453);LRRC37A2(eqtl:1:rs440778;sqtl:0.7:rs440778);MAPT(eqtl:1:rs62065453;sqtl:1:rs62065453);NSF(eqtl:0.8:rs440778;sqtl:0.1:rs147431626);PLEKHM1(eqtl:1:rs62065453;sqtl:1:rs62065453);SPPL2C(eqtl:0.9:rs62065453);WNT3(eqtl:0.9:rs16940676)
17q21.31	0	20395010	0.19 0.01 0.08 0.01 0.15	0.0 0.02 0.04 0.14 0.48	796440	796440	19996790	20793230	0.46	0.39	0	0	0	0	12	2	0	0	0	0
17q21.31	0	25986676	0.23 0.08 0.04 0.01 0.13	0.0 0.02 0.03 0.24 0.64	796440	796440	25588456	26384896	0.46	0.52	39	39	39	39	9	4	0	0	Galectin-9 levels(rs55740397:1:0.35)	KSR1(eqtl:0.5:rs55740397);LGALS9(eqtl:0.9:rs55740397;sqtl:0.9:rs55740397);WSB1(eqtl:0.4:rs55740397)
17q21.31	0	41251931	0.23 0.01 0.18 0.0 0.12	0.0 0.0 0.0 0.32 0.5	796440	796440	40853711	41650151	0.46	0.39	0	0	0	0	36	17	0	0	Neutrophil count(rs799923:1:0.02;rs799923:1:0.01;rs799923:1:0.02);White blood cell count(rs799923:1:0.01)	ARL4D(eqtl:0.7:rs799923);BRCA1(eqtl:0.7:rs799923);CCDC200(eqtl:0.1:rs799923);ETV4(eqtl:0.4:rs799923);NBR1(eqtl:0.4:rs799923);RND2(eqtl:0.3:rs799923);RUNDC1(eqtl:0.2:rs799923);TMEM106A(eqtl:0.3:rs799923);VAT1(eqtl:0.8:rs799923)
17q21.31	0	45941794	0.22 0.01 0.11 0.01 0.12	0.02 0.05 0.06 0.46 0.5	796440	796440	45543574	46340014	0.46	0.49	15	15	17	19	26	13	0	0	"Black | hair colour (natural, before greying)(rs61463979:0.72:NA;rs56104550:1:-0.14);Blond vs. brown/black hair color(rs72833470:0.76:NA);Blonde | hair colour (natural, before greying)(rs72833470:0.76:NA;rs56104550:1:0.12);Brown vs. black hair color(rs72833466:0.76:NA);Dark brown | hair colour (natural, before greying)(rs369784402:0.76:NA;rs56104550:1:-0.08);Hair color(rs72833466:0.76:-0.06;rs72833470:0.76:NA);Height(rs72823530:0.61:-0.02);Light brown | hair colour (natural, before greying)(rs61463979:0.72:NA;rs56104550:1:0.05);Platelet count(rs56104550:1:-0.02;rs56104550:1:-0.02);Plateletcrit(rs56104550:1:-0.02);Serum creatinine levels(rs72833461:0.6:-0.01);Skin colour(rs56104550:1:-0.01);Standing height(rs56104550:1:-0.13)"	CBX1(eqtl:0.3:rs56104550);CDK5RAP3(eqtl:0.6:rs56104550;sqtl:0.5:rs56104550);COPZ2(eqtl:0.7:rs56104550;sqtl:0.2:rs56104550);HOXB2(eqtl:0.8:rs56104550);HOXB4(eqtl:0.2:rs56104550);LRRC46(eqtl:0.8:rs56104550;sqtl:0.5:rs56104550);MRPL10(eqtl:0.8:rs56104550);OSBPL7(eqtl:0.2:rs56104550;sqtl:0.6:rs56104550);PNPO(eqtl:0.8:rs56104550;sqtl:0.3:rs56104550);SCRN2(sqtl:0.4:rs56104550);SNX11(eqtl:0.8:rs56104550;sqtl:0.7:rs56104550);TBKBP1(eqtl:0.5:rs56104550)
17q21.31	0	51375677	0.27 0.02 0.07 0.0 0.12	0.0 0.01 0.03 0.26 0.64	796440	796440	50977457	51773897	0.46	0.54	0	0	0	0	1	0	0	0	0	0
17q21.31	0	56527117	0.23 0.03 0.09 0.0 0.12	0.0 0.0 0.01 0.18 0.68	796440	796440	56128897	56925337	0.46	0.52	0	0	0	0	23	10	0	0	"Cardiovascular disease(rs2680707:0.92:NA;rs2680707:0.92:NA;rs28845883:1:0.01);High blood pressure | vascular/heart problems diagnosed by doctor(rs61339406:0.8:NA);Hypertension | non-cancer illness code, self-reported(rs61339406:0.8:NA);Mean corpuscular volume(rs28845883:1:-0.01);Mean reticulocyte volume(rs28845883:1:-0.02);Mean spheric corpuscular volume(rs28845883:1:-0.02);Medication use (agents acting on the renin-angiotensin system)(rs2680707:0.64:-0.04;rs2680707:0.92:-0.04);Monocyte count(rs28845883:1:0.02);Monocyte percentage of white cells(rs28845883:1:0.03);Monocyte percentage(rs28845883:1:0.04);Myeloperoxidase levels(rs28845883:1:0.15);None of the above | vascular/heart problems diagnosed by doctor(rs61339406:0.8:NA);Urate levels(rs389389:0.92:0.02)"	MPO(eqtl:0.9:rs28845883;pqtl:0.8:rs28845883);PPM1E(eqtl:0.6:rs28845883);RAD51C(eqtl:0.9:rs28845883;sqtl:0.4:rs28845883);RNF43(eqtl:0.6:rs28845883;sqtl:0.1:rs28845883);SEPTIN4(eqtl:0.4:rs28845883);SKA2(eqtl:0.7:rs28845883;sqtl:0.5:rs28845883);SMG8(eqtl:0.5:rs28845883);SUPT4H1(eqtl:0.9:rs28845883);TEX14(eqtl:0.6:rs28845883);TRIM37(eqtl:0.9:rs28845883;sqtl:0.6:rs28845883);TSPOAP1(eqtl:0.6:rs28845883;sqtl:0.2:rs28845883)
17q21.31	0	60175577	0.2 0.07 0.08 0.04 0.13	0.0 0.03 0.07 0.23 0.45	796440	796440	59777357	60573797	0.46	0.42	0	0	0	0	7	4	0	0	0	0
17q21.31	0	61675576	0.25 0.04 0.11 0.03 0.09	0.0 0.02 0.04 0.23 0.56	796440	796440	61277356	62073796	0.46	0.42	0	0	0	0	24	11	0	0	"Ankle spacing width(rs11871722:1:0.08);Appendicular lean mass(rs68076419:0.6:0.06;rs68076419:0.6:0.05;rs11871722:1:0.05;rs11871722:1:0.03;rs11871722:1:0.04);Arm fat percentage (left)(rs1204510093:0.73:-0.12);Arm fat percentage (right)(rs1204510093:0.73:-0.12);Arm fat-free mass (left)(rs11871722:1:0.01);Arm fat-free mass (right)(rs11871722:1:0.01);Arm predicted mass (left)(rs11871722:1:0.01);Arm predicted mass (right)(rs11871722:1:0.01);Basal metabolic rate(rs11871722:1:17.38);Body fat percentage(rs1204510093:0.73:-0.1);Body mass index(rs17631394:0.97:-0.02;rs8075273:0.8:-0.01;rs8075273:0.8:-0.01);Comparative height size at age 10(rs11871722:1:0.02);Forced expiratory volume in 1-second (fev1)(rs11867396:0.8:0.02;rs11871722:1:0.01);Forced expiratory volume in 1-second (fev1), best measure(rs11871722:1:0.01);Forced expiratory volume in 1-second (fev1), predicted(rs11871722:1:0.01);Forced vital capacity (fvc)(rs11542436:0.75:0.02;rs11871722:1:0.02);Forced vital capacity (fvc), best measure(rs11871722:1:0.02);Hand grip strength (right)(rs11871722:1:0.11);Height(rs11542436:0.75:0.04);Hemoglobin A1c levels(rs9896476:0.73:-0.01);Leg fat percentage (left)(rs1204510093:0.73:-0.11;rs11871722:1:-0.1);Leg fat percentage (right)(rs1204510093:0.73:-0.11;rs11871722:1:-0.1);Leg fat-free mass (left)(rs11871722:1:0.02);Leg fat-free mass (right)(rs11871722:1:0.02);Leg predicted mass (left)(rs11871722:1:0.02);Leg predicted mass (right)(rs11871722:1:0.02);Mean sphered cell volume(rs3817181:0.8:-0.01);Mean spheric corpuscular volume(NA:0.68:-0.02;rs11871722:1:-0.02);Sitting height(rs11871722:1:0.12);Standing height(rs11871722:1:0.31);Trunk fat-free mass(rs11871722:1:0.09);Trunk predicted mass(rs11871722:1:0.08);Type 2 diabetes [conditional](rs370739195:0.7:NA);Type 2 diabetes(rs17631783:0.98:NA);Waist-hip ratio(rs8075273:0.8:-0.01;rs12325866:0.79:-0.01);Whole body fat-free mass(rs11871722:1:0.15);Whole body water mass(rs11871722:1:0.11)"	CCDC47(eqtl:0.6:rs11871722);DDX42(eqtl:0.9:rs11871722;sqtl:0.4:rs11871722);FTSJ3(eqtl:0.9:rs11871722;sqtl:0.1:rs11871722);GH2(eqtl:0.6:rs11871722);LIMD2(eqtl:0.7:rs11871722);MAP3K3(eqtl:0.7:rs11871722;sqtl:0.3:rs11871722);PSMC5(eqtl:0.6:rs11871722);SMARCD2(eqtl:1:rs11871722;sqtl:0.2:rs11871722);STRADA(eqtl:0.7:rs11871722;sqtl:0.6:rs11871722)
17q21.31	0	81007439	0.21 0.02 0.21 0.01 0.11	0.01 0.06 0.14 0.26 0.63	796440	796440	80609219	81405659	0.46	0.44	0	0	0	0	10	2	0	0	0	B3GNTL1(eqtl:0.5:rs35316495);FN3KRP(eqtl:0.3:rs35316495);METRNL(eqtl:0.5:rs35316495);TBCD(eqtl:0.5:rs35316495)
18p11.21	1	12168768	0.33 0.35 0.43 0.75 0.43	0.0 0.0 0.0 0.65 1.57	116413	116412	12108386	12224798	0.02	0.02	0	0	0	0	2	0	0	0	0	ANKRD62(eqtl:0.9:rs4416083);CEP192(eqtl:0.2:rs12969296);CIDEA(eqtl:0.3:rs2276370);IMPA2(eqtl:0.2:rs149102882)
18p11.21	0	21696139	0.35 0.52 0.54 0.41 0.38	0.01 0.04 0.07 0.81 1.45	116413	116413	21637932	21754345	0.02	0.1	0	0	0	0	3	3	0	0	0	CABYR(eqtl:0.9:rs5018694;sqtl:0.5:rs5018694);OSBPL1A(eqtl:0.9:rs5018694;sqtl:0.9:rs5018694)
18p11.21	0	24687324	0.33 0.64 0.49 0.51 0.36	0.0 0.01 0.04 0.51 1.49	116413	116413	24629117	24745530	0.02	0.04	0	0	0	0	1	1	0	0	"Blood protein levels [CHST9, 11646_4_3](rs7233634:0.98:0.28);Circulating plasma alpha-Klotho levels(rs12607664:0.99:0.24;rs9949089:0.99:0.24;rs9961915:1:0.24;rs9961915:1:0.23);Serum levels of protein CHST9(rs9967454:0.97:0.27)"	CHST9(eqtl:0.4:rs9961915;pqtl:0.8:rs9961915)
18p11.21	0	43092829	0.33 0.77 0.38 0.33 0.41	0.01 0.02 0.08 0.8 1.38	116413	116413	43034622	43151035	0.02	0.11	0	0	0	8	1	0	0	0	Pulse pressure(rs7236548:0.63:0.03)	0
18p11.21	0	47849842	0.34 0.25 0.49 0.71 0.59	0.01 0.02 0.07 0.4 1.49	116413	116413	47791635	47908048	0.02	0.08	0	0	0	0	4	4	0	0	0	CXXC1(sqtl:0.4:rs7241082)
18p11.21	0	56366157	0.32 0.65 0.43 0.46 0.42	0.0 0.01 0.1 0.68 1.68	116413	116413	56307950	56424363	0.02	0.11	0	0	0	0	2	1	0	0	Multiple sclerosis(rs9955954:0.61:NA)	MALT1(eqtl:0.7:rs62094041)
18p11.21	0	58917590	0.34 0.58 0.38 0.43 0.51	0.01 0.02 0.04 0.81 1.46	116413	116413	58859383	58975796	0.02	0.04	0	0	0	0	0	0	0	0	0	0
18p11.21	0	60569102	0.3 0.34 0.52 0.64 0.41	0.0 0.01 0.02 0.44 1.76	116413	116413	60510895	60627308	0.02	0.02	0	0	0	0	1	1	0	0	Platelet crit(rs607153:0.61:0);Plateletcrit(rs505707:1:0.01)	PHLPP1(eqtl:0.9:rs505707;sqtl:0.7:rs505707)
18p11.21	0	67008819	0.36 0.64 0.28 0.54 0.4	0.0 0.09 0.1 0.83 1.75	116413	116413	66950612	67067025	0.02	0.11	0	0	0	0	0	0	0	0	0	0
18p11.21	0	69453144	0.33 0.5 0.42 0.52 0.42	0.0 0.04 0.07 1.09 1.55	116413	116413	69394937	69511350	0.02	0.1	0	0	0	0	1	0	0	0	0	0